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Human Mendelian genetics aims to define the link between the phenotypical 
manifestations of a disease, and the identity of the gene that when mutated 
causes disease. Rare ocular genetic disorders are typically difficult to manage 
due to an incomplete understanding of their genetic causes and clinical 
outcomes. However, in the last few years rapid advancements in high 
throughput genomic sequencing techniques has paved the way for the 
discovery of new genes causing inherited diseases, and provided new insights 
into the breadth of phenotypical manifestations associated with pathogenic 
variants in genes already known to be linked with ocular disease. The discovery 
of new disease-associated genes provides important diagnostic benefits for 
patients, and also aids scientific understanding of how the biological processes 
within cells work. In turn, this drives the development of new treatments and 
therapies.  
Chapter three documents a comprehensive series of genetic studies leading to 
the discovery of a novel founder mutation in the CLCC1 gene, associated with 
an autosomal recessive form of retinitis pigmentosa in families from Pakistan, 
as well as the characterisation of CLCC1 in zebrafish and mouse retina. 
Moreover, the chapter details extensive molecular studies to discover the 
functional role of CLCC1 in the cells. This includes the localisation of CLCC1 
within the endoplasmic reticulum, the identification of CLCC1 binding partners, 
and the exploration of a possible role of CLCC1 in endoplasmic reticulum stress 
and calcium signalling. This section also describes the generation of a CLCC1 
knockout cell line using CRISPR-Cas9, to enable future more extensive studies 
of CLCC1 molecular function.  
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Chapter four of this thesis entails a comprehensive investigation by way of 
genetic studies, and literature review, of novel and known genetic variants 
associated with a wide range of inherited retinal dystrophies in families from 
Pakistani. This data provides the most comprehensive repository of information 
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CHAPTER 1 INTRODUCTION 
1.1 Developmental origins of the eye 
The organogenesis of the eye is a multi-step process occurring in the ventral 
forebrain during the final stages of neuronal tube formation. After gastrulation, 
the eye primordium is specified in the medial anterior neural plate. In mice, the 
first structure indicating eye organogenesis is visible at embryonic (E) day 8.0 
and is named optic sulcus, while in humans the optic primordia appear at 
Carnegie Stage 10.  Eye field specification happens though the expression and 
regulation of eye field transcription factors Rx1/Rax, Pax6, Six3, Lhx2, tll/Tlx, 
Optx2/Six6 and ET/Tbx (Fig. 1.1) [2]. Mutation of any of these genes and many 
of their molecular pathway partners may be associated with developmental 
defects of the eye [3, 4]. 
Eye organogenesis begins with the evagination of the neuroepithelium, at E8.5-
9.0 of mouse development, forming bilateral optic vesicles. The optic vesicle is 
patterned in the dorso-ventral (D-V) and proximal-distal (P-D) axes, and 
regionalised in neural retina and retinal pigmented epithelium (RPE). Each 
compartment of the optic vesicle expresses specific sets of transcription factors 
important for the development of different types of cell. The D-V axis is 
established by the hedgehog-family gene Shh, which drives expression of the 
ventralising homeodomain transcription factors Vax1 and Vax2. Shh also drives 
the P-D patterning, regulating the localisation of Pax2 and Pax6 expression, 
which in turn maintains the P-D axis of the optic vesicle/optic cup boundary. The 
dorsal identity of the optic vesicle requires the induction of Tbx5 by bone 
morphogenetic protein 4 (BMP4) [2, 5].  
29 
 
The earliest gene expressed in the eye field, upstream to the above genetic 
interactions, is LIM homeobox transcription factor Lhx2; required for expression 
of Mitf and for retinal determinants in the optic vesicle [1]. Subsequent to this at 
E10.5 the optic vesicles invaginate giving rise to the optic cup. This invagination 
is induced by the contact between the distal portion of the optic vesicles with the 
overlaying ectoderm. From the optic cup two types of tissues generate different 
classes of retinal cell. The presumptive neural retina develops from the distal 
optic vesicle and becomes the inner layer of the optic cup; whilst the 
presumptive RPE derives from the proximal optic vesicle, forming the outer 
layer of the optic cup. An additional invagination occurs in the ventral optic 
vesicle, generating the optic fissure [5-8]. The presumptive RPE is specified by 
the TGFβ signalling from the extraocular mesenchyme, in particular, TGFβ 
induces the expression of bHLH transcription factor, Mitf, and Otx2 in the distal 
optic vesicle. As the optic vesicle approaches the surface ectoderm, Vsx2 
expression initiated from FGFs signals, coming from the ectoderm surface 
which specifies the D-V patterning of the optic vesicle as neural retina. Vsx2 
represses Mitf allowing the distal optic vesicle to develop into neural retina [2, 9, 
10]. Retinoic acid (via its receptors) and BMP signalling are involved in the 
maintenance of RPE in the ventral optic cup [6]. Wnt/β-catenin pathway also 
controls differentiation of the RPE in the optic cup; the activation of the Wnt/β-
catenin pathway results in cytoplasmic stabilisation of β-catenin, ultimately 






























































































































































































































































































































































































































The maturation of the neural retina gives rise to the retinal progenitor cells, 
which differentiate into all the classes of postmitotic neuronal and glial cells that 
will form the retina [11, 12]; the RPE instead gives rise to the pigmented 
epithelium cells [8]. Peripheral structures such as the iris epithelium and ciliary 
body originate from the margin between the RPE and the neural retina. The 
lens vesicle separates from the surface ectoderm and differentiates into the 
mature lens [6, 7].  
The neural retina is patterned along the D-V axis and the nasal-temporal (N-T) 
axis. The axons of the retinal ganglion cells enter into the optic stalk at E11.5. 
The optic nerve derives from the optic stalk, and its placement depends on the 
D-V signals of Vax1 and Vax2 in the optic stalk and ventral retina, between E9.5 
and E11.5. The N-T patterning of the optic cup ensures that the axons of the 
retinal ganglion cells reach their targets in the Geniculate Nucleus [5]. 
1.2 Anatomy of the eye. 
The eye (Fig. 1.2) is a fluid-filled sphere enclosed by three layers of tissue. 
Externally, the sclera forms a tough white fibrous tissue which becomes the 
cornea at the front of the eye. The cornea is a transparent, non-vascularised, 
layer which refracts the light onto the lens.  
The second layer is the choroid, a capillary-rich tissue containing melanin that 
absorbs excess of light. In the anterior part of the eye the lens is attached to the 
choroid through the ciliary body. The lens is a transparent biconvex structure, 
which refracts the incoming light and focuses it on the retina. Behind the cornea 
there is a ring-like structure, the iris, with a central opening though which the 
light enters in the eye, the pupil. The lumen between the cornea and iris, also 
called the anterior chamber, is filled with aqueous humor, a watery fluid rich in 
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nutrients, produced by the ciliary processes in the posterior chamber, the region 
between the lens and the iris. The inner chamber of the eye is filled with 
vitreous humor, a gel-like substance that helps to maintain the shape of the eye. 
The third layer of tissue, the inner one, is the retina. The serrated junction 
marking the transition between the retina and the ciliary body is called ora 
serrata. The retina is composed of different types of neurons sensitive to light. 
The internal surface of the retina presents an oval yellow spot at the back of the 
eye called the macula lutea, which supports high visual acuity. At the centre of 
the macula a small depression, called the fovea comprising the area of greatest 
visual acuity, supported by high density of cone photoreceptors in the fovea and 
one-to-one relationship with bipolar and ganglion cells [13]. Blood vessels and 

















1.3 Fundamentals of retina lamination 
The retina is a layered tissue responsible for light processing. To fulfil its 
function, at the cellular level the retina is highly organised, allowing fast and 
precise delivery of visual information. Vertebrates have an inverted retina, 
meaning that the light-sensitive cells are situated proximally to the choroid, so 
the light has to pass through the different layers before reaching the 
photoreceptors. Neuronal circuits in the retina are arranged following a layered 
pattern, where cell bodies and synapses are compartmentalised in different 
layers of tissue, disruption of which leads to impairment of the organ function 
[14]. The organisation and neuronal migration in the retina were firstly 
acknowledged by Ramon y Cajal in 1893. 
The retina is composed of five classes of neurons: photoreceptors, horizontal 
cells, amacrine cells, bipolar cells and ganglion cells; and a single class of glial 
cells, the Müller glia. Most of these cells have multiple subtypes, based on 
morphology and transcription profile, it has been estimated that over 55 types of 
cells are present in the retina [15]. 
Seven layers of tissue compose the retina [14, 16-18] (Fig. 1.3): 
1. The retinal pigmented epithelium (RPE) consists of a single layer of 
hexagonal cells, the retinal pigmented cells, separating the choroid from 
the retina. The cells contain melanin, a pigment, which absorbs reflected 
light. 
2. The outer segment layer hosts the membranous disks of the 
photoreceptor cells, rods and cones.  




4. The outer plexiform layer (OPL) harbours the synapses that the 
photoreceptors make with bipolar and horizontal cells.  
Horizontal cells provide inhibitory feedback to photoreceptors, while bipolar cells 
connect the photoreceptors with the ganglion cells. In this layer light stimuli are 
converted into electrochemical signals by modulation of tonic glutamate release 
from photoreceptors [15, 19].  
5. In the inner nuclear layer (INL) there are amacrine, bipolar, horizontal 
and Muller glia cell bodies. 
6. The inner plexiform layer (IPL) presents the synapse of axon of amacrine 
cells, bipolar cells and ganglion cells [14]. 
The amacrine cells refine the input delivered to the ganglion cells from the 
bipolar cells. 
7. The ganglion cell layer (RGL) contains ganglion cell, bearing the visual 
signal into the optic nerve. 
Among all these classes of cell, photoreceptors, cones and rods, are 
specialised for different aspects of vision. The shape of the outer segment gives 
the name to the respective cell type. Both types of cells contain visual pigments 
in the outer segment, a modified cilium formed by stacks of membrane disks in 
continuum with the plasma membrane. In rods, the visual pigment is rhodopsin 
(spectral peak sensitivity at 500 nm), while the cones embody three types of 
opsin: red-sensitive (564 nm; L cones), green-sensitive (533 nm; M cones), and 
blue-sensitive (437 nm; S cones). Photoreceptors have the ability to respond 
differently to light intensities. Rods are very sensitive to light, mediating dim light 
vision (also called scotopic vision) with low spatial resolution; while the cones 
are relatively insensitive to the light, working in bright environment (photopic 
36 
 
vision), and mediating the colour vision. Differences in transduction 
mechanisms contribute to the ability of the photoreceptors to respond differently 
to the light. Visual responses can be elicited in rods by a single photon, 
whereas more than 100 photons are necessary to activate the same responses 
in cones. Photoreceptors differ also in terms of number; there are 4.6 million 
cones, 100,000 cones are packed in the foveola- the centre of the fovea- 
allowing visual acuity, while there are 92 million rods, spread over the rest of the 










Figure 1.3 The visual sense organ. The retina is laminated. The nuclei of the 
photoreceptors constitute the outer nuclear layer (ONL). The nuclei of the 
bipolar cells, amacrine cells and horizontal cells are found in the inner nuclear 
layer (INL), and the nuclei of ganglion cells form the ganglion cell layer (GCL). 
The outer plexiform layer (OPL) contains the processes and synaptic terminals 
of photoreceptors, horizontal cells, and bipolar cells. The inner plexiform layer 
(IPL) contains the processes and terminals of bipolar cells, amacrine cells, and 





1.4 Mechanism of vision 
The mechanism of vision can be divided in two processes: the 
phototransduction, and the retinoid cycle. 
1.4.1 Phototransduction 
Phototransduction (Fig. 1.4) is the process by which photons captured in the 
photoreceptor’s OS are converted into a visual impulse. In the membranous 
disks, the combination of opsin, a light-sensitive seven-transmembrane-domain 
G-protein coupled receptor (GPCR), with 11-cis-retinal, a chromophore, forms 
the rhodopsin. Light initiates the isomerization of the 11-cis-retinal into all-trans-
retinal (also called R* or metarhodopsin II) which activates the heterotrimeric G 
protein transducin, by catalysing the exchange of GDP for GTP. The transducin 
Gα-subunit dissociates from the Gβγ subunit, and activates cGMP-
phosphodiesterase (PDE), which hydrolyses cytoplasmic cGMP into 5’GMP. 
The decrease of cytoplasmic cGMP concentration causes the dissociation of 
the cGMP from the cGMP-gated cation channels, causing their closure. This 
results in the reduction of the intracellular concentration of Ca2+ and Na+, and 
the hyperpolarisation of the membrane [22]. The phototransduction cascade is 
truncated when the photoactivated rhodopsin is inactivated by phosphorylation 
from the rhodopsin kinase GRK1 [23], and the subsequent binding of arrestin, to 
cap its catalytic activity [24]. At the end of the cascade the all-trans-retinal 
becomes all-trans-retinol, which detaches from the opsin and diffuses in the 
cytosol. Here, the chaperone inter photoreceptor retinoid binding protein (IRBP) 
transports the all-trans-retinol into the pigmented epithelium. At the same time 
the all-trans-retinol undergoes a series of enzymatic reactions, leading to the 
regeneration of 11-cis-retinal for the next visual cycle [20, 25].  
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Different levels of illumination give rise to different responses from the 
photoreceptors (Fig 1.4), the process is known as light adaptation. In the dark 
the cGMP binds the cGMP-gated channel, allowing the Ca2+ to enter the cells. 
At the same time the intracellular Ca2+ is removed by Ca2+/Na+ exchangers 
present on the plasma membrane, and the potassium exits the cell, inducing 
depolarisation. In bright light all the channels are closed and the levels of 
cytoplasmic Ca2+ are low, even though the Ca2+/Na+ exchanger operates 
independently [4]. S-modulin/recoverin and guanylyl cyclase activating protein 
(GCAPs) detect the concentration of Ca2+ and shorten the life of all-trans-retinal 













Figure 1.4 Phototransduction Opsins contained in rod and cone 
photoreceptor’s discs absorb photons, resulting in the opsins activation and 
inducing the activation of G protein, transducin, through the exchange of GDP 
to GTP. The Gα subunit dissociates from the Gβγ and binds and activates PDE 
(cyclic nucleotide phosphodiesterase), which breaks the cGMP in 5’ GMP. The 
decrease of cGMP concentration causes the closure of cyclic nucleotide 
channel (CNG) on the outer segment membrane, decreasing the Na+ current 







1.4.2 Retinoid cycle 
The retinoid cycle (Fig. 1.5) allows the reconstitution of the 11-cis-retinal after 
the phototransduction. All-trans-retinal released from the activated opsin into 
the lipid leaflet bi-layer of the optic disc is pumped into the photoreceptors 
cytoplasm by the transporter ABCA4 [26]. The dehydrogenases RHD8 and 
RHD12 reduce all-trans-retinal into all-trans-retinol (vitamin A), in a NADPH-
dependent reaction [27], which diffuses in the RPE cells though the binding of 
IRBP [28-31]. After entering the RPE, all-trans-retinol is transferred to the 
cellular retinoid binding protein (CRBP) [32] and delivered to the lecithin retinol 
acyltransferase (LRAT) which esterifies all-trans-retinol into retinyl esters [33]. 
RPE65 isomerises and hydrolyses the retinyl esters into 11-cis-retinol [34-37], 
which binds the cellular retinaldehyde binding protein (CRALBP) [38], allowing 
the delivery to the enzyme 11-cis retinol dehydrogenase (RDH5) [39, 40].  
RDH5 oxidises 11-cis-retinol into 11-cis-retinal, using NAD as cofactor. 11-cis-
retinal then diffuses back out of the RPE cell into the photoreceptor though 





Figure 1.5 Retinoid cycle. Once the all-trans-retinal dissociates from the 
rhodopsin, it is transported into the photoreceptor cytoplasm by the transporter 
ABCA4. Here, the enzymes RHD8 and RDH12 reduce all-trans-retinal into all-
trans-retinol, which is pumped by IRBP into the retinal pigmented epithelium. 
All-trans-retinol is esterified by LRAT into all-trans-retinyl esters, and converted 
into 11-cis-retinol by RPE65. RHD5 oxidases 11-cis-retinol into 11-cis-retinal, 
which is pumped back into the photoreceptor outer segment, ready for the next 






1.5 Inherited retinal dystrophies 
Inherited retinal dystrophies (IRDs) are a heterogeneous group of ocular 
diseases characterised by the loss of sight due to the death or dysfunction of 
photoreceptors, and their contacts with the RPE [43]. Collectively, Mendelian 
forms of retinal dystrophy have an estimated incidence of 1:2000 [44]. 
To date, a total of 260 disease genes (RetNet Retinal Information Network 
https://sph.uth.edu/RetNet/) have been identified as causing such diseases. 
Most are specifically involved in the visual cascade of photoreceptors and RPE, 
while others encode transcription factors regulating the progenitors cell fate 
such as OTX2 and CRX [45] (see Appendix A). Variants in the same gene may 
give rise to different clinical outcomes (Fig. 1.6), with phenotypes of variable 
severity, mode of inheritance, and progression, even between affected 
members of the same family. Therefore, a definite diagnosis may not always be 
straightforward.  
The clinical and genetic heterogeneity of IRD makes the classification of these 
conditions problematical. IRD is typically categorised based on the course of the 
disease (progressive or stationary), mode of inheritance (autosomal dominant 
(AD), recessive (AR), or X-linked), phenotype (rod-dominant, cone-dominant, 
macular), or whether it can be found as part of a wider syndromic presentation 
(non-syndromic forms of IRD, exclusively affect the eye, or syndromic forms if 
associated with additional systemic symptoms).  One important differential 
diagnosis for IRDs is retinal degeneration caused by injury. The most common 
injuries associated with retinal degeneration are laser-induced retinal 
degeneration and retinal degeneration which occurs as result of side-effects of 
drugs. One example is hydroxychloroquine, used for the treatment of 
rheumatoid arthritis and systemic lupus erythematosus, accumulates in tissues 
44 
 
with high melanin content as RPE and induces loss of central vision and 
irreversible macula changes [46]. 
1.5.1 Non-syndromic inherited retinal dystrophies 
Non-syndromic IRDs may be classified based on the progression or on the type 
of cells involved. Here, IRDs are classified based on the cell-type involved. 
1.5.1.1 Rod-dominant IRDs 
Amongst IRDs, non-syndromic retinitis pigmentosa (RP) (MIM: 268000) is the 
most common with a worldwide prevalence of ~1 in 4000 [44]. The term ‘retinitis 
pigmentosa’ was coined by the Dutch ophthalmologist F.C. Donders in the mid-
1800s. Non-syndromic RP is typically inherited as autosomal recessive in 15-
20% of the cases, autosomal dominant in the 20-25% of the cases, or X-linked 
(5-15%) [44, 47], depending on the particular community or geographical 
region. The clinical presentation of RP is highly variable, however the classical 
pattern that is observed is typified by the presence of bone spicules inside the 
retina (retinal pigmented epithelium cells migrated into the neural retina caused 
by photoreceptors death [48]), night blindness, difficulties in dark adaptation, 
narrowing of blood vessels, and tunnel vision in young adulthood. While the age 
of onset of the symptoms can range between early childhood to adulthood, the 
disease typically progresses to the loss of central vision around the age of 60 
years. The loss of colour vision is characteristic of advanced RP. Patients 
affected by RP also show a reduction or absence of electroretinogram (ERG) 
amplitudes due to the loss of rod and cone photoreceptors. Over 70 genes and 
loci have been reported as causative of RP on RetNet, most of which are 
involved in the photoreceptor’s phototransduction cascade and visual cycle or 
connecting structures (Appendix A).  
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The genetics of RP is complicated, and clear genotype-phenotype correlations 
are often not possible. Moreover, mutations in the same gene may cause 
differing phenotypes, including variability within the same family. A striking 
example is mutations in the RHO gene, encoding for rhodopsin which 
encompasses 26.5% of cases of adRP [47, 49]. The disease-associated variant 
p.Pro23His represents a founder mutation in North America [50] in individuals 
with western-European ancestry (about 10% of adRP cases) [51], and it is the 
most studied [52]. Mutations in RHO may also cause arRP, in particular the 
variants p.Glu150Lys, p.Met253Ile, p.Trp161*, and p.Glu249*; while other five 
variants in RHO have been associated with adCSNB [52]. Another common 
cause of adRP involves sequence alterations in PRPF31, encoding a pre-
mRNA splicing factor, which accounts for 1-8% of cases worldwide, a higher 
prevalence of PRPF31 associated RP has been found in the USA [53]. 
Similarly, another two splicing factors PRPF3 and PRPF8 have been found to 
account for 1% and 3% of adRP cases respectively [53]. RP1, a gene encoding 
a microtubule-associated protein involved in the maintenance of the 
photoreceptors outer segment, has been found associated with adRP in 5-10% 
of cases, half of which due to p.Arg677* [47, 49, 53, 54]. 
The most common gene associated with autosomal recessive RP is USH2A, 
estimated to account for  ~10% of cases, and shown to be causative of around 
6-9% of arRP in the Chinese population [55, 56], and Spanish population, 
where mutations in USH2A have also been associated with cone-rod dystrophy 
[47]. Mutations in CRB1 are responsible for ~6.5% of cases [53]; while 
mutations in PDE6B and CEP290 have also been commonly associated with 
arRP [47]. A study of a cohort of patients in Jerusalem (Israel) highlighted that 
the most common genes associated with arRP are DHDDS, FAM161A and EYS 
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[57]. The high prevalence of pathogenic variants in these disease-associated 
genes, which are very rare in western populations, indicated that this relatively 
genetically-isolated population has its own genetic make-up.  
X-linked RP accounts for 10-15% of RP inheritance pattern; patients display a 
more severe phenotype at early stages compared to adRP and arRP. 
Additionally, a mild phenotype may be present in carrier females due to skewed 
X chromosome inactivation. Six loci have been associated with this mechanism 
of disease, although to date mutations in only two genes have been 
established. RPGR-associated X-linked RP explains ~74% of cases [53], in 
which ~ 60% of all RPGR disease-associated alterations reside in a specific 
RPGR isoform (RPGR-ORF15) [58]. Sequence alterations in RP2 explain ~15% 
of cases [53]; this protein is a GTPase-activating protein (GAP) involved in 
trafficking between the Golgi and the ciliary membrane. 
Although RP is generally considered a monogenic disease, digenic inheritance 
has also been described. The first report of a digenic disease in humans was in 
1994, in which three families affected by RP segregated with variants in PRPF2 
and ROM1 [59]. Since then multiple diseases, especially syndromic RP, have 
been shown to follow this pattern. Despite many genes discovered causing RP, 
in ~20-30% of (mostly isolated or ‘sporadic’) cases a genetic cause of the 
disease remains to be determined. De novo mutations, deep intronic variants of 
uncertain significance, or incomplete penetrance could explain some of those 
cases. 
Leber congenital amaurosis (LCA) was first described by Theodore Leber in 
1869, and defines a group of severe recessively inherited, early infantile onset 
rod–cone dystrophies. LCA affects 2-3 people in every 100,000 worldwide. The 
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visual impairment starts during infancy and is usually associated with 
photophobia, nystagmus, hyperopia, reduced reactions of the pupil, and 
keratoconus. The fundus may appear abnormal, and the ERG is undetectable 
or severely abnormal. In rare cases, delayed development and intellectual 
disability have also been reported in people affected by more clinically complex 
forms of LCA, including CEP290 and AIPL1 [60, 61]. Out of 260 genes reported 
on RetNet as causative of retinal diseases, 25 have been associated with LCA 
(Appendix A). These genes typically have a highly restricted expression pattern 
within retinal cells [62], and together underlie approximately 70% of LCA cases 
[63]. The most common causes of LCA involve sequence variants in GUCY2D 
(accounting for 10-20% of cases), CEP290 (15-20% of cases), CRB1 (10% of 
cases), RDH12 (10% of cases) and RPE65 (accounting for 5-10% of cases); 
some of these genes show specific phenotypic features [62]. Patients with 
GUCY2D mutation have poor vision in early life, poor responses to visual 
stimuli, photophobia and nystagmus, whilst patients affected by mutation of 
RPE65 show night blindness as the most common feature, nystagmus, and 
poor vision. Cataract and myopia are also often associated with mutations in the 
RPE65 gene [64]. 
Congenital stationary night blindness (CSNB) is a group of non-progressive 
retinal disorders characterised by night blindness, decreased visual acuity, 
nystagmus, myopia, and strabismus. A meta-analysis reported that X-linked 
CSNB accounts for 50-60% of cases, autosomal recessive and sporadic CSNB 
accounted for 40% including 23.6% with a fundus abnormality, and the 
remaining 2.1% of cases had autosomal dominant CSNB [65]. Mutations in 
genes encoding for proteins involved in the phototransduction cascade (e.g. 
GNAT1 encodes for α-subunit of transducin, PDE6B encodes for γ-subunit of 
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PDE) and signal transmission from photoreceptors to bipolar cells (e.g. 
CACNA1F encodes the α1-subunit of an L-type voltage-dependent Ca2+ 
channel) are often the cause of this disease (Appendix A) [65].   
1.5.1.2 Cone-dominant IRDs 
Cone dystrophy (CD) or cone-rod dystrophy (CRD) (MIM: 615973) is a 
heterogeneous group of progressive retinal dystrophies affecting primarily the 
cone photoreceptors however, rod degeneration may also present in later 
stages of the disease. It affects 1 in 30,000 people, and clinical signs are 
absence of photopic ERG responses, decreased visual acuity, photophobia, 
loss of colour vision and peripheral vision, and night blindness. The inheritance 
pattern is mainly autosomal recessive, but it can also present as autosomal 
dominant, and rarely as X-linked forms. Sequence alterations in 35 genes have 
been described as associated with this disease (Appendix A) including the 
transcription factor CRX (~5-10% of autosomal dominant CRD cases). 
Sequence alterations in the transporter ABCA4, involved in retinoid metabolism 
(see Fig.1.4 and Fig. 1.5) and also associated with Stargardt disease and RP, 
encompass 30-60% of the autosomal recessive CRD cases. X-linked CRD is 
most often caused by mutation in the GTPase regulator RPGR (also associated 
with X-linked RP), expressed in the cilium of the photoreceptors. RPGR 
interacts with another protein expressed in the cilium, RPGRIP1, which is also 
associated with CRD and LCA [66-68].  
Achromatopsia (ACHM) is an autosomal recessive form of non-progressive 
cone dystrophy, affecting 1:30,000 people, consisting in partial or complete 
absence of colour vision, due to the degeneration of cone photoreceptors. 
Affected individuals also experience photophobia, nystagmus, and low visual 
acuity. Six genes have been identified as causative of this disease (Appendix 
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A). CNGA3 [69, 70], CNGB3 [69], are subunits of the cone photoreceptor CNG 
channel; GNAT2 [71, 72] encodes for the cone-specific alpha subunit of 
transducin; ATF6 [73-75] is a transcription factor involved in endoplasmic 
reticulum stress; PDE6C [76], PDE6H [77] encode for the photoreceptor’s 
phosphodiesterase (see Fig. 1.4 and 1.5).  
1.5.1.3 Macular dystrophies 
The most common macular dystrophy, a rare condition involving the 
degeneration of the macula, is Stargardt disease, an autosomal recessive 
progressive inherited disease cause by alteration in ABCA4 gene which has > 
900-reported disease-associated variants. Stargardt disease has a prevalence 
of 1:8000-1:10,000 with a carrier frequency of aa high as 1:20. Clinical signs, 
which present during childhood or early adulthood, are macular atrophy, loss of 
central vision, and yellow-white flakes at the level of RPE [78]. Loss of function 
mutations usually give rise to a severe and early onset disease, while missense 
mutations have been associated with late-onset and milder phenotype. Variants 
in ABCA4 are also associated with RP and CRD, however allelic heterogeneity 
makes genotype-phenotype correlations challenging [78].  
1.5.2 Syndromic inherited retinal dystrophies 
1.5.2.1 Usher syndrome 
The most common form of syndromic RP is Usher syndrome (USH), first 
described by the Scottish ophthalmologist Charles Usher in 1914, in which 
hearing loss combines with visual loss, and occasional balance problems. It has 
a prevalence of 1-4 per 25,000 people [44, 79, 80]. USH can be classified in 
three types, based on the clinical symptoms. USH type I (USH1) (MIM: 276900) 
patients are defined as having congenital severe-to-profound deafness, 
vestibular areflexia and onset of RP within the first decade of life. Six genes 
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have been associated with Usher syndrome type I, MYO7A [81-83], USH1C 
[82, 84-86], PCDH15 [87-89], CDH23 [90-92], USH1G [93, 94], CIB2 [95], 
ESPN [96]. USH2 (MIM: 276901, 611383, 605472) patients display congenital 
moderate-to-severe hearing loss, normal vestibular function and onset 
of RP within the second decade of life. The most common gene mutated is 
USH2A [97-99] however, it may be also caused by mutation in ADGRV1 [100], 
and DFNB31 [101]. Patients affected by USH3 (MIM: 276902, 614504) have 
hearing loss, vestibular dysfunction, with variable onset of RP [102]. Mutations 
in genes CLRN1 [103] and HARS [104] have been associated with this disease, 
as well as mutation in ABDH12 which has also been associated with PHARC 
(neurodegenerative disease involving polyneuropathy, hearing loss, ataxia, 
retinitis pigmentosa and cataract) and USH3 [105, 106]. Mutation in CEP250 
[107] and CEP78 [108] genes were reported as causing atypical USH. Most of 
the genes involved in the development of Usher syndrome encode for cilia 
components (Fig. 1.6) (Appendix A).  
1.5.2.2 Ciliopathies 
Ciliopathies are a group of disorders involving genes encoding for components 
of the primary cilia, which can manifest with a variety of features including 
retinal, renal, and cerebral abnormalities. Bardet-Biedl syndrome (BBS) was 
firstly described by Georges Bardet and Arthur Biedl in the early 1920s. BBS 
(MIM: 209900) is the second most common form of syndromic RP with an 
estimated prevalence of 1:100,000 people, which tends to be higher in 
populations with a high degree of consanguinity. It is a heterogeneous 
autosomal recessive ciliopathy characterised by RP, obesity, kidney 
dysfunction, polydactyly, behavioural dysfunction, and hypogonadism. These 
symptoms may also be associated with developmental delay, hypertension, 
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speech disorders, anosmia, strabismus, and dental anomalies. Twenty-one 
genes are associated with this group of diseases: BBS1 [109], BBS2 [110, 111], 
ARL6 [112, 113], BBS4 [114], BB5 [115, 116], MKKS [117, 118], BBS7 [119], 
TTC8 [120], BBS9 [121], BBS10 [122, 123], TRIM32 [124], BBS12 [125], MKS1 
[126], CEP290 [126], WDPCP [127], SDCCAG8 [128], LZTFL1 [129], BBIP1 
[130], IFT27 [131], IFT172 [132], CEP19 [133], and C8orf37 [134, 135] 
(Appendix A). The majority of these genes encode for components of the 
BBSome, an octameric protein complex, part of the basal body, involved in the 
cargo trafficking to the primary cilium [136]. In some patients more complex 
inheritance patterns have been indicated involving the interaction of multiple 
mutations and distinct BBS loci, in particular it has been proposed that BBS1, 
BBS4 and MKKS loci contributes to the triallelic inheritance [137-139], which 
modify the severity of phenotype and the age of onset of BBS [140]. 
Additionally, the hypomorphic variant p.Cys470Tyr in the CCDC28B gene has 
been shown to modify the severity of BBS primarily due to mutations in other 
BBS-associated genes [141]. Similarly, sequence alterations in MKS1, 
TMEM67, and WDPCP [127] genes, involved in ciliogenesis, may also modify 
the expression of BBS phenotypes.  
Alström syndrome (ALMS) is a recessive disease with a similar manifestation of 
BBS however, in ALMS progressive sensorineural hearing loss is often present 
alongside cone-rod dystrophy, nystagmus, photophobia, cardiomyopathy, 
insulin resistance and type 2 diabetes, progressive renal disease, and 
hypogonadism. Mutations in ALMS1, a gene encoding a centrosomal-
associated protein, have been associated with this disease, most of the 
pathogenic variants that have been identified are frameshift or nonsense [142, 
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143]. ALMS incidence is less than one per million in the general population 
[143]. 
Joubert syndrome (JBTS) is characterised by the “molar tooth sign”, a specific 
and recognisable mid-hindbrain malformation, hypotonia, ataxia, intellectual 
disability, oculomotor apraxia, retinal dystrophy, renal disease, ocular 
colobomas, episodic tachypnoea, and other abnormalities. JBST prevalence is 
between 1:80,000 and 1:100,000 [144]. Thirty-four genes have been associated 
to JBTS, and a study on 375 families with JBTS identified CCD2D2A, AHI1, 
C5orf42, CEP290 and TMEM67 as the most commonly mutated [145]. 
Meckel-Gruber syndrome (MKS) phenotypically overlaps with JBTS, affected 
individuals show occipital encephalocele, cystic dysplastic kidneys, polydactyly, 
retinal dystrophy and other minor features. The worldwide incidence is 
1:135,000 however, in consanguineous population is about 1:3500 [146]. 
Seventeen genes associated with this disease, with mutations in MKS1 
accounting for 7% of MKS cases and mutations in TMEM67 account for 16% of 
cases [146].  
Senior–Løken syndrome (SLS) is an oculo-renal syndrome with a prevalence of 
1:1,000,000. Classical signs are nephronophthisis and LCA, mutations in 
NPHP5 and CEP290 are associated with greater propensity of RP. However, in 
most of the cases linked with mutations in other NPHP genes, mild RP is 
diagnosed in the first decade of life, [147]. Currently, 10 genes have been 
associated with this disease [148]. 
1.5.2.3 IRDs with other systemic features 
Retinal dystrophies can occur as a consequence of many other disorders, in 
which retinal involvement may be secondary and highly variable in presentation. 
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In this landscape, mitochondrial disorders are one of the most common group of 
diseases, affecting 1:5000 adults [149]. Mitochondrial diseases, caused by 
mutations in the mitochondrial genome, affect energetic metabolism and 
manifest with a wide range of systemic features, neurological symptoms often 
being the principal manifestation. Retinal involvement is a variable feature and 
might manifest as ‘salt and pepper’ changes in the periphery to central vision 
loss. Mitochondrial disorder that include retinal dystrophy as a part of the 
associated clinical phenotype include: NARP (neuropathy, ataxia and RP) 
caused by mutations in MT-ATP6; MELAS (mitochondrial encephalomyopathy, 
lactic acidosis and stroke-like episodes) secondary to mutations in MT-TL1 and 
Kearns-Sayre syndrome (KSS) caused by a large-scale deletion in the 
mitochondrial DNA [150]. 
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Figure 1.6 Schematic representation of some genes/proteins causing 
retinal dystrophies. For the complete list of genes and their function see 
Appendix A. Image created with BioRender. 
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1.6 IRD treatment 
Recently, several therapies for IRDs have been developed, some of which are 
now in clinical trials, while other have been approved. The first gene therapy for 
RPE65 was described by Acland et al in 2001 [151], where the adeno-
associated vector AAV2 injection was successfully performed on dogs affected 
by RPE65 retinopathy. The success of the canine and (later developed) murine 
models led to the advancement of clinical trials. In 2017, the FDA approved the 
first gene therapy, Luxturna, to treat RPE65-associated LCA; the therapy is 
based on an AAV for biallelic replacement of RPE65 (AAV2-hRPE65v2) 
delivered by subretinal injection [152]. Results of the trial showed that Luxturna 
was able to improve light sensitivity, visual fields, and reduce night blindness in 
patients with RPE65 [152].  Moreover, gene therapies for LCA caused by 
mutations in AIPL1, RPGRIP1, LRAT and RDH12 are currently at various 
stages of clinical trials [62]. 
RNA therapies such as antisense oligonucleotide and RNAi have proved 
successful when a gene mutation in an intron-exon splice site leads to the 
presence of transcripts with a cryptic exon. An example of this includes the 
CEP290 c.2991+1655A>G alteration associated with LCA. Treatments with the 
antisense oligonucleotide QR-110 showed restoration of the correct mRNA 
transcript and function of human cilia in optic cups [153, 154]. Currently, QR-
110 is in phase III clinical trial. Similarly, other antisense oligonucleotides are in 
development/clinical trial for USH2A c.7595-2144A>G causing Usher 
syndrome, RHO Pro23His causing adRP, and ABCA4 c.5461-10T>C causing 
Stargardt disease (source: https://www.proqr.com/pipeline/). 
Another therapeutic avenue currently being explored is the transplant of human 
embryonic stem cells (hESC) or human-induced pluripotent stem cells (hiPSC)-
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derived RPE, some of these therapies are now in clinical trials for RP, Stargardt 
disease and age-related macular degeneration (AMD), and have shown to 
improve vision in some patients [155]. In particular, clinical trials using hESC-
derived RPE cells for the treatment of Stargardt have to date proved safe, and 
improved vision and showed subretinal hyperpigmentation probably related to 
the release of pigment of transplanted cells [156, 157]. Unfortunately, use of 
hiPSC from the same patient means that the genetic defect needs to be 
corrected before the autologous transplant and might be achievable for RPE, 
however, transplantation of hiPSC-derived photoreceptors still faces many 
challenges due to low transplantation efficacy and inaccurate host-graft 
synapses [158]. 
Supplementations of vitamin A, E, DHA (docosahexaenoic acid), lutein, and 
beta-carotene have been tested in patients with RP and Best disease, and only 
supplementation with vitamin A, lutein and beta-carotene showed small 
beneficial effects on the progression of RP [159].  
1.7 Next-generation technologies for gene discovery 
The completion of the Human Genome Project [160] opened up new avenues 
for studying human disease at the molecular level. Moreover, the development 
of high throughput genomic techniques has paved the way for the discovery of 
new genes causing inherited diseases, with a significant reduction of costs. 
Geographical and cultural isolation, and unions between individuals from the 
same community, has led to genetically distinct populations which may have an 
increased prevalence of certain inherited autosomal recessive disorders, 
typically due to the accumulation of regional founder genetic variants. This 
‘founder effect’ happens when a pathogenic genetic alteration occurs in a 
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founder community member, and is transmitted to subsequent generations 
becoming stably maintained in the population, leading to an increased 
prevalence of associated diseases. Determination of regional distribution of 
founder mutations helps scientists and clinicians to establish specific clinical 
testing and management strategies to target to the specific genetic variants 
involved [161]. Affected individuals originating from such populations are 
typically homozygous for the same ancestral pathogenic genetic variant, but 
also for an extended adjacent genomic DNA segment (haplotype) on which the 
variant first arose in the ancestral founder individual. This provides a particularly 
powerful means to map candidate loci for autosomal recessive genes via whole 
genome single-nucleotide polymorphism (SNPs) genotyping and autozygosity 
mapping. Whereas other homozygous stretches of DNA (runs of homozygosity; 
ROH), present in the genome will be shared randomly among unaffected and 
affected siblings, autozygous genomic regions which house the causative 
homozygous founder mutation will be shared exclusively and consistently 
amongst affected individuals [161, 162]. Genome-wide SNP mapping is often 
accompanied with a next-generation sequencing (NGS) technology such as 
whole-exome sequencing (WES) [162] to identify the specific causative genetic 
variant. Whole-exome sequencing enables investigation of protein-coding DNA 
sequences, exons and splice sites (and nearby intronic material), which 
together account for 1-2% of the whole genome. Sequence variants in the 
exome and associated intron/exon splice junctions are the most common cause 
of Mendelian disease accounting for ~85% of disease, for which missense and 
nonsense mutations account for ~60% of cases [163, 164]. Polymorphisms in 
non-coding genomic regions, such as non-coding elements and non-coding 
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RNAs, can be detected with whole-genome sequencing (WGS) however, 
assessing the functional significance of such mutations remains challenging. 
NGS panels specific for IRDs are also often used in the clinical setting, for 
example the Manchester Centre for Genomic Medicine offers an NGS mutation 
scan panel of 175 genes known to cause non-syndromic and syndromic IRDs. 
Interestingly, the panel does not cover RPGR-ORF15 as it is a highly repetitive 
region and the NGS is not able to sequence this region effectively, therefore 
dideoxy sequencing is necessary to uncover genetic alterations in that region.  
1.8 Eye diseases in Pakistan 
Pakistan (Fig. 1.7) is one of the largest developing countries in South Asia, with 
a population of 197 million people. Non-syndromic RP is considered one of the 
most common causes of inherited childhood blindness in the [58] South Asian 
population, encompassing 20% of cases in Pakistan [165]. A systematic review 
published in 2017 reported that the most common pattern of inheritance of 
retinal diseases in South Asian populations is autosomal recessive, with half of 
the genetic mutations reported to cause non-syndromic RP present in Pakistan 
[166] however, the lack of a proper collection of variants identified in Pakistan 
as associated with disease does not allow to have a detailed overview on the 
genetic causes of IRDs. The cultural and genetic make-up of Pakistan stems 
from the historical partition and then re-location of Indian Muslims, and later the 
immigration of populations from Afghanistan, Iran, and Bangladesh. This 
cultural diversity is reflected in the genetic diversity of each community, with 
distinct founder mutations being present in each region. This geographical and 
cultural isolation, and specific marriage practices typically within communities 
(first-cousin marriages reported to account for 50-70% of the total marriages in 
Pakistan), has led to numerous genetically distinct communities in which there 
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may be a high prevalence of certain inherited autosomal recessive disorders 
typically due to the accumulation of regional founder variants [167, 168]. While 
some papers report the exact regional location of affected individuals or 
families, many have failed on this, nevertheless the Punjabi population seems 
the more studied [169]. 
The isolation of these communities sometimes leads to atypical inheritance or 
intra-familiar locus heterogeneity which has been found associated with a 
cohort of Pakistani families with presumed autosomal recessive hearing loss 
[170]. It has also been found that in these communities where high rate of 
pathogenic variants are present due to the specific marriages pattern and 
geographical constraints, it is possible to find families in which the co-
occurrence of variants in two different genes segregate with the disease [171]. 
Similarly, compound heterozygous variants have been known to cause IRDs in 
several populations [172, 173], including Pakistani [174] where the there is an 
elevated carrier frequency in the general population [175].  
Isolation of certain communities in rural and remote areas with limited access to 
healthcare system and ophthalmic services, as well as limited possibilities to 
afford expensive diagnostic and genetic investigation, often makes the 
diagnosis of inherited ocular diseases challenging. This is often compounded by 
the highly heterogeneous nature (phenotypic and genetic) of inherited 
dystrophies. In this setting, knowledge of the community-relevant founder 
mutations is vital for providing improved care, counselling, and targeted genetic 






Figure 1.7 Map of Pakistan that highlight the major ethnic groups for each 
region https://en.wikipedia.org/wiki/Ethnic_groups_in_Pakistan 
 
1.9 Aims of this thesis 
While previous genetic and molecular studies have improved medical and 
scientific knowledge of the causes and biological basis of inherited retinal 
disease, a great deal remains to be learned in this area. However, recent 
progress in defining the molecular mechanisms underlying hereditary ocular 
disorders has proven to be instrumental for the development of personalised 
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therapies. Additionally, genomic knowledge of retinal disease is important to aid 
diagnosis and counselling due to overlapping phenotypes, and clinical 
heterogeneity, of rare retinal diseases. Therefore, a molecular genetic diagnosis 
is invaluable in aiding patient management, and in defining therapeutic options.  
The overarching aim of this thesis is to improve understanding, and 
characterise the genetic and phenotypic spectrum, of genetic retinal diseases in 
Pakistan while further improving scientific understanding of the genetic and 
biological basis of these conditions. The key aims of this study were: 
1. To define and confirm a new cause of autosomal recessive RP due to a 
founder mutation of the CLCC1 gene identified in families from Pakistan.  
2. To learn more about the molecular role of CLCC1, and pathomolecular 
basis of CLCC1-associated RP. 
3.  To more comprehensively characterise the molecular spectrum of 
inherited retinal diseases in Pakistan and relate specific pathogenic 
variants to particular regions and communities, to facilitate the future 
development of efficient and targeted genetic testing strategies to enable 




















CHAPTER 2 MATERIALS AND METHODS 
2.1 Buffers, reagents and stock materials 
All general-purpose chemicals and alcohols were purchased from Fisher 
Scientific and Sigma-Aldrich. All solutions for cell culture were supplied by 
Lonza, except for sera, Neurobasal media, DMEM:F12 Glutamax, and B27 
supplement which were obtained from Gibco. 
Plasticware for tissue culture was acquired from Greiner Bio-one and other 
general laboratory consumables purchased from Fisher Scientific. Kits for DNA 
gel extraction, PCR purification, Miniprep and Midiprep were purchased from 
Qiagen; restriction enzymes were supplied by Promega and New England 
Biolabs (NEB). 
Plasticware for PCR were purchased from 4titude and StarLab. 
Buffers used were reported in Table 2.1 
Table 2.1 Solutions used in this study 
4% PFA 4% (w/v) paraformaldehyde, in PBS, pH adjusted to 7.4 
4% PFA + 0.2% 
Glutaraldehyde 
4% (w/v) paraformaldehyde, 0.2% (v/v) glutaraldehyde, in PBS, 
pH adjusted to 7.4 
3T3 medium 10% (v/v) heat-inactivated calf serum (HI BCS), 100 U/ml 
penicillin, 100 µg/ml streptomycin, in DMEM 
Ampicillin 100 mg/ml in dd.H20 
Destain 40% (v/v) MeOH, 10% (v/v) acetic acid, in dd.H20 
DNA loading 
buffer 
30% (v/v) glycerol, 0.25% (w/v) bromophenol blue, 
0.25% (w/v) xylene cyanol 
HE lysis buffer 25 mM HEPES, 5 mM EDTA, 1 mM MgCl2, 10% (v/v) Glycerol, 
1% (v/v) Triton X-100, 100 μM PMSF 
HEK293 medium 10% (v/v) heat-inactivated foetal bovine serum (HI FBS), 100 
U/ml penicillin, 100 µg/ml streptomycin, in DMEM 
IP lysis buffer 20 mM Tris-HCl pH 8.0, 150 mM KCl, 0.1% Triton X-100, 1X 
complete protease and phosphatase inhibitors 
Kanamycin 50 μg/ml in dd.H20 
LAB Buffer 10 mM Lithium acetate, 10 mM Boric acid  
Laemmli sample 
buffer 
10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) β-2 mercaptoethanol, 
0.002% (w/v) bromophenol blue, 0.125M Tris-HCl (pH 6.8) 
LB agar 15 g/L agar, 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
LB broth 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
Lysine block 5% (v/v) horse serum, 5% (v/v) goat serum, 50 mM lysine, 0.2% 
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180 μM HEPES, 0.5 mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, 2% (v/v) B27 supplement, in Neurobasal 
media, Phenol Red-free, glutamine-free 
Running buffer 25 mM Tris-base, 19 mM glycine, 0.1% (w/v) SDS 
SHSY-5Y 
medium 
10% (v/v) heat-inactivated foetal bovine serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin, in DMEM:F-12 Glutamax 
Slagboom 
buffer 
5% (w/v) SDS, 1X TEN buffer 
SOC  10 mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 20 mM Glucose, 10 
mM MgCl2, sterilised by push filtration 
STE buffer 250 mM Sucrose, 5 mM Tris, 2 mM EGTA, pH 7.4 
TAE 40 mM Tris-base (pH 7.6), 20 mM acetic acid, 1 mM EDTA 
TBS 20 mM Tris base, 150 mM NaCl 
TBS-T 20 mM Tris base, 150 mM NaCl, 0.1% (v/v) Tween-20 
TEN buffer 10 mM Tris base, 1 mM EDTA, 100 mM NaCl 




2.2 Family recruitment and sample acquisition 
Research was carried out in compliance with the Code of Practice for Human 
Tissue and Research (code E) provided by the Human Tissue Authority (HTA), 
which defines human tissue as relevant material consisting of, or containing 
cells, therefore includes blood samples.  All blood samples, and subsequent 
DNA extractions, used in this project were used and stored in HTA-licensed 
premises with research carried out in accordance with the Human Tissue Act 
2004.  
Recruitment to this project requires submission of the appropriately signed 
consent (projects approved by Ethical Committees of International Islamic 
University, Islamabad, Pakistan; FBAS-2018-3598, Khyber Medical College; 
8936, the Institute of Biomedical and Genetic Engineering; Ethical board of 
University of Health Sciences, Lahore, National Centre of Excellence in 
Molecular Biology and National Institutes of Health, CNS USA, and the 
University of Exeter Medical School), clinical details and a blood or buccal 
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sample. Signed consent is given, in accordance with the HTA’s code of 
practice, only when individuals, or parents of individuals, feel they are 
sufficiently informed, about the purpose of the research, how their samples are 
to be stored and used and satisfied with the purpose of the research in which 
they are to be involved. All the individuals participating to this study were 
phenotypically assessed by local clinicians. Medical history and documentation 
of symptoms was collected when possible. For affected individuals, visual acuity 
testing using Snellen charts, colour vision testing using Ishihara charts and 
funduscopic examination by direct ophthalmoscopy was performed by clinicians 
locally. Additional targeted clinical investigations were undertaken subsequent 
to molecular genetic studies to clarify the clinical significance of any candidate 
variants identified. 
2.3 Data management 
On receipt of blood or DNA samples from their respective collection locations, 
each sample was assigned a sample ID, and this as well as clinical and 
molecular information was recorded in a password protected database. The 
vessels containing the samples were anonymised and labelled with the relevant 
sample ID.  
2.4 DNA extraction from whole blood 
Human DNA was extracted from whole blood using ReliaPrepTM Blood gDNA 
Miniprep system (Promega). Upon arrival blood samples were stored at -20 °C 
and thawed at room temperature. Samples were mixed for 10 minutes (min) in a 
rotisserie shaker and 200 µl of blood were mixed with 20 µl of Proteinase K. 200 
µl of cell lysis buffer (CLB) were added to the tube, the content vortexed for 10 
seconds (sec), and incubated at 56 °C for 10 min. Two hundred fifty µl of 
binding buffer (BBA) were added to the tube and mixed by vortexing for 10 sec. 
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The tube content was added to the ReliaPrep™ Binding Column, spun for 1 min 
at maximum speed and the flow-through was discarded. The column was 
moved into a clean collection tube and 500 µl of column wash solution (CWS) 
were added to the column and centrifuged for 3 min at maximum speed, the 
flow-though was discarded. This step was carried out 3 times. The column was 
placed in a clean microfuge tube and the DNA was eluted by addition of 50 µl of 
nuclease-free water to the column that was incubated for 1 min and then 
centrifuged for 1 min at maximum speed. 
The yield and quality of the DNA was assessed using the Nanodrop 200c UV-
Vis Spectrophotometer (Thermo Scientific), by measuring the absorption at 260 
nm (A260) of 1 µl of undiluted sample. The NanoDrop software automatically 
calculated the concentration (in ng/μl) using a modified Beer-Lambert equation. 
DNA purity was assessed simultaneously by measuring absorption at 280 nm 
(A280). A ratio of A260 to A280 of ~1.8 indicates “pure” DNA. A secondary 
measure of absorbance at 230 nm (A230) was also taken, values for a “pure” 
nucleic acid are often higher than the respective A260/A280 values being within 
the range of 1.8-2.2. 
2.5 Primer design 
DNA sequence was obtained from UCSC Genome browser 
(https://genome.ucsc.edu/), and PCR primer pairs were designed using Primer 
3 (www.bioinformatics.nl) following these rules: 
• Primer size were 18-25 bp.  
• Melting temperature was kept as similar as possible for both primers. 
• Where possible the guanine-cytosine (GC) content was kept below 60%. 
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• In silico PCR analysis was performed to assure the 100% matching with 
the desired sequence. 
• Primer sequences were not chosen if DNA stand contained common 
SNPs. 
• Primers sequences were not chosen if they bind repeated sequences. 
2.6 Optimisation of PCR conditions 
The optimal annealing temperature for oligonucleotide primers during PCR was 
determined using a temperature gradient of 52-64 °C across the PCR block of 
an Eppendorf Mastercycler thermocycler Ep Gradient. Twelve PCR reactions 
for each primer pair were set, using good quality control DNA. Each reaction 
had a different annealing temperature which increased incrementally across the 
PCR block from 52 °C to 64 °C, by approximately 1 °C.  PCR conditions, as the 
primer concentration or the addition of 10% (v/v) dimethyl sulfoxide (DMSO) if 
the GC content was above 60%, were altered if the PCR product produced 
weak or no product across the range of temperatures.  
2.7 Polymerase chain reaction (PCR), agarose gel electrophoresis and 
dideoxy sequencing  
Primers were purchased from Integrated DNA Technologies (IDT) and 
resuspended at 100 µM with molecular biology grade water. The PCR reaction 
mixture contained 10-20 ng of template DNA, 1x DreamTaq buffer (Thermo 
Fisher), 10 mM dNTPs (Solis BioDyne), 5 pM/µl of each primer, and appropriate 
units of DreamTaq polymerase. The mixture was placed in the thermocycler 
(Eppendorf Mastercycle ep Gradient S), following a ‘touchdown’ PCR protocol. 
This method improves the binding specificity of primers and helps to avoid 
amplification of other genomic regions. The method is based on incrementally 
lowering the annealing temperature by 2 °C every two cycles from an initial 
68 
 
temperature that is 4 °C greater than that of the annealing temperature (Tm) 
until the desired Tm is reached (Table 2.2). 




The Tm for each pair of primers is reported in Appendix F. The elongation step 
was performed for 30 sec for PCR product <500 bp or 45 sec for PCR products 
with a size between 500-1000 bp.   
After the PCR was performed, the presence of a single amplicon was verified 
on a 1.0% (w/v) agarose gel in LAB buffer containing ethidium bromide (Fisher 
Scientific), using 1 kb DNA plus ladder (Thermo Fisher) as reference. 
For Sanger sequencing 5 µl PCR product was purified from unwanted primers 
and nucleotides using 2 µl Exonuclease I - Shrimp Alkaline Phosphatase 
(ExoSap) (NEB). The mixture was heated at 37 °C for 30 min for digestion and 
then at 95 ˚C for 5 min to inactivate the enzyme. Sanger sequencing was 
performed by Source Bioscience. 
Number of cycles Temperature (°C) Time (Sec) 
1 95 (denaturation) 120 
2 95 (denaturation) 





2 95 (denaturation) 











1 72 (elongation) 300 
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2.8 Single nucleotide polymorphism (SNP) genotyping 
SNP genotyping was carried out using Illumina CytoSNP-12v2.1 array following 
the Infinium® HD Assay Ultra manual protocol and assistance from Dr Barry 
Chioza, University of Exeter.  
The protocol is undertaken over three days and the assay requires 200 ng of 
DNA per sample at a concentration of 50 ng/µl with each chip holding 12 
samples. 
Day 1: DNA samples were denatured using a buffer containing 0.1N NaOH and 
then neutralised in preparation for amplification. Samples were incubated 
overnight at 37 oC to amplify.  
Day 2: Amplified DNA samples were enzymatically fragmented using the 
Illumina FMS buffer which utilises end-point fragmentation (to avoid over-
fragmentation). The DNA was then precipitated using 2-propanol and the 
Illumina solution PM1, then collected via a 20 min centrifugation carried out at 4 
oC. Following resuspension, using the Illumina solution RA1, the DNA was 
denatured at 95 oC for 20 min. The denatured samples were cooled then 12 µl 
of each sample was loaded onto the BeadChip. This was then incubated in the 
Illumina Hybridisation Oven at 48 oC for a minimum of 16 h (but no more than 
24 h).  
Day 3: The BeadChips were prepared for the staining process. This involved 
washing away any un-hybridised and non-specifically hybridised DNA using the 
PB1 Illumina buffer. Following the wash step, labelled nucleotides were 
dispensed onto the BeadChip through the Flow-Through Chambers to perform 
single-base extension of primers hybridised to the DNA. The BeadChips where 
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then stained using the Illumina XStain HD BeadChip process then imaged on 
an Illumina iScan Reader.  
The iScan Reader uses a laser to excite the fluorophores of the single-base 
extension product on the beads of the BeadChip. Light emissions from the 
fluorophores were recorded by the reader, taking high-resolution images of the 
BeadChip. The data from these images were analysed using the Illumina 
GenomeStudio Integrated Informatics Platform allowing for the genotype to be 
determined. Further analysis was then undertaking by exporting the data into 
Microsoft Excel and using a macro to highlight notable regions of homozygosity 
(>1Mb) and to compare genotyping across samples.  
2.9  TruSight One sequencing panel 
The Illumina TruSight One capture kit (Illumina 5200 Illumina Way San Diego, 
California USA) targets 4811 clinically relevant genes. Next-generation 
sequencing was performed on the NextSeq 500 platform. Bioinformatic pipeline 
was performed as described in O’Gorman et al. 2019 [176]. FastQ data were 
aligned to the hg38 human reference genome with BWA-MEM (v0.7.12). GATK 
version 3.720 was used to call SNPs and short indels in a multisample VCF file. 
Annotation was performed using ANNOVAR v2015Dec to collate variant 
consequence, variant allele frequency (1000 Genomes Project, Exome 
Sequencing Project and Exome Aggregation Consortium) and pathogenicity 
scores with CADD and MaxEntScan for splice site variants. Further annotation 
was included from InterVar (2018) and Human Gene Mutation Database. 
Coverage was determined using SAMtools v1.3.1 and BEDtools v2.17.0. 
Variants were categorised on pathogenicity, and defined pathogenic in ClinVar. 




2.10 Whole-exome sequencing (WES) and Whole-Genome Sequencing 
(WGS) 
WES and WGS were performed by BGI Tech Solutions (Hong Kong) on the 
BGISEQ-500 sequencing system. Typically, a total of 1,403,229,858 clean 
reads were aligned to the human reference genome (GRCh37) using the 
Burrows-Wheeler Aligner (BWA), with on average, 99.79% of the whole 
genome excluding gap regions had at least 99.40% had at least 4X coverage 
and 98.20% at least 10X coverage. Average sequencing depth was typically 
~45X. 
The FASTQ files obtained from BGI were mapped to the reference genome 
using the Burrows-Wheeler Aligner BWA-MEM algorithm (version 0.7.17) [177, 
178]. This algorithm was used due to its improved performance, compared to 
other BWA algorithms, being faster and more accurate than previous versions 
as well as providing higher quality queries. The sequence alignment map 
(SAM), was converted to binary SAM format (BAM) to produce a smaller file 
and to increase the processing speed. 
Duplicate reads were marked by Picard (version 2.15). The BAM file was then 
realigned, to account for indels, with variants called using GATK-
HaplotypeCaller (version 3.70) and subsequently quality filtered based on; 
mapping quality, strand bias, the average position of a variant in a read and 
SNP quality. The variant call file (VCF) was annotated using the Alamut 
Software (version 1.8) Suite. Copy number variants were called using 
SavvyCNV (https://github.com/rdemolgen/SavvySuite) and ExomeDepth.  
Variants were quality control (QC) checked and filtered for rare, non-
synonymous exonic or splice variants, with a population frequency of <0.005 in 
control databases (including the Genome Aggregation Database; gnomAD, the 
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Exome Aggregation Consortium; ExAC, and the 1000 Genomes Project) 
(Interactive Biosoftware).  
2.11 Constructs 
Plasmids for expression studies (Table 2.3) were subcloned by PCR into a 
backbone containing the chick β-actin promoter, pCAβ, which allows expression 
in chick neurons (gift of Dr. J. Chilton). An intermediate step using the shuttle 
vector pILES, based upon pBlueScript, was necessary for the addition of 
restriction sites for convenient cloning into pCAβ. Maps of expression vectors 
and cloning schemes can be found in Appendix C. 
 
Table 2.3 Constructs. All fluorescent proteins were fused to the N-terminus of 
the protein of interest except where an asterisk (*) indicates fusion to the C-
terminus. CMV= cytomegalovirus, CAG = (C) Cytomegalovirus early enhancer, 
(A) promoter first exon and intron of chicken beta-actin gene, (G) splice 
acceptor of the rabbit beta-globin gene. 




J.Chilton  CLCC1 FLAG* CAG Ampicillin 
J.Chilton  CLCC1-
Asp25Glu 
FLAG* CAG Ampicillin 
J.Chilton  CLCC1 eYFP CAG Ampicillin 
J.Chilton  CLCC1-
Asp25Glu 
eYFP CAG Ampicillin 
IHC  CLCC1 eYFP and 
FLAG 
CAG Ampicillin 
IHC  CLCC1 
isoform 2 
eYFP CAG Ampicillin 
IHC  CLCC1 
isoform 3 
eYFP CAG Ampicillin 
IHC  CLCC1 
isoform 4 
eYFP  CAG Ampicillin 
IHC  KDEL mCherry CAG Ampicillin 
J.Chilton  R-Pre RFP CAG Ampicillin 
A.Ververis  SigmaR1 eGFP CMV Ampicillin 
Addgene 48138 hSpCas9 eGFP CBh Ampicillin 
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Figure 2.1 Schematics of fusion proteins reported in Table 2.3 
 
 
2.12 Plasmid preparation 
All work with live bacteria was carried out under sterile conditions, using a 
category 2 biological safety cabinet, sterile consumables and sterile media. 
Plasmids ordered from Addgene arrived as a live bacterial stab culture, they 
were streaked out onto Luria agar plates containing 1 µg/µl of ampicillin. Plates 
were incubated overnight at 37 °C for the formation of the colonies. 
Colonies were selected from the agar plate and individually cultivated in 5 ml of 
LB broth supplemented with the appropriate antibiotic in a 20 ml sterile bacterial 
tube (VWR), shaken at 220 rpm overnight at 37 °C. 
To assess the presence of the correct plasmid, 1.5 ml of bacterial culture was 
collected and centrifuged at 17,900 x g for 1 min, the supernatant was 
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discarded. The QIAprep Spin Miniprep protocol was followed (Qiagen): 250 µL 
of P1 solution (50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 µg/ml RNAse A, 
without LyseBlue reagent) was added to the tube and the bacterial pellet was 
resuspended by vortexing. 250 µL of P2 solution (200 mM NaOH; 1% w/v SDS) 
was added and tubes inverted 6 times, bacterial lysis was neutralised with 350 
µL of N3 buffer (a proprietary acetate-buffered solution containing chaotropic 
salt). The solution was then centrifuged at 17,900 x g for 10 min to eliminate the 
cellular debris, the supernatant was collected and placed in a QIAprep spin 
column and centrifuged at 17,900 x g for 1 min. The flow-throw was discarded 
and the column washed by addition of 750 µL of Buffer PE (proprietary solution 
with high ethanol and low salt concentrations). The column was again 
centrifuged at 17,900 x g for 1 min, the flow-through discarded, and the column 
was centrifuged as before to eliminate residual ethanol. The column was 
transferred to a clean microfuge tube and the DNA eluted with 50 µL of 
molecular biology grade water, the column was incubated 1 min before the final 
spin at 17,900 x g for 1 min. 
Midipreps were used to obtain high yields of plasmid DNA (approximately 0.3-
0.5 µg/µl), using HiSpeed Midi Prep Kit (Qiagen). Fifty µl of starter culture were 
diluted 1:1000 in 50 ml of LB broth with the appropriate antibiotic selection and 
grown overnight. Bacteria were spun at 4000 x g for 15 min and suspended in 6 
ml of pre-chilled Buffer P1. The cells were lysed by adding 6 ml of buffer P2, 
mixing by inversion 6 times and incubating for 5 min at room temperature. 
Precipitation of cellular debris was carried out using 6 ml of buffer P3 (3 M 
potassium acetate, pH 5.5) and the tube was inverted 6 times, the mixture was 
then added to a QIAfilter Midi Cartridge and incubated at room temperature for 
10 min.  At the same time the Qiagen HiSpeed Midi Tip was equilibrated with 
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the addition of 4 ml of Buffer QBT (750 mM NaCl; 50 mM MOPS, pH 7.0; 15% 
v/v isopropanol; 0.15% v/v Triton X-100), emptied by gravity. Cell lysate was 
pushed into the column where the lysate flowed through under gravity. The 
column was washed with 20 ml Buffer QC (1 M NaCl; 50 mM MOPS, pH 7.0; 
15% v/v isopropanol) and the DNA was eluted from the column adding 5 ml 
Buffer QF (1.25 M NaCl; 50 mM Tris-HCl, pH8.5; 15% v/v isopropanol). DNA 
was precipitated by the addition of 0.7 volumes of isopropanol, the tube was 
inverted 6 times to mix the components and incubated 5 min at room 
temperature. Precipitated DNA was pushed through a QIAprecipitator module 
and washed with 2 ml of 70% (v/v) ethanol. DNA was recovered by addition of 
750 µL of Buffer TE (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) 
The appropriate amount of DNA was precipitated using 2 volumes of 100% 
ethanol and 10% 3 M sodium acetate pH 5.2 for 30 min at -25 °C. The DNA was 
then centrifuged at 17,900 x g for 30 min, supernatant discarded, and once the 
ethanol had evaporated the DNA was resuspended in the appropriate amount 
of Buffer TE to obtain a final concentration of 1 µg/µl. 
Once the plasmid has been confirmed by restriction digestion the bacteria 
culture was stored in the form of a glycerol stock. Eight hundred µl of bacteria 
were added to 200 µl of sterile glycerol in a microfuge tube, mixed by vortexing, 
and stored at -80 °C. 
2.13 Restriction digestion 
Restriction digestion of plasmid DNA was carried out at 37 °C (or other optimal 
temperature for enzyme) for 1 h. One µg of plasmid DNA were mixed with 5.6 µl 
of water, 1 µl of the 10x buffer and 2-4 U of restriction enzyme. 
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2.14 Primers design for plasmid DNA 
All primers (Table 2.4) for cloning the gene of interest into pILES and pClink 
were designed having flanking sequences containing convenient restriction 
sites for restriction digest whilst following the general rules as described in 
Paragraph 2.5. 
 
Table 2.4 Primers used to clone the gene of interest into plasmids. 













































2.15 Polymerase chain reaction for amplifying plasmid DNA 
Plasmid DNA primers were designed to have flanking sequences containing 
restriction enzymes sites whilst following the rules described in paragraph 2.5. 
PCR was carried out in a total volume of 50 µl as follows: 100 ng of template 
DNA, 1X polymerase buffer, 200 µM dNTPs (NEB), 3 U Pfu polymerase 
(Promega), 25 pmol of each primer. The PCR was performed using the 
following programme: 95 °C for two minutes to denature the DNA, 30 sec of 
DNA strand melting, and 45 sec annealing step at 55 °C. The extension step 
lasted 1 min per Kb of final PCR product. Melting, annealing and extension 
steps were repeated 35 times, followed by a final heating to 72 °C for 10 min for 
the final extension. The PCR was performed using the SimpliAmp Thermal 
Cycler, Applied Biosystems by Life Technologies. A 5 μl aliquot was taken from 
the tube, combined with DNA loading buffer and subjected to electrophoresis on 
a 0.8 % (w/v) agarose gel in TAE buffer containing 1:20,000 SYBR Safe (Life 
Technologies) to verify that the amplicon was of the predicted size. The PCR 
product was purified from unwanted enzymes and nucleotides using QIAquick 
PCR purification kit before restriction digestion. One volume of PCR sample 
was mixed with 5 volumes of Buffer PB and 10 µl of 3 M sodium acetate pH 5.0. 
The mixture was placed in a QIAquick spin column and spun for 1 min at 17,900 
x g, the flow-through discarded and the column washed with 750 µl of Buffer 
PE, containing ethanol. The flow-though was discarded and the column spun for 
1 min at 17,900 x g to eliminate any residue of ethanol. The column was placed 




2.16 Plasmid DNA gel extraction 
After restriction digestion, plasmid DNA was run on a 0.8% (w/v) agarose gel in 
TAE buffer containing 1:20,000 SYBR Safe (Life Technologies) until DNA bands 
could be resolved and the appropriate fragment excised and placed into a 
microfuge tube. The DNA was purified using a QIAquick Gel Extraction Kit 
(Qiagen). Following the manufacturer’s instructions the volume of gel was 
estimated by weight 100 mg ≈ 100 µl. Three volumes of buffer QG were added, 
and the tube was incubated at 50 °C for 10 min to allow the agarose to melt. To 
ensure the correct pH of the mixture 10 µl of 3 M sodium acetate were added. 
The solution was placed into a QIAquick column and spun at 17,900 x g for 1 
min. The column was washed with 750 µL of Buffer PE (proprietary solution 
containing high ethanol and low salt concentrations) and spun at 17,900 x g for 
1 min. The flow-through was discarded and the column spun again at 17,900 x 
g for 1 min to remove the residual buffer.  The column was then transferred to a 
clean microfuge tube and DNA eluted in 30 µl of molecular biology grade water, 
by centrifugation at 17,900 x g for 1 min. 
2.17 Ligation 
To ligate DNA in the plasmid backbone the following mixture was used: 1 µl 10X 
T4 Ligase Buffer (500 mM Tris-HCl; 100 mM MgCl2; 10 mM ATP; 100 mM DTT; 
NEB); 2 U T4 DNA Ligase (NEB), 80 ng of restriction digest backbone and 240 
ng restriction digest insert. The mixture was incubated at 14 °C overnight. 
2.18 Bacterial transformation 
Forty µl of competent E.Coli DH5α (NEB) were thawed on ice and 1 µl of ligated 
DNA was added, and incubated for further 15 min on ice. Bacteria were heat 
shocked at 42 °C for 45 sec and immediately placed on ice for 2 min. Bacteria 
were added to LB broth supplemented with SOC (10 mM NaCl, 2.5 mM KCl, 10 
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mM MgSO4, 20 mM Glucose, 10 mM MgCl2) and placed in a shaker at 37 °C for 
1 hour at 225 rpm to allow the expression of bacterial proteins. The bacteria 
were centrifuged at 4000 rpm for 2 min, resuspended in 100 µl of media and 
plated in an agar plate containing the appropriate antibiotic. 
2.19 Embryonic chick retinal ganglion cell isolation and nucleofection 
Fertilized hens’ eggs (Gallus gallus) (Henry Stewart & Co. Ltd., Lincs.) were 
incubated in a humidified, forced-draft incubator (Lyon, USA) at 38 °C. Embryos 
were staged according to Hamburger and Hamilton, 1992 [179]. At embryonic 
day 7 (E7) the egg shell was punctured using sterile scissors and an aperture in 
the shell was made to allow the extraction of the embryo. The chicken embryo 
was placed in a sterile dish containing HBSS (Hank’s Balanced Salt Solution) 
Ca2+ and Mg2+-free media and the head was separated from the body using a 
sterile forceps. Normal development of head and limbs was assessed before 
proceeding with the dissection. Eyes were separated from the head using a 
forceps and the soft tissue surrounding the eye was removed. The retinal 
pigmented epithelium was gently separated from the retinal ganglion cell layer, 
the lens and the vitreous humor were carefully removed as well. The resulting 
white layer of tissue was the retinal ganglion cell (RGC) layer.  
Explants were centrifuged at 800 rpm for 3 min at room temperature (RT), 
HBSS aspirated and replaced with 1 ml of trypsin, the tube was placed at 37°C 
for 10 min to allow dissociation of the cells. Trypsin was inhibited by adding an 
equal volume of DMEM supplemented with 10% chicken serum, and cells were 
centrifuged at 1000 rpm for 5 min. Cells were resuspended in DMEM and 10% 
chicken serum and manually dissociated by trituration with a flame-polished 
glass Pasteur pipette. Cells were counted with a haemocytometer, and 5.0 x 
105 cells were resuspended in 20 µL of P3 Primary Cell Nucleofector solution 
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(Lonza) with 0.4 µg of DNA, transferred to the nucleocuvette strips and 
nucleofected using the 4D-Nucleofector system X-unit (Lonza), DR-114 
programme (parameters not disclosed by Lonza). Cells were removed from the 
strip and seeded in a 30 mm diameter plastic dish containing 2 ml of pre-
warmed Neurobasal medium (Phenol-red free, Glutamine free (Gibco)), 
supplemented with 180 μM Hepes (Sigma-Aldrich), 0.5 mM L-Glutamine, 10 
U/mL penicillin/streptomycin, and 2% B27 supplement, for 1h, to allow 
fibroblasts and other non-neuronal cells to adhere to the dish. The desired 
number of cells was then seeded on acid etched (1 M HCl, 1 hour at 65 °C), 
ethanol sterilised, 13 mm diameter glass coverslips (Karl Hecht, Thermo Fisher) 
treated with poly-D-Lysine (20 µg/ml, 30 min, room temperature) and Laminin 
(20 µg/ml, 1 hour at 37 °C).  RGC were cultivated overnight in fully 
supplemented Neurobasal media. After 24 h cells were fixed with a mixture of 
4% Paraformaldehyde and 0.2% Glutaraldehyde for 15 min at 37 °C. Fixative 
was removed and coverslips rinsed 3 times for 5 min each with 1XPBS.  
2.20 Cell line culture 
Each cell line was cultivated in its own medium as stated in the Table 2.1 and 
incubated at 37 °C, 5% CO2, and routinely passaged at 80-90% confluency. 
Cells were grown on 13 mm diameter glass cover slips and transfected with 
Lipotectamine LTX (Invitrogen) when 60-70% confluency was reached. 
Following the manufactures instructions plasmid DNA was combined with 
serum-free DMEM and incubated for 5 min at room temperature. The specified 
amount of Lipofectamine LTX was combined with the mixture and incubated 30 
min at room temperature. The mixture was then added to the culture media 
present in the dish and the cells were incubated for a further 18-20 h to allow 
expression of the transfected plasmid. 
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2.21 Cell treatments 
2.21.1 MitoTracker  
MitoTracker™ Red CMXRos (M7512, Thermo Fisher) was dissolved in DMSO 
and used at a final concentration of 150 nM, cells were treated for 15 min at 37 
°C. Cells were washed 3 times with 1X PBS and then fixed with 4% (w/v) of 
PFA. 
 2.21.2 ER stressors 
Thapsigargin (T-650; Alomone Labs) was dissolved in DMSO, cells were 
treated with a final concentration of 5 µM for 30 min at 37 °C. Tunicamycin 
(T7765; Sigma Aldritch) was dissolved in DMSO and cells were treated with a 
final concentration of 2 µg/ml for 30 min at 37 °C. 
2.21.3 Metabolic stressors 
2-Deoxy-D-glucose (2-DG) (D8375; Sigma Aldritch) was dissolved in NIH/3T3 
culturing media (Table 2.1) at a final concentration of 100 mM. Oligomycin A 
(75351; Sigma-Aldritch) was dissolved in DMSO and used at a concentration of 
50 µM. Lonidamine (1-(2,4-Dichlorobenzyl)-1H-indazole-3-carboxylic acid) 
(L4900; Sigma Aldritch) was dissolved in DMSO and used at a final 
concentration of 400 µM. 17-AAG (17-(Allylamino)-17-demethoxygeldanamycin) 
(A8476; Sigma Aldritch) was dissolved in DMSO and used at a final 
concentration of 100 nM. All these treatments were carried for 20 min at 37 °C. 
2.21.4 SigmaR1 agonist and antagonist 
PRE-084 hydrochloride (2-(4-Morpholinethyl) 1-phenylcyclohexanecarboxylate 
hydrochloride) (#0598; Tocris) was used as SigmaR1 agonist, while BD1047 
dihydrobromide (N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-
(dimethylamino)ethylamine dihydrobromide) was used as antagonist of 
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SigmaR1. Both of them were dissolved in DMSO and used at final 
concentration of 10 µM for 30 min at 37 °C. 
2.22 Freezing cell lines 
Cells were harvested using trypsin when plates were 70% confluent, and spun 
at 1000 rpm. Media was aspirated and cells were resuspended in freezing 
media containing 10% DMSO (Invitrogen), 20% FBS and 80% serum free 
DMEM and placed in cryovials (Starstead). Cryovials were inserted in Mr. 
Frosty (ThermoFisher) and kept at -80 °C for 24 h prior to long-term storage in 
liquid nitrogen. 
2.23 CRISPR/Cas9 gene editing 
sgRNA oligonucleotides were designed using Benchling (https://benchling.com/) 
to disrupt Exon 2 and Exon 3 of the human CLCC1 gene. sgRNA sequences 
(Table 2.5) were chosen based on the optimal prediction scores of on target 
and off target effects, and for the presence of the sequences in all known 
CLCC1 isoforms. Unique binding to the CLCC1 sequence was assessed with 
BLASTN (NCBI) (https://blast.ncbi.nlm.nih.gov) and BLAT (UCSC) 
(https://genome.ucsc.edu/). Oligonucleotides were purchased from Integrated 
DNA Technologies (IDT). 
Table 2.5 gRNA sequences 






caccGCCAGCAACAGACATTCACAA, 77.1 63.5 
Exon 2 
bottom 
aaacTTGTGAATGTCTGTTGCTGGC 77.1 63.5 
Exon 3 
top 
caccGTCATCAGCACATGACAAGTC 56.9 69.6 
Exon 3 
bottom 




 2.23.1 Annealing 
Oligos were reconstituted at 100 µM in ddH20 and annealed following the 
recipe: 1 µl sgRNA top, 1 µl sgRNA bottom, 1 µl of 10X T4 PKN Ligation buffer 
(700 mM Tris-HCl; 100 mM MgCl2; 50 mM DTT; pH 7.6; NEB), and appropriate 
units of T4 PKN ligase (NEB) (the PKN was used to phosphorylate the sgRNA, 
otherwise they are not able to be ligate with the plasmid). The thermocycler 
program followed the steps: 37 °C for 30 min, 90 °C for 5 min, ramp down to 25 
°C at 5 °C min-1, and then held at 25 °C infinite. 
2.23.2 Ligation 
Exon 2 gRNA was ligated into pSp-Cas9(BB)-2A-EGFP (PX458) (was a gift 
from Feng Zhang (Addgene plasmid # 48138 ; http://n2t.net/addgene:48138 ; 
RRID:Addgene_48138)) and Exon 3 gRNA was ligated into pU6-(BbsI)_CBh-
Cas9-T2A-mCherry (was a gift from Ralf Kuehn (Addgene plasmid # 64324 ; 
http://n2t.net/addgene:64324 ; RRID:Addgene_64324)) following the recipe: 100 
ng plasmid DNA, 2 µl gRNA diluted 1:200, 2 µl of 10X FastDigest Buffer 
(proprietary solution; Thermo Fisher), 1 µl of FastDigest Bpil (Thermo Fisher), 1 
µl 10mM DTT, 1 µm ATP, appropriated units of T4 ligase (NEB), 2 µl of 10X T4 
Ligation Buffer. Tubes were placed into the thermocycler and followed 6 steps 
of heat at 37 °C for 5 min, and 21 °C for 5 min. 
2.23.3 Digestion  
Bacterial transformation and minipreps were executed as described in sections 
2.12 and 2.16. 
The presence of gRNA inside the plasmid backbones was assessed with 
restriction digestion, using appropriate units of EcoRI (Promega) and FastDigest 
BpiI (Thermo Fisher) restriction enzymes and 1 µl of 10X Buffer H (900 mM 
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Tris-HCl; 100 mM MgCl2; 500 mM NaCl; pH 7.5; Promega), at 37 °C for 1 hour. 
The correct size of the DNA bands was assessed on a 0.8% agarose gel in TAE 
buffer.  
2.23.4 Nucleofection of SH-SY5Y cells 
At 80% confluency SH-SY5Y cells were washed with HBSS and harvested 
using trypsin for 5 min at 37 °C, collected in a centrifuge tube and centrifuged at 
1000 rpm for 5 min. Cells were resuspended in 5 ml of media and counted 
using a haemocytometer. One million cells per nucleofection were centrifuged 
and resuspended in 100 µL of SF Cell Line 4D-Nucleofector solution (Lonza) 
containing 2 µg total of a mixture of plasmid DNAs and transferred to the 
nucleocuvette vessel. Nucleofection was performed in the 4D-nucleofector X 
unit using the programme CA-137 (parameters are not disclosed by Lonza). 
Five-hundred µL of warmed media was used to resuspend the cells in the 
nucleocuvette and transferred to a 100mm diameter petri dish. Cells were 
incubated overnight at 37 °C to allow the expression of plasmid DNAs. 
2.23.5 Fluorescence-activated cell sorting  
Twenty-four hours after the nucleofection cells were harvested with trypsin and 
resuspended in 1 mL DMEM/F-12 phenol-red free supplemented with 10 U/mL 
penicillin/streptomycin and 10% foetal bovine serum. Using the FACS ARIA III 
(BD Biosciences), cells expressing GFP and mCherry were selected. EGFP 
was detected with an excitation wavelength of 488 nm and 530/30 nm 
bandpass filter, mCherry plasmid was detected with an excitation wavelength of 
561 nm and 610/20 nm bandpass filter. Single, sorted cells were placed in a 96 
well plate containing 100 µL of pre-warmed media and incubated at 37 °C. 
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2.23.6 DNA extraction  
Confluent cells in the 96 well plate were dissociated by pipetting, 20% of the cell 
suspension volume was seeded in a 24 well plate, the remaining 80% of cells 
was used for the extraction of genomic DNA. Cells were centrifuged at 1000 
rpm for 5min and resuspended in 250 µl of 1X Slagboom buffer (Table 2.1), and 
incubated at 37 °C for 45 min. Five µl of 10 mg/ml Proteinase K was added to 
the mixture and incubated at 60 °C for 1 hour. Genomic DNA was extracted 
using the phenol-chloroform method: 400 µl of 25:24:1 v/v UltraPure 
phenol:chloroform:isoamyl alcohol (Invitrogen) was added to the sample, mixed 
thoroughly and centrifuged at 14000 rpm for 2 min, this procedure was carried 
out twice.  As residues of phenol could affect subsequent analysis, a 
supplementary wash with 400 µl chloroform was performed. The mixture was 
spun at 17,900 x g for 2 min and the upper layer collected. The DNA was 
precipitated by addition of 400 µl of isopropanol and centrifugation at 17,900 x g 
for 2 min. The DNA pellet was washed with 400 µl of 70% (v/v) ethanol and 
spun at 17,900 x g for 2 min. The ethanol was removed and once the pellet air-
dried at 37 °C for a few minutes. The DNA was resuspended in 20 µl of Buffer 
TE, the concentration and quality of DNA were assessed as previously 
described. 
2.23.7 Genotyping of CRISPR colonies 
Primers for genotyping of CRISPR colonies were designed as described in 
Paragraph 2.5. Two pairs of primers were designed: one pair within the site to 





Figure 2.2 Schematics of genotyping strategy. A segment of about 516 bp 
was targeted for deletion between exon 2 and axon 3 of CLCC1. Primers set 1 
(Primer 1 F and Primer 1 R) were designed to amplify 300 bp of exon 2, inside 
the deleted region. An amplicon corresponding to the 300 bp would be present 
only if the deletion does not happen. If the deletion occurred, the primers set 2 
(Primer 2 F and Primer 2 R) would be able to amplify a stand of about 663 bp of 
DNA corresponding to the initial segment of exon 2 and the final segment of 
exon 3. If the deletion doesn’t occur, primers set 2 will amplify 1179 bp of DNA, 
corresponding to exon 2 and exon 3 and their surrounding introns. 
 
2.24 Western blotting 
2.24.1 Cell lysate preparation for co-immunoprecipitation 
To analyse the levels of endogenous proteins or fusion protein expression, cells 
were seeded in a 100 mm diameter dish and lysed when the 80% confluence 
was reached. Media was aspirated from the dish, and cells washed with 1X 
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PBS. Cells were trypsinised for 5 min at 37 °C, collected and centrifuged at 
1000 rpm for 5 min. Media was aspirated and the cell pellet resuspended in 10 
ml of ice-cold PBS, spun at 1000 rpm for 5 min. PBS was removed and cells 
resuspended in 700 µl of lysis buffer (20 mM Tris-HCl, 150 mM KCl, 0.1% Triton 
X-100, 1 mM PMSF, complete protease and phosphatase inhibitors (Sigma-
Aldritch)), placed in a microfuge tube and rotated at 4 °C for 30 min. Afterwards, 
the lysate was centrifuged at 17,900 x g for 20 min at 4 °C, and the supernatant 
carefully transferred to a clean microfuge tube. For positive control whole lysate 
was used, while for negative control whole lysate minus the immunoprecipitated 
complexes was used. 
2.24.2 Co-immunoprecipitation with Dynabeads 
Co-immunoprecipitation (Co-IP) is used to study protein-protein interactions.  
Antibodies against the protein of interest are used to pull-down the protein 
complexes which are then visualised by Western blotting. 
The co-immunoprecipitation was carried out using Dynabeads Protein A 
(Invitrogen). 25µl of beads were transferred to a clean microfuge tube, the 
supernatant was removed and the required concentration of antibody (see 
Appendix B) diluted in 200 µl of PBS + 0.02% (v/v) Tween-20 was added to the 
beads, incubated at room temperature for 1 hour, on a rotating wheel. The 
supernatant was removed and beads washed gently with 200 µl of PBS + 
0.02% (v/v) Tween-20. Once the PBS was removed and the cell lysate was 
added to the beads and resuspended, the tubes were incubated for 2 hours at 4 
°C, on a rotating wheel. The supernatant was collected and placed at -20 °C for 
further analysis. The beads were washed three times with washing buffer (20 
mM Tris-HCl pH 8.0, 150 mM KCl, 10% (v/v) Triton X-100, and protease 
inhibitors) and transferred to a clean microfuge tube. Supernatant was removed 
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and the elution of protein was carried out using 50 µl of elution buffer (4X Nu 
Page LDS Sample buffer (Invitrogen), 10% beta-mercaptoethanol (v/v)), heating 
the sample for 10 min at 70 °C. The supernatant containing the precipitated 
proteins was collected in a clean tube and used immediately for Western 
Blotting or frozen at -80 °C for future use. 
2.24.3 Co-immunoprecipitation with GFP-Trap 
GFP-Trap was carried out to immunoprecipitate proteins tagged with GFP/YFP. 
HEK293 cells in a 100 mm plate were transfected with YFP CLCC1 
WT/Asp25Glu, as previously described in Paragraph 2.20. After 24h from the 
transfection, cells were harvested using trypsin and spun at 1000 rpm for 5 min. 
Supernatant was aspirated and the cell pellet was resuspended in ice-cold PBS, 
spun again and cells were resuspended in GFP-Trap lysis buffer (1% NP-40, 
130 mM NaCl, 20 mM Tris, ph 8.0). Tubes were placed on a rotating wheel at 4 
°C for 30 min, and the lysate was clarified through a centrifugation at max 
speed (14800 rpm) for 15 min at 4 °C (Thermo Scientific Heraeus Fresco 21 
Centrifuge). 
Ten µl of GFP-Trap beads (Chromotek) (per 100 mm plate) were transferred to 
a centrifuge tube and spun at 700 x g for 1 min. The tube was rotated at 180 o 
and centrifuged again at 700 x g for 10 sec. Beads were left 1 min to incubate 
on ice and then the supernatant was discarded. Beads were washed with 500 µl 
of lysis buffer and centrifuged for 1 min at 700 x g. The supernatant was 
discarded, the beads were resuspended in protein lysate and incubated 
overnight on a rotating wheel at 4 °C. Beads were centrifuged for 1 min at 700 x 
g and the supernatant was removed and stored at -80 °C (subsequently used 
as the Co-IP negative control). Beads were washed twice with 400 µl of lysis 
buffer and spun for 1 min at 700 x g, 4 °C.  Immunocomplexes were eluted 
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using Laemli buffer at 95 °C for 5 min, in a total volume of 30 µl. Tubes were 
spun at 700 x g for 1 min and stored at -80 °C. 
2.24.4 Subcellular fractionation 
SH-SY5Y cells (wild type and CLCC1-/- KO) were seeded on 150 mm dish, and 
harvested once 90% confluent. Cells were resuspended in 1.5 ml of 1X STE 
(Sucrose – Tris – EGTA buffer, Table 2.1) + 0.5% BSA and homogenate in a 
manual homogeniser with 20 strokes. Homogenate was clarified with a spun at 
1000 x g for 10 min at 4 °C. Ultracentrifuge tubes were filled with 25% Percoll 
solution (1/4 Percoll, 1/4 2X STE buffer, 2/4 1X STE + 0.5% BSA) and the 
clarified homogenate was put on top. Tubes were spun at 80.000 x g average 
for 40 min at 4 °C (Beckmann Coulter). The supposedly upper layer containing 
the ER and lower mitochondria layer were collected separately and washed 3 
times with STE buffer without BSA, the layers were spun at 10.400 x g for 10 
min at 4 °C. The pellet obtained was resuspended in STE buffer without BSA, 
and spun at max velocity for 2 min. The pellet was resuspended with STE buffer 
without BSA and spun, this process was repeated again and the pellet 
resuspended in PBS, spun again and finally resuspended in 200 µl of PBS.  
2.24.5 Protein quantification 
Quantification of protein concentration in clarified cell lysate was carried out 
using the Pierce bicinchoninic acid (BCA) Protein Assay Kit (Thermo) according 
to the manufacturer’s protocol. In a 96-well plate, bovine serum albumin (BSA) 
protein standard at 2 mg/ml was diluted to 0.2-1.2 µg/ml in 1:10 lysis 
buffer:PBS. Samples were also diluted 1:10 with PBS. Both samples and 
standards were loaded into wells in triplicate. BCA solution was prepared mixing 
50 parts of reagent A and 1 part of reagent B, 200 µl were added to each well 
containing samples and standards. 
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Plate was shaken for 8 min at RT on an orbital shaker (LSE Low Speed Orbital 
Shaker, Corning), and absorption at 562 nm was measured using PHERAstar 
FS microplate reader (BMG Labtech) and the concentrations of each sample 
were calculated against the standard curve.  
2.24.6 SDS polyacrylamide gel electrophoresis. 
To separate the proteins based on their size, electrophoresis on polyacrylamide 
gel was carried out. The procedure is also called SDS-Page (Sodium Dodecyl 
Sulphate Poly Acrylamide Gel Electrophoresis). The percentage of acrylamide 
inside the gel determines the separation of proteins (Table 2.6). 
 
Table 2.6 Determination of gel percentage 









SDS-PAGE gels were prepared using the Mini-PROTEAN TM Tetra Handcast 
System (BioRad), according to the recipe in the Table 2.7. Ammonium 
persulphate (APS) and N,N,N',N'-tetramethylethane-1,2-diamine (TEMED) were 
added last to initiate polymerisation of the acrylamide. For Co-IP 10 µl of each 




Table 2.7 Gel recipes. The volumes (in ml) are for 40% Acrylamide/Bis solution 
(Fisher Scientific) 37.5:1 ratio and makes 2 gels. 
 
 Stack   Resolve   
% 4 7.5 10 12 15 20 
dd.H2O 5.28 13.7 12.1 10.9 9.0 2.5 
40% 
Acrylamide/Bis 
0.7 4.7 6.3 7.5 9.4 12.6 
1.5M Tris HCL pH 
8.8 
- 6.25 6.25 6.25 6.25 6.25 
1.0M Tris HCL pH 
6.8 
0.88 - - - - - 
10% SDS 0.07 0.25 0.25 0.25 0.25 0.25 
10% ammonium 
perisulfate (APS) 
0.07 0.125 0.125 0.125 0.125 0.125 
TEMED 0.0025 0.0025 0.0025 0.0025 0.0025 0.0025 




2.24.7 Transfer to membrane 
After separation of proteins, the gel was allowed to equilibrate in transfer buffer 
for 10 min and re-hydrate. The gel was sandwiched between chromatography-
grade filter paper (GE Healthcare) and proteins were transferred onto 
Immobilon-P polyvinylidene difluoride (PDVF) transfer membrane (Merck), 
applying current at 250 mA. 
2.24.8 Probing and immunodetection 
To prevent non-specific binding of the antibody to the membrane, after the 
transfer of the proteins, the membrane was blocked in 5% (w/v) skimmed milk 
(Oxoid) or 5% BSA (Sigma) in Tris-Buffered Saline + 0.01% (v/v) Tween-20 
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(TBS-T) for 1 h at RT. The membrane was removed from the blocking solution 
and incubated overnight with the appropriate primary antibody (Appendix B, 
Table 1). Afterwards the membrane was washed three times for 5 min with TBS-
T to remove excess antibody and incubated for 1 h with the appropriate 
horseradish peroxidase (HRP) conjugated secondary antibody (Appendix B, 
Table 2). Proteins were detected using electrochemiluminescence and the LI-
COR C-DiGit (LI-COR). 
2.25 Immunocytochemistry 
Cells were seeded at 1x104 cells per 13 mm diameter coverslip and cultured for 
two days. Cells were fixed for 15 min at room temperature with 4% (w/v) 
paraformaldehyde, pre-warmed to 37 °C, added directly to the culture medium 
as matching volumes and then replaced with fresh pre-warmed 
paraformaldehyde. Coverslips were rinsed 3 times for 5 min each with 1X PBS 
to eliminate residual paraformaldehyde. Cells were permeabilized and the non –
specific binding sites were blocked using lysine block (5% goat serum, 5% 
horse serum, 5 mM L-lysine, 0.2% Triton-X) for 15 min at room temperature. 
Primary antibodies (Appendix B, table 1) were diluted in lysine block and 
incubated with the cells for 1 hour at room temperature. Following 3 washes 
with 1X PBS, 5 min each, to eliminate unbound primary antibody, cells were 
incubated with the secondary antibody (Appendix B, table 2) for 1 hour at room 
temperature. DAPI (4,6- diamidino-2-phenylindole, dihydrochloride, Invitrogen) 
was used to stain the nuclei diluted 1:5000 in PBS for 5 min. Coverslips were 
washed 3 times for 5 min each to eliminate any residual antibody and DAPI, 
and were mounted on glass slides (VWR) using FluorSave (Calbiochem) 
mounting media, left to dry in the dark, at room temperature, overnight. 
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2.26 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) 
assay 
To assess cell viability the MTT assay (Abcam) was used. The assay is based 
on the assumption that the metabolic activity of SH-SY5Y cells reflects the 
number of viable cells present in the dish. Water-soluble MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) can be converted to 
insoluble formazan crystals through the mitochondrial succinate 
dehydrogenase. The measure of the resulting absorbance at OD 590nm is 
taken as proportional to the number of viable cells present in the plate. 
Following manufacturer’s instructions 10000 cells/well were seeded in a 96-well 
plate and cultivated for 24, 48, 72, and 96 h in 100 µl of SH-SY5Y media. Prior 
to the addition of MTT reagent, cells were treated for 30 min at 37 °C with 5 µM 
of Thapsigargin (Alomone Labs) or 2 µg/ml of Tunicamycin (Sigma-Aldritch). 
Control cells were treated with the same amount of DMSO. After the treatments, 
media was aspirated and 50 µl of serum-free media and 50 µl of MTT reagent 
were added to each well. For the background control wells 50 µl of fully 
supplemented media and 50 µl of MTT reagent were used. The plate was 
incubated at 37 °C for 3 h. Afterwards, 150 µl of MTT solution were added into 
each well and the plate was wrapped in foil and shaken for 15 min. Absorbance 
at OD 590 nm was read using the PHERAstar FS microplate reader (BMG 
LABTECH).  
2.27 Microscopy and image analysis 
Fluorescence microscopy was performed with a Leica TSC SP8 inverted 
confocal laser scanning system with a piezoelectrict stage, HC Plan-
Apochromat x63 (1.4 NA) oil objective, and temperature-controlled 
environmental chamber. Leica Application suite X was used to control the 
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microscope on the PC. Image analysis was performed using Fiji [180]. 
2.28 Statistical analysis 
Statistical analysis was performed using Graphpad Prism 5. Differences 
between groups were assessed using two-way ANOVA with a post-hoc 
Bonferroni test. 
For not normally distributed data, a Kruskal-Wallis test with Dunn’s multiple 
comparisons post hoc test was used to assess differences. Not normally 
distributed data were also analysed with Mann Whitney U test.  






















MUTATION IN THE INTRACELLULAR CHLORIDE 
CHANNEL CLCC1 ASSOCIATED WITH 







CHAPTER 3: MUTATION IN THE INTRACELLULAR CHLORIDE 
CHANNEL CLCC1 ASSOCIATED WITH AUTOSOMAL 
RECESSIVE RETINITIS PIGMENTOSA. 
3.1 Introduction  
RP is a heterogeneous retinal disease caused by alteration of genes involved in 
a broad range of molecular roles in the maintenance and function of 
photoreceptors. The molecular pathways affected by the pathological events 
leading to the disease are multiple, they involve both photoreceptor-specific 
functions, and more generic pathways related to proteins associated with RNA 
or development [181].  
One of the most common and best studied genes associated with RP is RHO, 
which encodes for rhodopsin. Most of its alterations are associated with adRP 
however, it could also cause arRP and CSNB. Pathways affected were 
classified depending on where the variant resides within the protein; C-terminus 
variants affect the post-Golgi trafficking and OS targeting, transmembrane 
domains alterations cause misfolding, ER retention and instability, a single 
variant in the position Asp135 has been associated with disruption of vesicular 
traffic and endocytosis [52]. Post-translational modifications and reduced 
stability have been associated with variants in the N-terminus of RHO [52]. 
Recently, REEP6 gene variants have also been associated with RP [182] lack 
of REEP6 results in the increased amount of endoplasmic reticulum (ER) 
membrane present near the OS, the number of mitochondria and the trafficking 
of cGMP to the OS [183].  
RNA splicing can be also affected in genetic alterations associated with RP, for 
example an Asp170Gly variant in RP9 may cause RP by altering splicing of 
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retinal genes through a decrease in RP9 phosphorylation [184, 185]. Similarly, 
the pre-mRNA splicing factor DHX38 has been associated with RP and it was 
first discovered in a Pakistani family [186]. 
Proteins associated with developmental pathways have been also linked to RP, 
an example of this is SEMA4A [187, 188], semaphorins act as repulsive or 
attractive cue for growth cones during axon guidance. Loss of function of 
SEMA4A in mice showed reduced length of the OS and defect in the RPE layer, 
therefore it has been suggested that Sema4a functions as transmembrane 
ligand for a receptor present on photoreceptors [189]. Another report suggested 
that variants in SEMA4A cause oxidative stress, ER stress, and defective 
endosomal sorting [190, 191]. Variants in this gene have been firstly reported in 
Pakistani families [187]. 
As introduced above, genes identified in Pakistan have helped to understand 
the molecular bases of RP. Alongside SEMA4A and DHX38, ZNF513 and 
CC2D2A have also been described for the first time in Pakistani population. 
ZNF513, a zinc finger DNA-binding protein, regulates gene expression of 
photoreceptor-specific genes; sequence alterations in this gene cause the loss 
of binding of ZNF513 with its targets [192]. CC2D2A, which has been 
associated with RP and mental retardation [193], is involved in Rab8-dependent 
vesicular trafficking [194].  Loci on chromosomes 1, 2, and 11 have also been 
associated with RP exclusively in the Pakistani population [169, 195, 196] 
however, the genes alteration within the loci which cause RP have not been 
defined yet.  
Every year new genes and new molecular pathways associated with RP in 
Pakistani communities have been highlighted, expanding the knowledge in 
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terms of clinical presentation, genetic, and molecular aspects, as well as the 
potential new treatments and management strategies that can be developed,  
In this chapter, eight Pakistani families affected by arRP were investigated 
using cutting-edge genetic technologies, and a new genetic cause of their 





3.2.1 Clinical findings of eight families affected by arRP 
As part of an international study we investigated eight families with multiple 
affected individuals with arRP. Three families (families 1-3) were investigated at 
the University of Exeter (IBCS), and five (families 4-8) were investigated at the 
NEI, USA. Families 1 and 2 originated in Pakistan, Family 2 was from Bhakkar 
district, Punjab. Family 3 was a British-Bangladeshi family, investigated at 
Moorfields Eye Hospital. Families 4 to 8 originated from Punjab region in 
Pakistan. 
Due to regional constraints, a variable amount of clinical information was 
available on each family. Affected individuals demonstrated broadly consistent 
findings typical of arRP. These included retinal findings of pale optic discs, 
retinal vessel attenuation, and intra-retinal pigment migration on fundoscopy, 
typical clinical presentations for arRP with night blindness being the initial 
symptom in the first or second decade of life in all affected individuals. Clinical 
findings of Family 5 and 8; the presenting symptom in both families were 
reported to be night blindness by approximately 10 years of age. All affected 
family members displayed moderate loss of visual acuity. The clinical 
characteristics of Family 4 were previously published [195]. 
 







Fundus photographs of individual V:1 of Family 5 (Fig. 3.1 (i-ii)), individual V:3 
of Family 8 (Fig. 3.1 (iii-iv)) and individual IV:3 of Family 1 (Fig. 3.1 (vii-viii))  
revealed findings similar to those seen in Family 4, including obvious bone 
spicule-shaped pigment deposits in the mid-periphery, waxy-pale optic discs, 
attenuation of the retinal arteries, and a generalised grayish carpet-like retinal 
degeneration as compared to a normal fundus (Fig. 3.1 (v-vi)). Affected 
members of Families 4 and 1 also showed maculopathy, which was not 
observed in Families 5 and 8. ERGs of affected individuals when performed as 
adults were non recordable (Fig. 3.2). 
Family 3, individual II:1 presented with a history of night blindness from 1-2 
years of age and an intermittent divergent squint with long-standing 
photophobia. Presenting visual acuity was 6/9 in each eye and at last review at 
age 18 years had deteriorated to 6/60 each eye with severely restricted visual 
fields to less than 15 degrees to confrontation (Table 3.1). There was a myopic 
astigmatic refractive error of right 0.25/-1.25 x 21° and left 0.25/-2.25 x 160°. 
Electrophysiology performed at age 7 was unrecordable. Colour fundus 
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photographs for the affected individual in family 8 revealed attenuated retinal 
vessels, mid-peripheral coarse pigment clumping and white dots at the level of 
the retinal pigment epithelium. Fifty-five degree fundus autofluorescence 
imaging show widespread loss of autofluorescence more marked over the 
pigment clumps in the mid-periphery. Optical coherence tomography (OCT) 
demonstrated loss of outer nuclear and photoreceptor layers throughout the 






Figure 3.1 Fundus photographs. (i-ii) Individual V:1 of Family 5 (right eye and 
left eye, respectively), (iii-iv) individual V:3 of Family 8 (right eye and left eye, 
respectively) and; (vii-viii) individual IV:3 of Family 1 showed bone spicule-
shaped pigment deposits in the mid-periphery, pale optic discs, attenuation of 
the retinal arteries; (v-vi) healthy individual  (right eye and left eye, respectively) 






Figure 3.2 ERG recordings of affected individuals. (i) rod (green) and cone 
(orange) response: right eye and left eye, respectively; and (ii) 30Hz flicker 
response: right eye and left eye, respectively of an healthy individual. (iii) rod 
(green) and cone (red) response: right eye and left eye, respectively; and (iv) 
30Hz flicker response of individual V:1 of Family 5. (v) rod (green) and cone 
(orange) response: right eye and left eye, respectively; and (vi) 30Hz flicker of 
individual V:3 of Family 8. The affected individuals demonstrate loss of ERG 








Figure 3.3 Fundus photographs of individual II:1, Family 3. (i-ii) Fundus 
photographs (right eye and left eye, respectively) showed attenuated retinal 
vessels and mid-peripheral pigment clumping. (iii-iv) 55 degree fundus 
autofluorescence imaging (right eye and left eye, respectively) showed loss of 
autofluorescence more marked over the pigment clumps. (v-vi) OCT (right eye 
and left eye, respectively) demonstrated loss of outer nuclear and photoreceptor 
layers throughout the macula with occasional small foci of retained 
photoreceptors. Photographs of individual II:1, Family 3 was taken at the 
Moorfield Eye Hospital. (vii) Healthy control. Section vii was adapted from 
Meunier et al [197]. 
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3.2.2 Genetic findings  
For Family 1, 2 and 3, studies at IBCS involved whole-genome SNP mapping 
which identified a single notable homozygous region particular to affected 
individuals of a small 1.2Mb interval on chromosome 1p13.3 (flanked by 
markers rs17020437 and rs587727) [hg38]), demarcating the likely disease 
locus and indicative of the presence of a founder mutation causing the disease. 
In order to identify the causative mutation, WES was performed on a single 
affected individual for each family (III:1, Family 1; III:2, Family 2; II:1, Family 3). 
After filtering for call quality, potential pathogenicity, and population frequency, a 
single candidate genetic alteration was identified genome-wide which was 
located within the 1.2Mb critical interval; a missense alteration within the 
chloride channel CLCC-like 1 (CLCC1) gene (rs750180668; 
chr1:g.108950363G>T, NM_001048210.2:c.75C>A), predicated to result in a 
p.(Asp25Glu) amino acid substitution. The p.Asp25Glu substitution in CLCC1 is 
predicted to be damaging by bioinformatic analysis using Polyphen2 (HumDIV, 
1, HumVar, 0.998), not tolerated by SIFT (0), and deleterious by Condel 
(0.546). It is absent from >200 ethnically matched control chromosomes, and 
the dbSNP and 1000 Genomes databases, although it is listed in heterozygous 
form in 12 individuals in the Genome Aggregation Database [198] (gnomAD: 12 
heterozygotes and no homozygotes in the South Asian population, allele 
frequency = 0.0003924 in South Asians, 0.00004778 overall, 
(https://gnomad.broadinstitute.org/variant/1-109492985-G-T)). 
In parallel with this, studies of families 4 to 8 were undertaken at NEI. Family 4 
[61030] was screened using microsatellite genome-wide mapping, which 
identified a 3.4cM (3.05Mb) homozygous interval of chromosome 1p13.3 shared 
by all affected family members. To identify the causative gene, whole exome 
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sequencing was undertaken in a single affected family member (Individual 12, 
Family 4). The data was filtered (allele frequency in genome databases, and 
prioritising deleterious variants in the genetic interval, as well as genome-wide). 
As with studies of families 1-3 (above), this identified only a single candidate 
gene variant, again within the linked region (Fig. 3.4), involving the same 
homozygous c.75C>A, p.(Asp25Glu) missense variant in exon 1 of the CLCC1 
gene. Dideoxy sequencing confirmed co-segregation of CLCC1 variant in 
families 1-8, and in 123 additional Pakistani arRP families identified 4 further 
additional apparently unrelated families in which the same c.75C>A, 
p.(Asp25Glu) alteration co-segregated with the condition (Families 5 [61031], 6 
[61328], 7 [61244], and 8 [61224]). All four families were found to be linked to 
markers in the chromosome 1p13,3 region containing the CLCC1 c.75C>A 
variant, producing maximum LOD scores of 8.9, 5.0, 3.86, 2.44, and 2.45 at θ=0 







Figure 3.4 Family pedigrees and CLCC1 locus haplotypes of Families 4-8. 
Haplotypes of the CLCC1 region of families 4-8 showing the CLCC1 c.75C>A 
mutation, and surrounding microsatellite markers included.  Figure made at the 
NEI. 
 
Importantly, whole genome SNP mapping in all eight families confirmed that all 
affected individuals were likely homozygous for the same single ancestral 
founder mutation event (p = 2x10-11), and enabled a further refinement in the 
extent of the extended genomic haplotype on which the original founder 
mutation occurred to a very small ~322kb interval flanked by rs1333130-
rs587727 (chr1: 108,820,610-109,142,651 [hg38]), containing 10 RefSeq genes 
(Fig 3.5, Fig 3.6). This includes the British-Bangladeshi family (Family 3), which 
is also likely to be of the same Pakistani (Punjab) origin. The identical SNP 
haplotype (Fig. 3.5), has an estimated frequency of 0.03 by the EM algorithm as 





Figure 3.5 Conserved founder SNP haplotype encompassing the CLCC1 
c.75C>A (p.Asp25Glu) genomic region. SNP Haplotypes of the 8 families 
extending across the region show conservation in a 322kb region of 
chromosome 1 are shown in yellow. In red were highlighted the SNP flanking 
CLCC1. F.1, family 1; F.2, family 2; F.3, family 3; F.4, family 4; F.5, family 5; 
F.6, family 6; F.7, family 7; F.8, family 8. Figure made by Dr. Barry Chioza. 
 
The p.(Asp25Glu) variant  co-segregated in all the affected individuals of the 
eight families (Fig. 3.6 (i)), and is located in a well conserved region of CLCC1 
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across all 22 species examined ranging from human to zebrafish, and is 
particularly highly conserved amongst mammals (Fig. 3.6 (iii)).  
To robustly identify any other putative mutations in in non-coding regions of the 
common 322kb critical interval including in non-exonic regions, DNA from a 
single affected individual (III:1, Family 1) was subjected to whole genome 
sequencing (WGS). This failed to identify any intronic, splice site, promotor or 






Figure 3.6 Co-segregation and conservation of CLCC1 c.75C>A alteration. 
(i) Pedigrees of families involved in this study. Presence of the variant is 
indicated with ‘+’, while absence with ‘-‘. (ii) Electropherograms the sequence of 
an affected individual (top, V:8, Family 5), the sequence of a heterozygous 
carrier (middle, V:9, Family 5) and unaffected control sequence (bottom) 
surrounding the CLCC1 c.75C>A alteration. (iii) Amino acid sequence 
alignment around the Asp25 amino acid of CLCC1 (red) in 22 species ranging 
from human to zebrafish. Asp25 conserved in all species and the entire region 




Studies undertaken at IBCS as part of a collaborative study with workers at a 
number of other Institutions internationally provide extensive genetic, clinical 
and functional datasets defining CLCC1 alteration as a new cause of arRP. Our 
genetic findings of seven extended Pakistani Punjab families, as well as an 
eighth British-Bangladeshi family, determine that all families likely stem from the 
same ancestral origin, defining CLCC1 alteration as a new cause of arRP. 
Whole genome-SNP mapping identified a homozygous interval of 322 kb 
shared between affected individuals, an interval containing ten genes: AKNAD1, 
GPSM2, CLCC1, WDR47, TMEM167B, C1orf194, KIAA1324, SPATA42, 
TAF13 and SCARNA2. None of these genes have been associated with retinal 
disease. AKNAD1 has been associated with type 2 diabetes [199], WDR47 has 
been linked to brain development [200], C1orf194 variants cause Charcot-
Marie-Tooth [201], and TAF13 has been related to intellectual disability [202]. 
Interestingly, GPSM2, which codes for the putative whirlin protein complex-
interacting molecule, previously implicated in Usher syndrome, been associated 
with Chudley-McCullough Syndrome (CMCS [MIM 604213]), a rare autosomal 
recessive disorder characterised by sensorineural deafness, agenesis of the 
corpus callosum, frontal polymicrogyria, interhemispheric cyst, and ventricular 
enlargement. Gpsm2 is important for stereocilia elongation, interacts with 
whirlin, and regulates actin dynamics in the growth cones of developing neurons 
[203]. Importantly none of the non-ocular features characteristic of CMCS are 
present in the affected individuals presented here. WES, WGS, and dideoxy 
sequencing of this interval identified only a single deleterious sequence 
alteration in the putative chloride channel CLCC1 c.75C>A as the likely cause 
of the condition. Exon twelve of CLCC1 overlaps with exon sixteen of GPSM2, 
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indicating that the c.75C>A variant at the genomic level may theoretically affect 
binding of transcription factors during CLCC1 transcription, some of which are 
known to be active in the retina. However, the distance from promoter regions 
of GPSM2 (or CLCC1), may not be consistent with an effect on transcription 
factor binding being the pathogenic mechanism, as opposed to functional 
effects on the CLCC1 protein itself. Consistent with this, genome sequencing of 
the c.75C>A CLCC1 haplotype identified no additional intronic, promotor of 
other sequence alterations in the vicinity of GPSM2 (or in other genes in the 
322kb region) that might influence functionality. While these findings do not 
support involvement of GPSM2 in the condition reported here, it remains 
unclear whether there may be any functional relationship between the two 























CHAPTER 4: CHARACTERISATION OF CLCC1 
4.1 Introduction 
The previous chapter described the discovery of CLCC1 as a RP-associated 
gene.  
CLCC1 (also called MCLC) cDNA was first isolated in 1996 [204], as a gene 
differentially expressed in X. laevis melanotropes in response to different 
coloured background (X92871, EMBL-EBI database, www.ebi.ac.uk) [204]. 
Subsequently, in 2001, Nagasawa et al. [205], looking for stretch- activated 
channels in rat genome with a sequence similar to the MID1 gene in S. 
cerevisiae, found an expressed sequence tag homologous to X92871. From the 
partial sequence of the rat MID-1, the full-length of Mid-1- related chloride 
channel (MCLC) cDNA sequence was obtained. However, there were no close 
sequence similarities between MID-1 and MCLC, or between MCLC and known 
channel families. MCLC was predicted to have four transmembrane domains, a 
consensus sequence for nuclear localisation, and an amino acid sequence in 
the third transmembrane domain resembling the CLIC family of chloride 
channels. MCLC has been shown to be expressed in rat spleen, liver, testis, 
brain, kidney and heart [205]. In Chinese hamster ovary (CHO) cells, MCLC 
localised to the perinuclear region, endoplasmic reticulum (ER) and in the Golgi 
apparatus, but not in the nucleus. Activity of the presumptive channel was 
assessed by microsomal insertion into a lipid bilayer: the channel was 
preferentially permeable to anions however blockers of anion channels, such as 
4,49-diisothiocyanatostilbene-2,29-disulfonate (DIDS), did not block the channel 
activity [205].  
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A retrotransposon insertion in CLCC1, resulting in loss of function was reported 
in 2015 associated with cerebellar neurodegeneration in mice [206]. Moreover, 
ER localisation of CLCC1 was confirmed in HEK293 cells, and the loss of 
CLCC1 was linked with UPR (unfolded protein response) response and ER 
stress [206]. CLCC1 loss of function has also been reported as increasing the 
levels of the ER chaperone BiP (GRP78), consistent with the induction of ER 
stress [206].  
Although the presence of anion channels in the ER including a member of the 
CLIC family, CLC4, have been reported [207-209], the functions of CLCC1 
either as a chloride channel or a mediator of ER stress remains to be confirmed. 
The ER is involved in calcium storage, lipid and protein metabolism, protein 
folding, secretion and degradation. Protein synthesis occurs on the cytosolic 
side of the ER, to which ribosomes localise and where the complex 
ribosome:mRNA:nascent polypeptide bind the signal recognition particle (SRP) 
receptor, and the nascent polypeptide is co-translationally translocated into the 
ER lumen though Sec61/SecY channel [210]. Proteins must fold correctly 
before leaving the ER through secretory pathways, if they cannot reach a native 
structure due to mutations or misfolding, proteins are degraded though the ER-
associated degradation (ERAD). Misfolded or unfolded proteins are recognised 
by chaperones and lectines, and diverted to the dislocon through which proteins 
are translocated. Polyubiquitination of those proteins ensure the degradation 
though the cytosolic 26S proteasome [211].  
Stress signalling, collectively called the unfolded protein response (UPR), 
occurs when there is an imbalance between unfolded protein load and 
chaperone reserve [212]. Triggering of the UPR may result in restoration of 
cellular homeostasis or apoptosis. Misfolded proteins are translocated into the 
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cytosol where they are ubiquitinated and degraded via the 26S proteasome; a 
process called ER-associated degradation (ERAD). Several studies report the 
ER as a major organelle implicated in retinal dystrophies, glaucoma, diabetic 
retinopathy [213, 214]. For example, the P23H mutation in rhodopsin, a gene 
associated with RP, induces misfolding of the protein and ER stress [52, 215]. 
The UPR (Fig. 4.1) is controlled by three sensors: inositol requiring enzyme 1 
(IRE1) [216, 217], protein kinase RNA-activated (PKR)-like ER kinase (PERK) 
[218], and activating factor 6 (ATF6) [219]. All of them consist of three domains: 
a cytosolic domain, a single pass transmembrane domain, and an ER luminal 
domain. In homeostatic conditions, the ER luminal domains of the three sensors 
are bound to the heat shock protein A5 (also known as GRP78 or BiP), which 
keeps the sensors in an inactive state [213]. Accumulation of misfolded protein 
in the ER lumen induces the disengagement of BiP from the sensors, IRE1 and 





Figure 4.1 Unfolded protein response (UPR) signalling. The UPR signalling 
starts in the ER when there is an imbalance of misfolded proteins. The 
chaperone BiP is released from the three UPR sensors; IRE1, PERK and ATF6. 
IRE1 auto-phosphorylation induces the splicing of the transcription factor 
usXBP1 into sXBP1, which migrates into the nucleus. Active PERK, 
phosphorylates eIF2α, blocking protein synthesis, and induces the translocation 
into the nucleus of the transcription factor ATF4. The release of BiP from ATF6 
induces the translocation of ATF6 to the Golgi apparatus, where the bZIP 
domain is cleaved and acts as a transcription factor in the nucleus. sXBP1, 
ATF4 and ATF6 induce the expression of genes that will help to increase the 
protein folding capacity of the ER. Figure created with BioRender. 
 
IRE1 activation induces a selective cleavage of dual stem loops within the X-
box binding protein 1 (usXBP1; unspliced XBP1), which is a basic leucine 
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zipper (bZIP) transcription factor. The sXBP1 (spliced XBP1) activation induces 
the transcription of chaperones and metabolic pathways which help to reduce 
the protein load in the ER [220].  
Active PERK phosphorylates eukaryotic translation initiation factor-2α (eIF2α) 
inhibits eIF2B activity, blocking protein synthesis and translation. Activation of 
PERK induces synthesis of ATF4 that can bind to the C/EBP-ATF site of 
CAAT/enhancer-binding protein (C/EBP) homologous protein 
(CHOP)/GADD153. ATF4 and CHOP induce genes involved in the UPR to 
enhance folding capacity (Fig. 3.1). The activation of ATF6 results in its export 
to the Golgi apparatus where it is cleaved by the two Golgi-resident proteases, 
releasing a fragment of ~400 amino acids corresponding to ATF6 cytosolic N-
terminal portion (ATF6f). ATF6f comprises a transcriptional activation domain 
(TAD), a bZIP domain, a DNA-binding domain, and nuclear localisation signals. 
In the nucleus, bZIP induces UPR gene expression of CREB, XBP1, CHOP 
[213, 221] (Fig. 4.1). 
The ER is the major storage site of intracellular calcium (Ca2+), rapid release of 
Ca2+ in the cytoplasm is necessary for diverse cell functions; cytoplasmic Ca2+ 
acts as second messenger and regulates cytosolic Ca2+- dependent proteins. 
Cytosolic Ca2+ deregulation induces cell damage and may lead to cell death 
[222]. Preservation of correct Ca2+ gradients in the ER is important as the ER 
relies on the correct Ca2+ concentration, or folding, apoptosis, stress and 
transcriptional activities. Total Ca2+ concentration within the ER is ~1 mM, of 
which 200 µM is free Ca2+, while the rest is buffered via ER resident proteins 
[223]. Ca2+ release from the ER lumen happens via the inositol-1,4,5-
triphosphate receptor (IP3R) and/or the ryanodine receptor (RyR) [224]. ER 
Ca2+ uptake from the cytosol ensures the maintenance of cytoplasmic calcium 
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concentration ([Ca2+]cyt) at about 100 nM [223] through the activity of 
sarcoplasmic–endoplasmic reticulum Ca2+ -ATPase (SERCA) [225].  
In the ER, calcium homeostasis is maintained by calcium-binding proteins such 
as calreticulin, a 46-kDa soluble protein found in the ER lumen and consisting of 
three domains. The N and P domains are essential for the chaperone activity, 
while calreticulin’s high binding capacity for Ca2+ (25 mole of Ca2+ per mole of 
protein) originates from the C-domain, containing clusters of acidic amino acid 
residues consisting of aspartic and glutamic acid interrupted with basic residues 
of lysine and arginine. Calreticulin alone binds approximately 50% of the Ca2+ 
stored in the ER lumen [226, 227]. Calreticulin is also implicated in many other 
cellular processes, such as folding of glycoproteins together with calnexin, a 90 
kDa membrane protein [227]. Calnexin and calreticulin share ~39% of 
sequence identity and have identical lectin-binding specificity. Calnexin possess 
the same high affinity for calcium of calreticulin [228]. Other important calcium-
binding proteins are GRP94 and BiP. BiP is a 78 kDa protein that binds calcium 
at relatively low capacity (1-2 mole of Ca2+ per mole of protein) and low affinity 
however, it is expressed at higher levels than calreticulin and therefore 
responsible for as much as 25% of the Ca2+ binding capacity of the ER [227, 
229, 230]. GRP94 (94 kDa protein) binds Ca2+ at high capacity (15 to 28 mol of 
Ca2+ per mol of protein) through its four sites of high affinity with Ca2+ [231]. 
Store-operated Ca2+ entry (SOCE) is a mechanism activated when the 
concentration of Ca2+ in the ER is decreased. The major regulatory components 
of SOCE are stromal interaction molecule (STIM) proteins, STIM1 and STIM2. 
Upon store depletion, STIM1 translocates to the ER-plasma membrane junction 
and couples with ORA1, a Ca2+-selective ion pore present on the plasma 
membrane, creating the Ca2+ release-activated Ca2+ (CRAC) channels, thus 
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inducing the entrance of Ca2+ directly into the ER from the extracellular space 
[224, 232]. 
Secretory pathways from the ER to the Golgi (and vice versa), though vesicular 
movements, ensure the transport of newly synthesised proteins and lipids 
between compartments [233]. Lipids are a major component for energy 
production in cells, they are stored and transported under the form of lipid 
droplets, emerging from the ER. Lipid droplets contain neutral lipids 
(triacylglycerols and sterol esters), as well as proteins, mainly enzymes, 
involved in lipid metabolism. During periods of starvation or growth, lipids 
enclosed in lipid droplets sustain membrane biogenesis and metabolic 
processes [234]. 
This chapter describes the studies undertaken to identify the subcellular 
localisation and functional role of CLCC1, a new gene causing arRP in the 
Pakistani population, including defining likely molecular binding partners and 
pathways in which CLCC1 might be involved, using proteomics and genetic 









4.2.1 Expression of CLCC1 in the retina during development 
Studies of mouse and zebrafish were coordinated through our collaborators at 
the NEI. 
Levels of Clcc1 expression in mouse eye (FVB/N mouse strain), at different 
stage of life, from four weeks to nine months, were assessed using qPCR. In 
the retina, Clcc1 was highly expressed at four weeks, with a peak at six weeks, 
decreasing from eight weeks to nine months. Iris, optic nerve, sclera, and 
cornea showed moderate expression (Fig. 4.2 (i)). Clcc1 was not expressed in 
the lens at any developmental stage.  
In developing zebrafish larvae clcc1 mRNA expression was assessed with in 
situ hybridization, using digoxigenin-labelled cRNA probe.  At 24 hours post 
fertilisation (hpf), high expression of clcc1 was present in hindbrain (HB), swim 
bladder (SB), and the eye (Fig. 4.2 (ii-iii), arrows). At 72 hpf (Fig. 4.2 (iv), 
arrows), the expression was most prominent in the retina, especially the GCL, 
ONL, and RPE, (Fig. 4.2 (v-vi), arrows).  
Expression of CLCC1 in adult human eye (NEI core histology lab) was 
assessed using formalin fixed and paraffin embedded retinas. 
Immunohistochemistry detected the presence of CLCC1 in the lamina cribrosa 
(LC), optic nerve (ON), GCL, INL, ONL and RPE (Fig. 4.2 (vii-x), arrows). 
These results indicate that CLCC1 is important during retinal development in 









Figure 4.2 Relative expression of Clcc1 in mouse, zebrafish and human 
retina. (i) Levels of Clcc1 mRNA expression in mouse cornea, lens, iris, optic 
nerve, and retina by qRT-PCR at different ages. Values represent the mean (± 
SD) on an arbitrary scale (y axis) and were calculated from at least three 
independent experiments. (ii-vi) In situ hybridization of clcc1 probes in zebrafish 
showed positive staining in the HB, SB, and eye at 24 hpf, and in the GCL, 
ONL, and RPE at 72 hpf ; scale bar: 100 μm. (vii-x) Immunohistochemistry on a 
human retina demonstrated CLCC1 is expressed extensively in the retina and 
optical nerves. More intense CLCC1 staining (arrow) was present in the LC, 
ON, GCL, INL, ONL and RPE in the retina (counter stain is methyl green). Scale 
bar: (vii-viii), 50 μm; (ix-x) 20μm. 
 
4.2.2 Knockdown and knockout of clcc1 expression in zebrafish 
To evaluate the functional role of clcc1 in developing retina in vivo, morpholino 
oligonucleotide (clcc1-MO) knockdown of clcc1 was performed in zebrafish 
embryos. The specificity of the clcc1-MO was validated by demonstrating 
inhibition of translation of EGFP mRNA fused to a morpholino sensitive 
sequence at its 5’-end (5’-modified EGFP) by injection of a clcc1-MO, but not a 
mismatch morpholino (MM-MO). In contrast, translation of unmodified EGFP 
mRNA was not affected by injection of either clcc1 or MM-MO (Fig. 4.3 (i-vi)).  
At 24 hpf, embryos treated with the clcc1-MO showed normal development 
however, at 36 hpf clcc1-MO embryos showed reduced eye size (N=30, 0.13 
vs. control 0.178 mm2, p= 7.942x10-9), compared to the MM-MO (N=30) or 
buffer control embryos (N=30) (Fig. 4.3 (vii-xii)). Interestingly, lens size was 
decreased proportionately (0.019 vs. control 0.026mm2, p= 2.8x10-8), so that 
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the lens/eye ratio was unchanged (0.146 vs. control 0.149, p=0.48) (Fig 4.3 
(xiii)). These results indicate that reduced expression of clcc1 influences eye 










Figure 4.3 clcc1 morpholino validation. Embryos at 24 hpf (i) injected with 
the 5’-modified EGFP or (iv) the unmodified EGFP showed a fluorescent signal 
(arrowheads). (ii) Co-injection of the clcc1-MO eliminated the fluorescent signal 
from morpholino-sensitive 5’-modified EGFP mRNA but (v) not unmodified 
EGFP. (iii, vi) Co-injection of the MM-MO had no effect. Eye size at 36 hpf: 
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(viii, xi) injection of the clcc1-MO significantly reduced eye size (black arrows) 
compared to (ix, xii) MM-MO, and buffer-injected. Scale bar (i-ix) 1 mm; (x-xii) 
100 µm. 
 
Retinal frozen sections of 4 dpf MM-MO- (Fig. 4.4 (i-ii)) and clcc1-MO-injected 
(Fig. 4.4 (iii-iv)) embryos were stained for PKCß1 to evidence bipolar cell, Zpr-1 
for cone photoreceptors, 1D1 for rod photoreceptors, and DAPI. Retinal layers 
as IPL, and ONL of clcc1-MO-treated larvae were significantly thinner in the 
clcc1-MO-treated than MM-MO-treated larvae (7.82 vs. control 12.30μm p= 
4.75 x 10-5 and 9.1 vs. control 12.9μm, p=1.8x10-7) (Fig. 4.3). In contrast, the 
INL showed little change (36.78 vs. control 36.12μm, p=0.21) and the GCL 
increased in thickness (40 vs. control 25.48μm, p<0.0011). The clcc1-MO-
treated larvae showed a reduced number of rod cells (22.5 vs. control 63.3, 
p=1.5x10-7) (Fig. 4.3). Those rod cells present were visible for the most part 
only at the retinal margin, a region of persistent neurogenesis in fish, and even 
at the margin, rod cells often showed abnormal morphology or were pyknotic 
(Fig. 4.4 (i,iii)). Cone opsin positive staining was also decreased, and disrupted 
photoreceptor cell bodies were apparent for clcc1-MO-injected embryos 
compared to the MM-MO injected (Fig. 4.4 (ii, iv)).  Retinal sections were also 
stained for the different cone opsins: anti-blue opsin (v-vi), anti-green opsin (vii-
viii), anti-red opsin (ix, x), or anti-UV opsin (xi, xii), and 4D2 to mark rhodopsin. 
All photoreceptors in clcc1-MO-injected embryos show reduced staining and 
damaged photoreceptor cell structure however, the greatest decreases was 
seen in blue and green opsin cones.  
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Specificity of the morpholino effect was confirmed by co-injection of clcc1 RNA 
in 1-cell embryos with the clcc1-MOs, to rescue the phenotype. Rescue of the 
normal eye size phenotype was almost complete (87%) with co-injected WT 
mRNA suggesting that the observed phenotype was specifically caused by 




Figure 4.4 Retinal sections of embryos at 4 dpf. (i-ii) MM-MO- and (iii-iv) 
clcc1-MO-injected embryos stained for PKCß1 (bipolar cells, green), Zpr-1 
(cone receptors, red, (ii, iv)), 1D1 (rod receptors, red, (i, iii), and DAPI (nuclei, 
blue).clcc1-MO injected embryos show decreased thickness of ONL and IPL 
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layers. (v-xii) MM-MO-injected and clcc1-MO-injected embryos were stained 
with anti-blue opsin, anti-green opsin, anti-red opsin, or anti-UV opsin, and 4D2 
(Rhodopsin). All photoreceptors in clcc1-MO-injected embryos showed reduced 
staining and damaged photoreceptor cell structure, with the greatest decreases 
in blue and green opsin cones. (xiii) clcc1-MO injection and rescue by co-
injected clcc1 WT mRNA. Forty clcc1-MO-treated embryos and forty-one MM-
MO-treated embryos were analysed. Scale Bar: (i-iv) 50 μm; (v-xii) 10 μm. 
 
In order to further confirm the specificity and nature of the phenotypic effects of 
the clcc1 mutant in zebrafish larvae a transcription activator–like (TAL) effector 
nuclease (TALENs) was used to produce a 7 bp deletion in exon1, 
(c.100_106het_delAATGATG, p.Asn34Argfs*9) of clcc1 at one allele 
(clcc1+/TALEN). The homozygous clcc1-/- genotype alteration was lethal at 
around 11 dpf with no clcc1-/- larvae detected at 15 dpf, suggesting that clcc1 
plays an essential role in vertebrate development. Similar to morpholino 
knockdown fish, 5 dpf clcc1-/- KO larvae showed abnormalities in the various 
retinal layers including the IPL, the ONL, the rod photoreceptor layer (Fig. 4.5 (i-
iv)), and less severe effect on cones. When clcc1-/- KO zebrafish embryos were 
injected with WT and p.Asp25Glu mutant clcc1 mRNA, the WT but not mutant 
mRNA was able to reverse changes in both the ONL thickness and rod cell 
numbers (Fig. 4.5 (ix)). While the ONL thickness did not return to the values in 
the WT injected with buffer control (11.26 ± 0.4 vs. 12.54 ± 0.21, p = 0.22), it is 
well above the KO value of 9.9 ± 0.28, p = 0.00819, and that of the KO injected 
with p.Asp25Glu mutant clcc1 mRNA (9.04 ± 0.50, p = 0.0082). It should be 
noted that morpholino and TALENS KO eyes were separate approaches 
examined on different equipment and by different investigators, so while 
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changes relative to controls are consistent, the absolute values for some of the 
measurements vary. The TALENS induced clcc1 mutant also allowed 
confirmation of the functional effects of absence of clcc1 expression on the 
retina. The cone responses (PIII) for 6dpf WT and TALEN clcc1 mutants were 
isolated with Na Aspartate, which blocks post-synaptic ERG signals arising from 
inner retinal neurons. Stimuli were saturating at 490 nm. Cone PIII ERGs 
showed a 50-60% depression of both cone amplitudes and sensitivity in clcc1+/- 
KO zebrafish relative to WT fish at 6 dpf (Fig. 4.5 (v, vii)). ON bipolar responses 
(b2) were isolated by the AMPA/KA antagonist CNQX, which blocks excitation 
for OFF bipolar, horizontal, amacrine, and ganglion cells (Fig. 4.5 (vi, viii)). ON 
bipolar cell spectral sensitivity was reduced by 50% in 5 dpf mutants (Fig. 4.5 
(vi, viii)). Thus, the structural disarray and degeneration seen in clcc1+/- KO fish 




Figure 4.5 Retinal morphology and function is altered in TALEN clcc1+/- 
KO zebrafish. (i-iv) Merged photographs of frozen retinal sections prepared 
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from the heads of 5 dpf larvae. Merged photos of frozen sections from WT (i-iii)  
and KO (ii-iv) embryos stained for PKCß1 (bipolar cells, green), 4D2 (rod 
receptors, red, (i) and (iii)), Zpr-1 (cone receptors, red, (ii) and (iv)), and DAPI 
(nuclei, blue). clcc1+/- KO embryos show destruction of the rod photoreceptor 
layer compared with WT. While somewhat better preserved than in the 
morpholino Clcc1 knockdown embryos, cone photoreceptors and the other 
retinal layers also appear decreased. Scale bar 100 µm. (v) Mutant cone 
responses are 50% depressed relative to WT. (vi) Cone spectral sensitivity is 
depressed about 60% in mutants. (vi) For signals from ON bipolar cells, which 
are 2X more sensitive than cone signals, TALEN clcc1 mutant responses 
decrease by over 50%. Stimuli are saturating at 490nm. (viii) ON bipolar cell 
spectral sensitivity is depressed over 50% in mutants. Sensitivity axis is in units 
of nV per quantum as calculated from the amplitude of responses to constant 
quanta stimulation across the spectrum (Eq.1). The quanta level of 2500 
hν⋅μm−2⋅s−1 at the cornea is below semi-saturation for all cone types. (ix) co-
injection of zebrafish embryos with WT but not p.D25E mutant clcc1 mRNA can 
rescue the KO phenotype. *p 0.022 vs. WT injected with buffer control, p = 
0.0082 vs KO injected with Asp25Glu mutant clcc1 mRNA, ** p = 0.00095 vs. 
WT injected with buffer control *** p > 0.00012 vs. WT injected with buffer 
control. Buffer control injected in WT zebrafish (N=5), and in KO zebrafish 
(N=4); injection of WT CLCC1 mRNA in WT zebrafish (N=5) and in KO 
zebrafish (N= 4); injection of Asp25Glu CLCC1 mRNA in WT zebrafish (N=4) 




4.2.3 Ocular characteristics of CLCC1+/-  knockout mice 
To gain further insight into the effects of loss of CLCC1 function on retina, vision 
and retinal morphology in mammals, Clcc1 KO mice (Jackson Laboratories, 
stock number: 027239, B6N(Cg)-Clcc1tm1b(KOMP)Mbp/2J) were investigated. A lack 
of Clcc1-/- KO mice in intercrosses of Clcc1+/- KO mice suggested that total lack 
of Clcc1 activity was embryonic lethal, so the effect of heterozygosity for the 
Clcc1 KO on the retina was studied (Fig. 4.6). Mice showed no abnormalities in 
their extraocular phenotypes. Haematoxylin & eosin staining of 7-months old 
Clcc1+/- KO mice retinas showed that the overall structure of the retina was 
preserved however, the photoreceptor layer showed disarray and reduced 
thickness, with reduction of cells in the outer and inner nuclear as well as OPL 
and IPL (Fig. 4.6 (i)) in Clcc1+/- KO mice compared to the WT. 
Reduction of the number of cone cells was confirmed with 
immunohistochemistry when retinal sections were stained for the antibody 
against cone arrestin.  Clcc1+/- KO mice displayed were about the half the cone 
density in compared to the WT (Fig. 4.6 (ii)).  The ability to respond to light 
stimuli of retinal neurons was assessed using ERGs. Clcc1+/- KO mice showed 
depression of amplitude responses of scotopic a-wave, derived from the rods, 
and b-wave, derived from the inner retina, predominantly Muller and ON-bipolar 
cells, compared with WT mice (Fig. 4.6 (iii)), suggesting degeneration of rods 
and secondary order neurons. Moreover, Clcc1+/- KO mice exhibited a 
significant decreased amplitude of the photopic b-wave, derived from cones, 
compared with WT mice (Fig. 4.6 (iv)), indicating possible dysfunction of the 
cone photoreceptors response. These results were also consistent with the 






Figure 4.6 Effects of heterozygosity for Clcc1 KO on mouse retinas. (i) 
Haematoxylin & eosin staining of WT and Clcc1+/- knockout 7-month-old mouse 
retinas. While the overall structure of the retina was preserved, staining 
revealed decreased cell density in the outer and inner nuclear layers, as well as 
the outer and inner plexiform layers as well as structural disarray of the 
photoreceptor layer in Clcc1+/- KO mice compared with the WT mice. (ii) 
Immunostaining of cone arrestin in WT and Clcc1+/- KO mice. The WT mice 
exhibit normal cone photoreceptors staining pattern while Clcc1+/- KO mice 
revealed reduced number of cone photoreceptors. (iii-iv) Electroretinography of 
wild-type and Clcc1+/- KO mice showed approximately 20-50% decreases in the 
amplitude of both the scotopic and photopic a- and b- wave amplitude 
responses in Clcc1+/- KO mice compared to WT at all levels of luminance. 
Figure made at NEI. 
 
4.2.4 CLCC1 localises in the ER 
To confirm the ER localisation of CLCC1 reported by Jia et al. [206], HEK293 
cells were cultivated, fixed, and immunolabelled with CLCC1 antibody and ER 
markers including calreticulin, KDEL, and calnexin. The tetrapeptide KDEL is 
located at the C-terminus of several ER luminal proteins, and it is a retrieval 
motif essential for the precise sorting of proteins along secretory pathways 
[235]. These markers have been chosen based on what was already available 
in the lab, and based on the compatibility with CLCC1 antibody. CLCC1 staining 
showed a punctate distribution in the cytoplasm, in particular in the perinuclear 
region and nuclear envelope. CLCC1 showed partial co-localisation with KDEL 
(Fig. 4.7 (i), arrows), but not with calnexin the expression of which appeared 
more defined (or clustered) than CLCC1 (Fig. 4.7(i)). NIH/3T3 cells were also 
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used to verify the distribution of endogenous CLCC1 in mouse fibroblasts (Fig. 
4.7(ii)). The localisation pattern of CLCC1 in murine cells was punctate and 
comparable to that seen in human cells, indicating conservation of function. It 
was not possible to double stain the cells with CLCC1 and calreticulin as both 
antibodies were raised in rabbit.  This result indicates that CLCC1 may co-
localise with proteins carrying the KDEL sequence at their C-terminus. 
 
Figure 4.7 CLCC1 localisation with ER markers. (i) In HEK293 cells, 
endogenous CLCC1 co-localises with KDEL but not with calnexin. (ii) In 
NIH/3T3 cells, the endogenous distribution of CLCC1 was similar to HEK293 
cells, also the localisation of CLCC1 relative to calnexin was similar as well. 
Scale bar 10 µm. 
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To overcome problems in compatibility between antibodies and to verify the 
localisation of mutated CLCC1, expression studies were performed using N-
terminal YFP-tagged CLCC1 and C-terminal FLAG tagged CLCC1 (gifts of Dr. 
John Chilton). Both YFP and FLAG tags were used because of the tendency of 
fluorescent proteins to impair the folding or binding sites of the tagged protein; 
the FLAG tag is smaller in size, therefore less likely to affect the activity of a 
target protein. Overexpression of both YFP tag or FLAG-tag plasmids did not 
influence the localisation of CLCC1 within the ER, as demonstrated by co-
staining with calreticulin. (Fig. 4.8), giving confidence that the tagged forms of 
CLCC1 may faithfully represent the localisation of the endogenous molecule. 
Moreover, there were no observable differences in localisation between 
endogenous CLCC1 and tagged constructs, or between the wild type protein 





Figure 4.8 CLCC1 localisation with Calreticulin in HEK293 cells. HEK293 
cells were transiently transfected with different constructs containing CLCC1-
WT and CLCC1-Asp25Glu. Both CLCC1-WT and CLCC1-Asp25Glu show co-
localisation with calreticulin. Scale bar 10 µm. 
 
To assess the localisation of CLCC1 in a more physiologically relevant cell type, 
E7 chick retinal ganglion cells (RGC) were investigated. E7 RGC cells were 
chosen for two main reasons: (i) RGC differentiate at early stages of 
development, therefore at E7 a relatively pure population of primary neurons 
can be readily obtained and (ii) they are routinely available in the laboratory and 
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they are straightforward to culture. Unfortunately, the expression of endogenous 
CLCC1 could not be assessed as the antibody did not recognise the chick 
epitope. However, based on our earlier data showing that epitope-tagging did 
not appear to interfere with the localisation of CLCC1 (Fig. 4.8) it was decided 
to nucleofect RGC with CLCC1-WT FLAG/CLCC-Asp25Glu FLAG, and 
mCherry-KDEL, as tubular ER marker [236]. CLCC1 was found to co-localise 





Figure 4.9 CLCC1 wild type and Asp25Glu variant in E7 chick retinal 
ganglion cells.  E7 RGC were dissociated and co- nucleofected with CLCC1 
WT or Asp25Glu and mCherry-KDEL. CLCC1 WT and mutant co-localise with 
KDEL in the RGC cell bodies (i) and growth cones (ii). Scale bar 5 µm. 
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4.2.5 CLCC1 isoforms  
CLCC1 is predicted to have four different isoforms produced by alternative 
splicing (www.uniprot.org) (Fig. 4.10). The canonical isoform (isoform 1) is 
stems from twelve CLCC1 exons encoding 551 amino acids (aa) with a 
predicted molecular weight of ~62 kilodalton (kDa) (Fig. 4.10 (i)); isoform 2 is 
shorter than the canonical isoform, using an alternate splice site in the 5' UTR, 
lacking exon 1, but maintaining the reading frame (Fig. 4.10 (i)). It has a length 
of 501 aa and a predicted molecular weight of ~56 kDa. Both isoforms 1 and 2 
contain three transmembrane domains, with a cytoplasmic N-terminus (N-term) 
and a luminal C-terminus (C-term) (Fig. 4.10 (ii)). The third isoform differs in the 
5' UTR, lacking two consecutive exons in the coding region (exon 5 and 6) (Fig. 
4.10 (i)); it comprises 430 aa with a predicted molecular weight of ~47 kDa with 
a single transmembrane helix (Fig. 4.10 (ii)). Isoform 4 is the shortest isoform, 
lacking four consecutives exons (from exon 5 to exon 8) (Fig. 4.10 (i)), with a 
length of 366 aa and a predicted molecular weight of ~39 kDa. It differs from the 
other isoforms by the presence of two transmembrane domains and 
cytoplasmic C- and N-termini (Fig. 4.10 (ii)). Transmembrane domains (TM) of 
isoform 1 were encoded by amino acids Val185 to Thr205 (exon 5 and 6), 
Leu217-Phe237 (exon 6), and Ile330-Cys350 (exon 9 and 10). Isoform 2 TMs 
were encoded by amino acids Tyr133-Trp154 (exon 5 and 6), Val166-Trp183 
(exon 6), Ala282-Ala302 (exon 9 and 10). Isoform 3 TM was encoded by exon 
10 Ala211-Ala232, while for isoform 4 they were encoded by amino acids 
Ile103-Thr124 in exons 4 and 9, and Ile145-Gly169 in exons 9 and 10. 
While the TM domain encoded by exons 9 and 10 were common to all isoforms, 
isoforms 1 and 2 showed two TM domains encoded by exon 5 and 6, and 6 
respectively. Isoform 4 instead presented a TM domain encoded by exon 4 and 
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exon 9. Absence of a publicly available 3D structure does not allow the 
prediction of which exon encodes for a precise TM, and the location of each TM 
region remains hypothetical. Additionally, tagged gene constructs indicated that 
all isoforms were restricted to the ER (Fig. 4.11). However it has been possible 











Figure 4.10 Topology of CLCC1 predicted isoforms. (i) Schematic 
representation of CLCC1 isoforms. The numbers indicate the exons, while the 
colours indicate which part of exons code for a TM domain. (ii) CLCC1 isoform 
1 has 3 transmembrane domains and 18 aa signal peptide indicated by the 
green bar. Isoform 2 is similar to isoform 1 but lacks the signal peptide at 
5’UTR. The third isoform has only one transmembrane domain. Isoform 4 has 
two transmembrane helices and both C- and N-termini are cytoplasmic. The 




Figure 4.11 Co-localisation of CLCC1 isoforms with calreticulin. HEK293 
cells were transiently transfected with the different YFP CLCC1 isoforms and 
immunolabelled for calreticulin.  All CLCC1 isoforms localise in the ER, co-
localising with calreticulin. Scale bar 10 µm. 
 
The orientation of full-length CLCC1 within the membrane was assessed using 
a vector incorporating YFP at the N-terminus of CLCC1, and the FLAG tag at 
the C-terminus. HEK293 cells were transfected with YFP-CLCC1-FLAG, fixed 
and stained with anti-FLAG and calreticulin antibodies (Fig. 4.12 (i)). To assess 
the relative co-localisation the Pearson’s coefficient was calculated using 
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ImageJ plug-in JACOP, for YFP vs calreticulin and FLAG vs calreticulin. There 
was no significant difference between the two sets of data (Fig 4.12 (ii)). To 
further investigate and obtain a more definitive result, a semi-permeabilisation 
with 0.1% saponin was performed on NIH/3T3 cells transfected with CLCC1-WT 
FLAG and stained calreticulin (Fig.4.12 (iii)). With the assumption that if the C-
termini of CLCC1 was in the ER lumen, no fluorescence of FLAG and 
calreticulin should have been detected, as the antibody should not be able to 
enter inside the ER, while if the C-termini of CLCC1 was cytoplasmic, only the 
FLAG fluorescence should have been detected. However, inconsistent results 
amongst replicates did not gave a conclusive answer, an example of these 












Figure 4.12 Assessment of C- and N-termini localisation (i) HEK293 cells 
were transfected with YFP-CLCC1-FLAG vector, and stained with calreticulin. 
(ii) Co-localisation of YFP vs calreticulin and FLAG vs calreticulin was 
calculated using Pearson’s coefficient. Mann-Whitney U-test was used to 
determine that there was no significant difference between the groups (n=9; 
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p=0.6048). (iii) Semi-permeabilisation of NIH/3T3 cells gave inconsistent 
results. Scale bar 10 µm.  
 
4.2.6 Co-immunoprecipitation of CLCC1 and calreticulin 
To determine if CLCC1 directly interacts with calreticulin, immunoprecipitation 
was performed using the CLCC1 antibody as bait, and proteins were visualised 
by Western blot. In the immunoprecipitated sample (IP) two bands were 
detected when the blot was probed with the CLCC1 antibody, one band of ~65 
kDa and a second band of ~50-55 kDa (Fig 4.13 (i)), indicating the successful 
pull-down. No CLCC1 was present in the ‘-‘ lane, corresponding to the negative 
control of the IP (it contains proteins that are not interacting with the 
immunoprecipitated protein), and in the input sample. A band corresponding to 
calreticulin (~50-55 kDa) was detected when endogenous CLCC1 was 
precipitated (Fig 4.13 (ii)). Conversely, when endogenous calreticulin was pulled 
down, a single band corresponding to a single CLCC1 isoform was present on 
the blot (Fig 4.13 (iii-iv)). 
To define if the interaction of CLCC1 with calreticulin happened also when 
CLCC1 was overexpressed, HEK293 cells were transiently transfected with 
CLCC1-WT/Asp25Glu FLAG and YFP CLCC1-WT/Asp25Glu, and pulled down 
using the tags as bait. Western blot (Fig. 4.14 (i)) revealed that calreticulin was 
not present in the CLCC1-WT FLAG sample (lane 1), as well as in the CLCC1-
Asp25Glu sample (lane 3). However, some calreticulin was detected in lanes 2 
and 4, respectively the negative controls of CLCC1-WT FLAG and CLCC1-
Asp25Glu FLAG, indicating that the FLAG tag at the C-terminus of CLCC1 likely 
impairs the binding between CLCC1 and calreticulin. 
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To evaluate if the C-terminal FLAG tag may obstruct the binding site of CLCC1 
with calreticulin, HEK293 were transiently transfected with N-terminal YFP 
tagged CLCC1. The immunoprecipitation was performed using the GFP-trap as 
widely used for co-immunoprecipitation of GFP/YFP plasmids. Western blot 
(Fig. 4.14 (ii)) showed that calreticulin was exclusively present in negative 
controls (lanes 2 and 4) and absent in the IP samples (YFP CLCC1-WT in lane 
1, and YFP CLCC1-Asp25Glu in lane 3). These results indicate that the function 
of CLCC1 may be related to calreticulin however, the multitude of pathways in 
which calreticulin is involved makes it difficult to predict which CLCC1 may 
participate in. Also, the pulldown of plasmids expressing CLCC1 showed no co-
immunoprecipitation of calreticulin, suggesting that tags on either the C-
terminus or N-terminus may prevent the association of CLCC1 with other 
proteins.  
In future studies it would be interesting to perform a pull-down using an anti-
KDEL antibody however the validity of this approach needs to be carefully 





Figure 4.13 Endogenous CLCC1 co-immunoprecipitates with calreticulin.  
(i) immunoprecipitation of endogenous CLCC1 using CLCC1 antibody. The 
membrane was stained with CLCC1 and GAPDH to evaluate the efficacy of the 
pulldown. In the ‘IP’ lane the two bands of weight ~65 kDa and ~50-55 kDa 
indicate the presence of two CLCC1 isoforms. It was not possible to detect 
CLCC1 in the input sample and in the ‘-‘ lane, which contains all the proteins 
except those present in the ‘IP’ sample. GAPDH was only present in the ‘-‘, and 
input samples. (ii) A band corresponding to calreticulin was identified in the ‘IP’ 
samples, indicating that calreticulin co-immunoprecipitates with CLCC1. (iii) 
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Endogenous calreticulin was pulled down using calreticulin antibody. Western 
blot showed a band corresponding to calreticulin (~50-55 kDa) in all the lanes. 
Presence of calreticulin in the ‘-‘ lane indicates that not all calreticulin attached 
to the beads during the pulldown. (iv) When endogenous calreticulin was pulled 
down, a band corresponding to the size of CLCC1 (about 50 kDa) was present 









Figure 4.14 Calreticulin does not co-immunoprecipitate with CLCC1-
WT/Asp25Glu FLAG or YFP CLCC1-WT/Asp25Glu. (i) HEK293 cells were 
transiently transfected with CLCC1-WT FLAG or CLCC1-Asp25Glu FLAG, the 
co-immunoprecipitation was performed using the FLAG epitope as bait. 
Western blot showed that calreticulin was only present in lanes 2 and 4, 
corresponding to the negative controls of CLCC1-WT FLAG and CLCC1-
Asp25Glu FLAG. Absence of calreticulin proteins was detected in the IP of 
CLCC1-WT FLAG and CLCC1-Asp25Glu FLAG. Pulldown of endogenous 
CLCC1 and endogenous calreticulin were used as positive controls. (ii) 
pulldown of YFP CLCC1-WT and YFP CLCC1-Asp25Glu using GFP trap 
155 
 
showed that calreticulin was not present in the IP samples (lanes 1 and 3) 
however, it was possible to detect a small amount of calreticulin in the negative 
controls.  
 
4.2.7 Mass spectrometry analysis of CLCC1 binding partners 
To identify other putative CLCC1 binding partners and learn more about CLCC1 
function, Liquid Chromatography with tandem Mass Spectrometry (LC-MS/MS) 
analysis was performed at the University of Bristol, Proteomics Facility. 
Endogenous CLCC1, CLCC1-WT FLAG, and CLCC1-Asp25Glu FLAG from 
HEK293 cells were immunoprecipitated using the Co-IP protocol as described 
before.  For each experimental condition, the analysis was performed in two 
replicates. Results of the mass spectrometry were filtered following the pipeline 
described in Fig 4.15. Proteins identified in the controls were labelled as 
‘Negative’ and each CLCC1-#-FLAG replicate was compared to the ‘Negative’. 
Proteins not present in the ‘Negative’ or present with a 2.5-fold, or greater, 
increase in the protein score were added to the ‘True Positives’ lists. All the 
proteins present in both ‘True Positives’ lists were then included in the ‘Double 
Positives’ list. To classify the proteins based on score, the average of the 
scores of each replicate was performed.  STRING (https://string-db.org/) was 
used to visualise connections and networks between proteins. Connections 
were visualised based on experimental data and information derived from 
curated databases, disconnected nodes were not shown. Clustering was 











For endogenous CLCC1, hits were filtered against the control data sets used for 
FLAG tagged proteins pulldown. This identified 116 proteins as possible 
interactors with endogenous CLCC1, for which cluster analysis with STRING 
identified three main clusters. The biggest cluster contained 17 ribosomal 
proteins, RLPs proteins (Figure 4.16 (i), light green cluster), related to mRNA 
processing, which constitute one out of five major biological processes (Figure 
4.16 (ii)) and molecular function gene ontology (GO) terms (Figure 4.16 (iv)). 13 
proteins (Figure 4.16 (i), dark green cluster) were related to protein processing, 
in particular the cluster contained chaperones as HSPA8, and members of the 
TRiC chaperone complex, CCT3, CCT4, CCT5, which regulates telomere 
maintenance [237] and BBSome assembly [238]. The third cluster identified 
with STRING contained proteins related to intracellular transport (Figure 4.16 
(i), blue cluster) as tubulins, TUBB2B and TUBB4A, cytoplasmic dynein 
DYNC1H1, coatomer complex COPB1, and KDELR1, a receptor involved in 
retention of proteins in the ER.  
These results indicate that CLCC1 may be involved in folding, protein transport, 
or translation of proteins. The enrichment of mRNA-related hits could also be 
explained by the ability of the antibody used to pulldown CLCC1 to recognise 
the nascent CLCC1 protein still attached to the ribosome during protein 
translation. 







Figure 4.16 STRING analysis of endogenous CLCC1 interactions. (i) 
Clusters of proteins were highlighted with different colours. Light green cluster 
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contained proteins related to the ribosome and mRNA processing, dark green 
cluster was composed by proteins with chaperone activity, while the blue cluster 
indicates proteins involved in intracellular trafficking. Proteins that do not belong 
to either cluster are shown in red. Line thickness represents the strength of the 
data support. (ii) GO terms for biological processes. (iii) GO terms for cellular 
components. (iv) GO terms for molecular function.  
 
When CLCC1-WT FLAG was pulled down, 236 proteins were identified as 
possible interactors; STRING network analysis identified three main clusters of 
proteins. A cluster contained hits related to the proteasome (Fig. 4.17 (i), light 
green), as PSMB1, PSMD4, PSMC1, other proteasome subunits, and ubiquitin. 
The second main cluster (Fig. 4.17 (i), dark green) contained proteins related to 
the ER, in particular proteins associated to the translocon such as SEC61A, 
SPCS3, SSR1; proteins related to ribosomes such as RPS12, RPLP0; recycling 
carriers as SCAMP3; and proteins associated to N-glycosilation like ALG10, 
MAGT1, KRTCAP2 and DDOST. The third cluster (Fig. 4.17 (i), blue) was made 
of proteins necessary for transport like tubulins, TUBB2B, TUBB4B; dyneins, 
DYNC1H1 and DYNC1LI1; non-clathrin coated vesicles such as COPA, 
COPB2, COBP1; and KDELR1 and KDELR2 which retain soluble proteins into 
the ER. All the other proteins (Fig. 4.17 (i), red) showed no clustering with either 
of the three main clusters. Some of them had ATPase activity such as ATP1A1, 
ATP1B3; others had chaperone activity like HSPA8, HSPA5 and CALX. GO 
terms for cellular components identified all the proteins as related to the ER and 
nuclear outer membrane-ER interface (Fig. 4.17 (iv)). This is consistent with the 
observed pattern of CLCC1 expression seen in HEK293 and RGC on the 
boundary between the nuclear envelope and the ER (Fig. 4.8 and Fig. 4.9).   
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Interestingly, the proteasome cluster was not present in the endogenous 
CLCC1 dataset which instead presented the ribosomal cluster, much less 
represented in the CLCC1-WT FLAG dataset. The presence of high 
represented proteasome pathway might be caused by the overexpression of 
plasmids itself, as the cells might increase protein degradation levels to reduce 
the protein overload which was caused by overexpression. Overexpression of 
proteins could also explain the presence of the high number of hits related to 
protein translocation into the ER, induced by higher levels of translation than in 









Figure 4.17 STRING analysis of CLCC-WT FLAG interactions. (i) Clusters of 
protein were highlighted with different colours. Three main clusters were 
highlighted by different colours. Light green cluster contained proteins related to 
the proteasome, dark green cluster was composed by proteins related to the 
ER, while the blue cluster indicates proteins involved in intracellular transport. In 
red were highlighted proteins that do not belong to either cluster. Line thickness 
represents the strength of the data support. (ii) GO terms associated with 
biological process. (iii) GO terms for cellular components. (iv) GO terms for 
molecular function. 
 
To investigate whether the Asp25Glu alteration may have a substantial effect on 
CLCC1 molecular interactions, two datasets (CLCC1-WT and CLCC1-
Asp25Glu) were investigated to define interactions lost and/or gained with the 
alteration. From the list of proteins interacting with CLCC1-WT FLAG, 95 out of 
the 236 were present exclusively in the WT list when compared with the 
Asp25Glu mutant list (Fig. 4.18 (i)). These potentially represent the interactions 
lost in presence of the Asp25Glu alteration. As expected, most of the interactors 
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belonged to clusters already present into the WT list, the proteasome (Fig. 4.18 
(i) light green), protein translocation into the ER (Fig. 4.18 (i) dark green), and 
protein trafficking (Fig. 4.18 (i) blue).  
Mass spectrometry for CLCC1-Asp25Glu FLAG identified 249 binding partners, 
109 were present exclusively in the Asp25Glu mutant, representing the 
interactions that were potentially gained following the alteration (Fig. 4.19). 
STRING clustering analysis highlighted a set of proteins related to intracellular 
transport such as ACTR1A, TMED10, GOSR2 (Fig. 4.19 (i) blue). The second 
cluster (Fig. 4.19 (i) dark green) contained proteins related to translocation into 
the ER, such as SEC61B and RPS5; and N-Glycosylation such as DAD1 and 
STT3B.  The third cluster (Fig. 4.19 (i) light green) contained proteins involved 





Figure 4.18 STRING analysis of CLCC-WT FLAG interactions not present 
in CLCC1-Asp25Glu FLAG. These interactions represent lost binding partners 
caused by the Asp25Glu alteration. (i) Clusters of protein were highlighted with 
different colours. Light green cluster contained proteins related to the 
proteasome, dark green cluster was composed by proteins related protein 
165 
 
translocation into the ER, while the blue cluster indicates proteins involved in 
intracellular transport. In red were indicated proteins that do not belong to either 
cluster. Line thickness represents the strength of the data support. (ii) GO terms 
associated with biological process. (iii) GO terms for cellular components. (iv) 








Figure 4.19 STRING analysis of proteins gained with the CLCC1-Asp25Glu 
FLAG. These interactions were present exclusively in the CLCC1-Asp25Glu 
FLAG, indicating new protein interactions gained with the Asp25Glu alteration. 
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(i)Clusters of protein were evidenced with different colours. Lines thickness 
represents the strength of the data support. (ii) GO terms associated with 
biological processes. (iii) GO terms for cellular components. (iv) GO terms for 
molecular function. 
 
Comparison between cellular component GO terms of different data sets (Fig. 
4.20) identified that for CLCC1-WT FLAG the interactions mainly represented 
ER proteins (59%) or nuclear outer membrane-ER proteins (20%). Binding 
partners lost with the Asp25Glu alteration were mostly ER related (37%), 
although a substantial number were cytoplasmic (28%) relating to the 
endomembrane system (18%), and the organelle membrane (17%).  The 
analysis of cellular component terms of binding partners gained with the 
Asp25Glu mutant identified a majority of them as cytoplasmic proteins (40%), 
28% of which were related to the ER, 14% related to the nuclear outer 
membrane-ER boundary, and 18% of proteins related to organelle membrane. 
KEGG (Kyoto Encyclopaedia of Genes and Genomes) analysis of pathways 
indicated that most of the proteins CLCC1 interacted with were related to 
metabolic pathways, the proportion of them slightly increasing in both lost and 
gained interactions caused by the Asp25Glu alteration. Proteasome-related 
proteins are not represented in the dataset interactions gained by the alteration, 
which might indicate that the alteration per se does not increase protein 
degradation.  
These results indicate that the function of CLCC1 may mainly relate to the 
cytoplasm and the ER, with limited involvement of other organelles. 
Interestingly, the nuclear outer membrane-ER compartment is not represented 
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in the set of proteins lost with the alteration. Amongst all datasets false 
discovery rate (FDR) confidence for cellular components GO terms was several 












































Figure 4.20 Cellular components and KEGG pathways analysis of mass 
spectrometry hits for the three data sets. 
 
Mass spectrometry hits were also manually searched on PubMed to define 
which proteins have been reported as expressed in the retina (Fig. 4.21). 
Proteins were considered only if the protein score was over 10. Thirty-nine 
proteins were found reported as expressed in the retina, four of them present 
exclusively in the CLCC1-WT dataset, and twelve of them present exclusively in 
the CLCC1-Asp25Glu dataset. Twenty-three proteins were present in both 
datasets.  
Subdivision of the thirty-nine proteins based on subcellular localisation found in 
UniProtKB/Swiss-Prot (www.uniprot.org/) and Human Protein Atlas 
(www.proteinatlas.org) showed that the compartments most represented were 
the cytosol, nucleus, and ER (Fig. 4.22).   
Taken together, these results confirm that CLCC1 interacts primarily with ER 
proteins, consistent with ours and others immunocytochemical localisation 
studies (Fig. 4.8-4.9) [206]. The Asp25Glu alteration causes loss of ER 
interactions in favour of cytoplasmic ones. Identifying what is lost from the ER 
and what is gained in cytoplasm might provide evidence for CLCC1 function. 
The cellular components analysis suggests that, even though no change in 
subcellular localisation was detected, the alteration may alter interactions that 
occur at/in the ER. Interestingly, the mass spectrometry analysis did not report 
as binding partner calreticulin, supporting the evidence that the tag on proteins 
might interfere with the binding of functional partners. 
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From the analysis and clustering of mass spectrometry results we choose four 
interactions to analyse further: HSPA5 (BiP), SGMR1, CALX and EMC1. These 
proteins were present exclusively in the datasets where CLCC1 was 
overexpressed and absent in the endogenous CLCC1 dataset. All four proteins 
were expressed in the retina (Fig. 4.21) and located in the ER (Fig. 4.22), 








Figure 4.21 Genes reported as expressed in the retina. Pubmed search of 
proteins/genes resulting from the mass spectrometry as expressed in the retina. 
Mass spectrometry protein scores over 50 are indicated with red squares, 
scores between 50 and 20 indicated by orange squares and scores lower than 
20 indicated by green squares. White squares indicate protein/gene not 





Figure 4.22 Subdivision of proteins based on intracellular 
compartmentalisation. Subcellular localisation was searched on 
UniProtKB/Swiss-Prot and Human Protein Atlas.  Mass spectrometry protein 
scores over 50 are indicated with red squares, scores between 50 and 20 
indicated by orange squares and scores lower than 20 indicated by green 




4.2.8 Analysis of CLCC1 binding partners 
From mass spectrometry analysis four proteins were chosen to further 
investigate their relationship with CLCC1. EMC1 is part of the ER membrane 
protein complex (EMC), a multi protein complex present in eukaryotes, which 
has 10 members. EMC1 disruption has been reported as associated with 
neurological degeneration [239] and retinal dystrophy [240]. EMC serves as 
insertase for weakly hydrophobic transmembrane domains of tail-anchored 
proteins [241], modulates the co-translational expression of multi-pass 
membrane proteins with challenging TMDs [242], promotes accuracy of G-
protein-coupled receptor (GPCR) biogenesis through insertion of their first trans 
membrane domain [243], and maintains cholesterol homeostasis by promoting 
biogenesis of sterol-related enzymes [244]. Moreover, in Drosophila 
photoreceptors, EMC has been reported as an essential component for the 
stabilisation of immature rhodopsin and other multi-pass membrane proteins 
[245]. 
SGMR1 (also called SigmaR1) has been associated with hereditary motor 
neuropathy and amyotrophic lateral sclerosis [246, 247], and reported as 
expressed in the retina [248]. The SigmaR1 is a receptor, localising in 
mitochondria-associated membrane (MAM), which are the contact sites 
between ER and mitochondria, where calcium handling proteins such as IP3Rs, 
are high compartmentalised. Normally, SigmaR1 binds BiP, but upon 
stimulation SigmaR1 dissociates leading to a prolonged Ca2+ signalling into the 
mitochondria via IP3R.  Upon ER stress or loss of calcium from the ER, 
SigmaR1 moves in the ER and is able to interact with PM proteins. Increased 
expression of SigmaR1 leads to the reduction of ER stress, probably this is 
related to the chaperone activity the SigmaR1 possess [249]. The association of 
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SigmaR1 with STIM1 induces a slow recruitment of STIM1 to ER-PM junction 
and reduces the binding to Orai1 [250]. 
BiP belongs to Hsp70 family of chaperons and has a major role in the ER. BiP 
is involved in chaperoning newly synthesised proteins, export of misfolded 
proteins to the proteasome, UPR signal transduction, calcium homeostasis, and 
protein translocation into the Sec61 complex [251-253]. 
Calnexin (CALX) is a transmembrane calcium-binding protein, a soluble 
paralogue of calreticulin. Calnexin binds partially folded glycoproteins to 
determine if they can be released from the ER or sent to the proteasome [254], 
and controls intracellular Ca2+ oscillation via interaction with SERCA [255].  
To confirm that the selected proteins pulled-down with CLCC1 we co-
immunoprecipitated endogenous CLCC1, and CLCC1-WT FLAG and CLCC1-
Asp25Glu FLAG molecule after overexpression in HEK293 cells. Membranes 
were stained for EMC1, BiP, calnexin and SigmaR1. While the probing with BiP 
and EMC1 did not work, probing with anti-mouse SigmaR1 and calnexin 
showed a band in exclusively present in the lanes 1 and 3 corresponding to 
CLCC1-WT FLAG pull-down and CLCC1-Asp25Glu FLAG pull-down (Fig. 4.23), 
although absent in the endogenous CLCC1 pulldown. This indicates that these 
proteins co-immunoprecipitated with CLCC1 when overexpressed, confirming 







Figure 4.23 Calnexin and SigmaR1 co-immunoprecipitated with CLCC1-
WT and Asp25Glu FLAG HEK293 cells were transiently transfected with 
CLCC1-WT FLAG or CLCC1-Asp25Glu FLAG, the co-immunoprecipitation was 
performed using the FLAG epitope as bait, and CLCC1 antibody was used to 
co-immunoprecipitate the endogenous CLCC1. Western blot showed that 
calnexin and SigmaR1 were only present in lanes 1 and 3, corresponding to the 
CLCC1-WT FLAG and CLCC1-Asp25Glu FLAG. Both proteins were absent in 








To confirm co-localisation between CLCC1 and the chosen proteins, NIH/3T3 
cells were seeded and transfected with CLCC1-WT/Asp25Glu FLAG or YFP 
CLCC1-WT/Asp25Glu and stained with the various antibodies. Staining of 
CLCC1-WT/Asp25Glu FLAG transfected cells with EMC1 antibody showed 
punctate pattern; EMC1 primarily localised in the perinuclear area likely 
corresponding to ER sheets, and unexpectedly on the plasma membrane (Fig. 
4.24 (i)). Co-localisation of EMC1 with CLCC1 was partial for both WT and 
Asp25Glu mutant. To confirm whether EMC1 was present in the ER, cells were 
co-transfected with YFP CLCC1-WT/ Asp25Glu and mCherry-KDEL. Again, 
EMC1 appeared to localise with the ER with and positive staining was again 
present on what were likely the ER sheets, and on the plasma membrane (Fig. 
4.24 (ii), arrows). Presence of EMC1 at the plasma membrane may be the 
result of inappropriate binding of the antibody to other (i.e. non-EMC) targets, as 










Figure 4.24 Partial co-localisation between CLCC1 and EMC1. NIH/3T3 
cells were transfected with (i) CLCC1-WT/Asp25Glu FLAG and stained for 
EMC1 or (ii) mCherry-KDEL and YFP CLCC1-WT/Asp25Glu and stained with 
EMC1 antibody. In both cases EMC1 localises on the plasma membrane 
(arrows) and structures that resemble ER sheets (asterisks). Scale bar 10 µm. 
 
Staining of CLCC1-WT/ Asp25Glu FLAG transfected cells with SigmaR1 
antibody showed a punctate pattern. SigmaR1 displayed a similar localisation to 
CLCC1 (to both WT and Asp25Glu FLAG tagged molecules), where SigmaR1 
and CLCC1 were in close proximity (Fig 4.25 (i), arrows). SigmaR1 also partially 
co-localised with mCherry-KDEL, indicating its presence in the ER. However, its 
expression was also delocalised from the ER (Fig 4.25 (ii), arrows), indicating 
that SigmaR1 was probably present at the contact sites between ER and 
probably mitochondria. To confirm that SigmaR1 was near mitochondria, cells 
were treated with 150 nM of MitoTracker Red for 15 min at 37 °C (Fig. 4.26). 
The labelling indicated the presence of SigmaR1 and CLCC1 in a region 
between the ER and mitochondria, consistent with it being located at the 
contact sites (or MAM). Unfortunately, co-labelling of MitoTracker Red and 
mCherry-KDEL was not possible as both were associated with a red fluorescent 
protein, therefore the relative position of SigmaR1 with respect to the ER and 
mitochondria was not verifiable with the tools available in laboratory, in a time-
appropriate manner. These results indicate that CLCC1 and SigmaR1 occupy 






Figure 4.25 Co-localisation between CLCC1 and SigmaR1. NIH/3T3 cells 
were transfected with (i) CLCC1-WT/Asp25Glu FLAG and stained for SigmaR1 
or (ii) mCherry-KDEL and YFP CLCC1-WT/Asp25Glu and stained with 
SigmaR1 antibody. SigmaR1 partially co-localised with CLCC1 and ER marker, 





Figure 4.26 CLCC1 transfected cells stained with MitoTracker Red showed 
the presence of SigmaR1and CLCC1 in the region of ER-mitochondria contact 






Cells transfected with CLCC1 FLAG or YFP CLCC1 (both WT and Asp25Glu; 
not shown) displayed an increase of SigmaR1 (anti-rabbit SigmaR1, 
SigmaR1(R)) fluorescence (Fig. 4.27 (i) arrows), compared to untransfected 
cells. This effect was independent from the species in which the antibody was 
raised, anti-mouse SigmaR1 (SigmaR1(M)) showed a similar pattern. This 
effect was not likely specifically caused by the overexpression of CLCC1 
because cells transfected with R-pre-mRFP (gift of Dr. John Chilton), a probe 
based on the C-terminus of K-Ras [256] to evidence the plasma membrane, 
showed the same increase of SigmaR1 fluorescence. This experiment may 
indicate that plasmid overexpression can’t be used effectively in combination 
with SigmaR1 antibody. Increased lipid burden due to transfection with 
liposome fusion to the cell membrane might increase the amount of SigmaR1 
associated with lipid rafts on both plasma membrane and other compartments 
[257]. 
To verify if overexpression of SigmaR1 caused increased CLCC1 fluorescence, 
NIH/3T3 cells were transfected with EGFP-SigmaR1 (gift of Dr. Antonis 
Ververis) and stained with CLCC1 antibody or co-transfected with CLCC1-WT 
FLAG. Cells transfected with EGFP-SigmaR1 and stained with the CLCC1 
antibody (Fig. 4.27 (ii) upper panel) showed a high degree of co-localisation, 
similar to the one seen when cells were transfected only with CLCC1 plasmid or 
the combination CLCC1 and mCherry-KDEL (see Fig. 4.26 (i-ii)). In comparison, 
cells overexpressing both CLCC1 and SigmaR1 (Fig. 4.27 (ii) lower panel, 
asterisks) displayed a slightly different expression. This might be caused by the 
overexpression itself, therefore co-transfection of CLCC1 and SigmaR1 were 






Figure 4.27 Co-localisation between EGFP-SigmaR1 and CLCC1. (i) 
NIH/3T3 cells transfected with CLCC1 plasmids and mCherry-KDEL showed 
higher fluorescence of SigmaR1, of both mouse (M) and rabbit (R) antibodies, 
in comparison with untransfected cells. Similarly, higher fluorescence of 
SigmaR1 was present when cells were transfected with R-pre-RFP, indicating 
that transfection of cells with plasmid is not compatible with SigmaR1 antibody 
staining. (ii) Cells transfected with EGFP-SigmaR1 plasmid and stained for 
endogenous CLCC1 showed co-localisation, while cells co-transfected with 
CLCC1 and SigmaR1 plasmid showed less co-localisation compared to cells 
transfected only with SigmaR1. Scale bar 10 µm. 
 
4.2.9 Effects of ER calcium stores depletion on CLCC1 
One of the major functions of the ER is maintaining calcium homeostasis, 
therefore we looked at the potential involvement of CLCC1 in calcium signalling 
in the ER. The involvement of CLCC1 in those pathways was also supported by 
the results of the mass spectrometry, as one of the possible CLCC1 binding 
partners was ATP2A2, which encodes SERCA2. Moreover, SigmaR1 has been 
shown to inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 
with Ora1. A potential co-localisation with STIM1 was investigated instead of 
SERCA2 due to its’ link with SigmaR1. To verify if CLCC1 co-localises with 
STIM1, NIH/3T3 cells were stained with antibodies against CLCC1 and STIM1; 
CLCC1 was often in proximity of STIM1, however there was no apparent 
colocalisation (Fig. 4.28 (i)) consistent with its absence from the mass 
spectrometry results. To understand if CLCC1 might interact with STIM1 
following depletion of ER calcium stores, NIH/3T3 cells were transfected with 
mCherry-KDEL and CLCC1-WT FLAG and 24h later treated with 5 µM of 
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thapsigargin, a non-competitive inhibitor of the SERCA, or DMSO for 30 min at 
37 °C. Thapsigargin induces the activation of the translocation of STIM1 at the 
PM-ER junction where it couples with ORAI1 to allow the influx of Ca2+ in the 
ER. Fixed cells were stained with the STIM1 antibody and cells were analysed 
by confocal microscopy. Cells treated with thapsigargin showed the 
translocation of STIM1 at the membrane (Fig. 4.28 (ii), arrow) however CLCC1 
seemed to be unaffected. Co-localisation between the endogenous CLCC1 and 
endogenous STIM1 was not significantly affected by treatments with 
thapsigargin (Fig. 4.28 (ii)). Cells were double transfected with mCherry-KDEL 
and CLCC1-WT FLAG and treated with thapsigargin. In both DMSO-treated and 
thapsigargin-treated cells the overexpression of CLCC1 appeared to increase 
the fluorescence however, cells treated with DMSO showed less co-localisation 
between STIM1 and CLCC1 (Fig. 4.28 (iii), arrow), compared to the 
thapsigargin-treated cells where the pattern of distribution of STIM1 and 
CLCC1-WT FLAG was similar. The increase of localisation between STIM1 and 
CLCC1 could be the results of the overexpression itself, as showed for 
SigmaR1, therefore the link between calcium and CLCC1 needs to be 
evaluated in term of calcium currents though calcium imaging and recording, for 






Figure 4.28 Localisation of CLCC1 with STIM1. (i) Cells stained for the 
endogenous CLCC1 and STIM1 showed very little co-localisation. (ii) Cells 
were nucleofected with mCherry-KDEL and treated with DMSO or 5 µM 
thapsigargin for 30 min and stained with anti-STIM1 and anti-CLCC1. Cells 
treated with thapsigargin showed a localisation of STIM1 at the membrane 
however no change in CLCC1 localisation was noted. Quantification of the co-
localisation coefficient between CLCC1 and STIM1 in DMSO (N=9; 40 cells) or 
thapsigargin-treated cells (N=10; 20 cells) was not significant (Mann Whitney U 
test; p=0.18)  (iii) Cells co-nucleofected with mCherry-KDEL and CLCC1-WT 
FLAG and stained with STIM1 showed a higher degree of localisation between 
the CLCC1 and STIM1 when cells were treated with thapsigargin compared to 
cells treated with DMSO where STIM1 was still having a distinct pattern. 
 
4.2.10 Pharmacological manipulation of SigmaR1 
To determine whether CLCC1 is associated with the function of SigmaR1 we 
took advantage of the fact that SigmaR1 can be pharmacologically manipulated 
with a variety of commercially available drugs; Pre-084 as agonist and BD1047 
as antagonist of the receptor were selected. NIH/3T3 cells were transfected with 
CLCC1-WT FLAG and mCherry-KDEL or with EGFP-SigmaR1 and mCherry-
KDEL and 24h later treated with 10 µM of Pre-084 or 10 µM of BD1047, for 30 
min at 37 °C, control cells were treated with the same amount of DMSO.  
Cells transfected with CLCC1-WT FLAG and mCherry-KDEL were not stained 
with SigmaR1 antibody because the overexpression of proteins cause the 
increased fluorescence of SigmaR1, as previously assessed. Therefore, focus 
was placed on the effects of activation or de-activation of SigmaR1 on CLCC1 
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localisation. While cells treated with DMSO showed the classical pattern of 
localisation of CLCC1 within the ER, both cells treated with Pre-084 and 
BD1047 showed less co-localisation between CLCC1 and the ER marker 
mCherry-KDEL (Fig. 4.29 (i), arrows), in particular CLCC1 seemed to localise 
more on the plasma membrane.  
To determine if CLCC1 changed position as a result of SigmaR1, avoiding 
artefacts due to CLCC1 overexpression, cells were co-transfected with EGFP-
SigmaR1 and mCherry-KDEL and stained with CLCC1 antibody. In this case, 
overexpression of Sigma did not impact the levels of fluorescence of CLCC1. 
Moreover, the localisation of the endogenous CLCC1 did not seems to change 
when compared across the three treatments (DMSO, PRE-084 and BD1047) 
















Figure 4.29 Effects of SigmaR1 manipulation on CLCC1. (i) Cells 
transfected with YFP CLCC1-WT and mCherry-KDEL and treated with 10 µM of 
agonist (PRE-084) or 10 µM of antagonist (BD1047) for 30 min at 37 ºC showed 
reduced localisation in the ER with increased of expression on the plasma 
membrane. (ii) Cells transfected with EGFP-SigmaR1 and mCherry-KDEL 
showed no change in localisation of CLCC1 when treated with SigmaR1 agonist 
and antagonist.  
 
4.2.11 Analysis of metabolic stress on CLCC1 
KEGG pathway analysis of mass spectrometry data suggested that proteins 
related to metabolic pathways were highly represented in all datasets examined 
however, no indication was given about the specific subtype of metabolic 
pathway in which those proteins were involved.  Moreover, when proteins 
expressed in the retina were divided by organelle in which they localise, the 
mitochondria section presented proteins related to glycolysis and tricarboxylic 
acid (TCA) pathway. Therefore, to examine the potential involvement of CLCC1 
in energetic pathways cells were NIH/3T3 cells were transfected with mCherry-
KDEL, and 24h later treated with a variety of drugs already available in lab. The 
effects on the localisation of endogenous CLCC1 was examined with confocal 
fluorescent imaging. 
2-Deoxy-D-Glucose is a glucose analogue that inhibits glycolysis as it is 
phosphorylated by hexokinase to 2-Deoxy-D-glucose-6-phosphate which 
cannot be metabolised, resulting in cellular ATP depletion [258]. Cells were 
treated with 100 mM, for 20 mins at 37 °C. Treatments with 2-DG (Fig. 4.30 (i)) 
190 
 
showed that the localisation of CLCC1 within the ER in treated cells was similar 
to the control cells.  
Oligomycin A acts as an inhibitor of mitochondrial H+-ATPase function, thus 
blocking oxidative phosphorylation. Treatments with 50 µM of Oligomycin for 20 
min at 37°C did not have any effect on CLCC1 localisation and expression 
patterns (Fig. 4.30 (ii)). 
Lonidamine has several targets, it principally inhibits aerobic glycolytic activity 
through the blocking of hexokinase, it blocks voltage-dependent anion channel 
(VDAC) which regulates mitochondria-initiated apoptosis, and acts on Complex 
II of electron transport chain, also known as succinate dehydrogenase [259]. 
Cells were treated with 400 µM of Lonidamine or the same volume of DMSO for 
20 min at 37°C (Fig. 4.30 (iii)). The pattern of both CLCC1 and mCherry-KDEL 
looked substantially different from the other treatments (e.g. Oligomycin), the 
staining was much more punctate, and the ER tubules were less defined. 
However, this pattern was consistent between DMSO-treated cells and 
Lonidamine-treated cells and may likely be caused by the high concentration of 
DMSO with which the cells had been treated. Apart from the mentioned 
difference, no other distinction in terms of CLCC1 localisation was noted.  
Having defined that changes in energetic state do not affect the localisation of 
the endogenous CLCC1, in future it would be interesting to analyse the 
metabolic rates of aerobic and anaerobic glycolysis in cells lacking CLCC1 or 
carrying the Asp25Glu alteration to define whether the lack or the alteration of 
CLCC1 indirectly induce changes in energetic metabolism. It would also be 







Figure 4.30 Treatments of NIH/3T3 with energetic metabolism inhibitors. (i) 
Treatments with 100 mM of 2-DG did not change localisation of CLCC1 within 
the ER. (ii) Cells treated with 50 µM of Oligomycin A did not show any 
difference of CLCC1 localisation compared to the DMSO-treated cells. (iii) Cells 
treated with 400 µM of Lonidamine or the same volume of DMSO showed a 
more distinctive punctate pattern of both CLCC1 and mCherry-KDEL which was 
probably caused by high DMSO concentration. Scale bar 10 µM. 
 
The potential involvement of CLCC1 was also investigated in pathways related 
to protein processing and folding. To this purpose, NIH/3T3 cells transfected 
with mCherry-KDEL were then treated with 17-N-Allylamino-17-
demethoxygeldanamycin (17-AAG), or tanespimycin, and tunicamycin. 17-AAG 
binds Hsp90 which mediates protein folding and maturation, and is considered 
a potential cancer treatment [260]. Interestingly, Hsp90 inhibition protects 
against degeneration of photoreceptors in a model of RP [261]. Treatment of 
mCherry-KDEL transfected cells with 100 nM of 17-AAG for 20 min did not 
induce any change in localisation of endogenous CLCC1 within the cell (Fig. 
4.31 (i))  
Tunicamycin inhibits N-linked glycosylation by preventing core oligosaccharide 
addition to nascent polypeptides and thereby blocking protein folding and transit 
through the ER thus inducing ER stress [262]. Cells transfected with mCherry-
KDEL and treated with 2 µg/ml with tunicamycin for 30 min did not show any 





Figure 4.31 NIH/3T3 cells treated with 17-AAG and Tunicamycin. (i) cells 
treated with 500 nM of 17-AAG for 20 min did not showed any change in 
localisation of CLCC1. (ii) cells treated with 2 µg/ml of tunicamycin for 30 min 
did not show changes in localisation of CLCC1. 
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Taken together, these results indicate that metabolic stress does not influence 
the localisation of CLCC1, however, these results do not exclude the 
involvement of CLCC1 in metabolic pathways though the action of CLCC1 on 
other proteins. 
4.2.12 CLCC1 knockout in SH-SY5Y cells. 
To provide an important resource for more wide-ranging studies to define the 
physiological role of CLCC1 in cells, gene knockout was performed in SH-SY5Y 
cells using CRISPR-Cas9 by deletion spanning CLCC1 exons 2-4, which were 
common between the predicted isoforms, and are predicted to create a 
frameshift alteration. SH-SY5Y were considered a suitable cell line for carrying 
the knockout as they are diploid, able to survive in single-cell colonies, express 
CLCC1, are already available in the laboratory, and even though they are not 
retinal cells they are considered a pseudo-neuronal cell line.  In brief, SH-SY5Y 
cells were co-nucleofected with the plasmid containing the gRNA for 
CLCC1_exon 2 and CLCC1_exon 3; both plasmids were labelled with different 
fluorescent proteins, mCherry and GFP. Double positive cells were selected 
with FACS sorting and grown as a single cell colony in a 96-well plate. Once 
confluent, cells were collected, and DNA extracted. PCR spanning exons 2 to 4 
was performed; colonies showing a single amplicon of about 600 bp 
corresponded to homozygous KO cells, while heterozygous KO cells showed a 
band of about 600 bp and one of about 1200 bp (Fig. 4.32 (i)) Homozygous KO 
cells were Sanger sequenced to verify that the deletion between exon 2 and 4 
was present and that it resulted in a frameshift alteration (Fig. 4.32 (ii)). 
Morphology was assessed with the brightfield microscope, CLCC1-/- colonies 
did not show changes in morphology compared to WT cells (Fig. 4.32 (iii)). 
Unfortunately, as explained in paragraph 5.2.3 western blot for CLCC1 on 
195 
 
whole lysate did not work, therefore, to assess the protein levels of CLCC1 in 
KO vs WT, cells were stained with the CLCC1 antibody and analysed at the 
confocal microscope (Fig. 4.32 (iv)). WT cells showed high levels of CLCC1 
staining while CLCC1-/- KO cells showed only background stain, probably due to 
the secondary antibody. The immunofluorescence experiment supported the 





Figure 4.32 Assessing CRISPR colonies genotype for CLCC1. (i) PCR of 
DNA extracted from cultures derived from single cell colonies, spanning CLCC1 
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exon 2-4. WT cells showed a single amplicon of about 1500 bp, homozygous 
KO cells showed a single amplicon of about 600 bp, while heterozygous KO 
cells showed two amplicons, one corresponding to the WT band and to the KO 
band. (ii) Dideoxy sequencing for homozygous KO cells showed the presence 
of a frameshift alteration and the absence of the intended deleted region. (iii) 
Inverted microscopy photographs of WT and CLCC1-/- cells showing their 
morphology. (iv) Immunofluorescence of CLCC1-stained WT and KO cells 
showed absence of CLCC1 in CLCC1-/- cells, indicating the successful 
knockout. Scale bar 10 µm. 
 
To verify that the knockout of CLCC1 did not induce major defects on 
organelles, WT and CLCC1-/- KO cells were stained with antibodies already 
available in the laboratory. Cytoskeleton was labelled with Tubb4 for 
microtubules, and Phalloidin for F-actin (Fig. 4.33 (i)), while endosomal 
trafficking was identified with Rab11 (Fig. 4.33 (ii)), mitochondria with ATP5A 
(Fig. 4.33 (ii)), and the ER with calreticulin and calnexin (Fig. 4.33 (iii)). None of 
the above markers showed substantial change, indicating that the knockout of 
CLCC1 does not cause gross morphological alterations of organelles. In 
particular, ER proteins calreticulin and calnexin seem to have the same 
distribution within the ER in CLCC1-/- KO compared to the WT, indicating that 






Figure 4.33 Staining of CLCC1-/- KO cells. (i) Tubb4 and phalloidin showed 
that the CLCC1-/- KO cells did not induce any changes in the cytoskeleton. (ii) 
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Both Rab11 (endosomes) and ATP5A (mitochondria) showed the same pattern 
of localisation in CLCC1-/- cells compared to the WT. (iii) ER proteins 
calreticulin and calnexin showed the same distribution in CLCC1-/- cells, 
indicating that the knockout does not affect their localisation. 
 
To assess the effect of the knockout on targets identified with the mass 
spectrometry, WT and of CLCC1-/- KO cells were stained with several 
antibodies. In SH-SY5Y cells, EMC1 showed a similar localisation to that seen 
in NIH/3T3 cells, staining was present near the nucleus and on the plasma 
membrane (Fig. 4.34 (i)). These results indicate that the localisation of EMC1 in 
the cells is not directly linked to CLCC1, however the disruption of the binding 
might have effects not visible using this assay. Similarly, staining with STIM1 
did not showed any mis-localisation of the protein due to the knockout of 




Figure 4.34 Localisation of EMC1 and STIM1 in CLCC1-/- KO cells. (i) EMC1 
showed similar localisation between WT and CLCC1-/- KO cells. (ii) STIM1 





Expression pattern of SigmaR1 in CLCC1-/- KO cells (Fig 4.35 (i)) was also no 
different to wild type cells. The dynamics of ER and SigmaR1 movements in 
cells were also assayed, using live cell imaging. Wild type and CLCC1-/- KO 
cells were co-nucleofected with mCherry-KDEL and EGFP-SigmaR1 and 24h 
later were imaged. Cells showed the presence of SigmaR1 in the ER, and while 
wild type cells showed a very dynamic remodelling and movement of ER 
tubules containing SigmaR1, in CLCC1-/- KO cells these this dynamic 
remodelling seemed slower (Appendix E, media 1 and 2). Similarly, cells treated 
with PRE-084 and BD1047 (Appendix E, media 3, 4, 5, 6) were imaged to verify 
if the overactivation of SigmaR1 might overcome the presumptive reduced 
dynamic remodelling of the ER in of CLCC1-/- KO. Unfortunately, a method to 
quantify those movements was not found therefore these remain simple 
observations.  
Staining with BiP antibody showed a punctate pattern consisting of the 
presence of very bright and well-defined spots. This pattern seemed consistent 




Figure 4.35 CLCC1 KO cells stained with BiP and SigmaR1. (i-ii) BiP 






As Jia et al [206] showed that loss of CLCC1 increases the expression of BiP, 
we took advantage of the fact that BiP showed such defined expression pattern, 
and quantified its expression by counting puncta. (Fig. 4.36). For each image, 3 
z-stacks were taken in 1 µm depth; with consistent zoom and laser gain. 
Particles (n. of BiP dots) were counted using Fiji, all the images were processed 
in the same way.  CLCC1-/- KO cells (N=18; 268 cells) did not show a significant 
increase of BiP expression when compared to the wild type (N=18; 427 cells) 
(Mann Whitney U test; p=0.93), indicating that the lack of CLCC1 does not 
induce ER stress (Fig 4.36 (i)).  To understand if the CLCC1-/- KO cells were 
more sensitive to ER stress inducers, wild type and CLCC1-/- KO cells were 
treated with 5 µM of thapsigargin or 2 µg/ml of tunicamycin for 30 min at 37 °C, 
and the same volume of DMSO as control. Both wild type and CLCC1-/- KO cells 
treated with tunicamycin (Fig. 4.36 (ii)) did not show an increase of BiP 
expression when compared to the DMSO-treated cells (Kruskal-Wallis test with 
Dunn’s multiple comparison test; ns). The treatment with thapsigargin (Fig. 4.36 
(iii)) instead caused a significant increase of BiP expression in CLCC1-/- KO 
cells (N=12; 307 cells) when compared with CLCC1-/- KO cells treated with 
DMSO (N=18; 334 cells) (Kruskal-Wallis test with Dunn’s multiple comparison 
test; p<0.05; *). CLCC1-/- KO cells treated with thapsigargin also showed a 
significant increase in BiP expression when compared with wild type cells 
treated with thapsigargin (N=18; 368 cells) (Kruskal-Wallis test with Dunn’s 
multiple comparison test; p<0.05; *), and wild type cells treated with DMSO 
(N=18; 312 cells) (Kruskal-Wallis test with Dunn’s multiple comparison test; 
p<0.05; ***).   
These results demonstrate that basal levels of BiP do not change in cells 
lacking the CLCC1 gene, and that treatment with tunicamycin does not increase 
204 
 
BiP expression. As an increase of BiP was expected in wild type cells and these 
results also were not consistent with what demonstrated by Jia et al [206] and, 
western blot analysis is needed to further evaluate the impact of tunicamyin on 
wild type and CLCC1-/- KO cells. Thapsigargin instead increases expression of 
BiP in CLCC1-/- KO cells when compared to the same cells treated with DMSO, 
and wild type cells treated with thapsigargin.  However, thapsigargin-treated 
wild type cells did not show a significant change of BiP expression when 
compared to the wild type cells treated with DMSO. Again, these results need to 
be confirmed by western blot. 
These results showed that the homozygous loss of CLCC1 in SH-SY5Y did not 
have major effects on the organelle shape, and in particular did not affect the 
localisation of BiP, SigmaR1, EMC1, STIM1 and calnexin. These results also 
indicated that the Asp25Glu alteration did not affect the localisation of those 
proteins as well. This also showed that while basal levels of BiP were present in 
both wild type and knockout cells, those displayed a significant higher 














Figure 4.36 Quantification of BiP expression. (i) Wild type (N=18; 427 cells) 
and CLCC1-/- KO cells (N=18; 268 cells) showed no difference in BiP (Mann 
Whitney U test; p=0.93). (ii) Tunicamycin treatment did not influenced 
expression of BiP in both wild type (N=23, 388 cells) and CLCC1-/- KO cells 
(N=21; 419 cells) (Kruskal-Wallis test with Dunn’s multiple comparison test; ns).  
Wild type + DMSO treated cells (N=22; 432 cells); CLCC1-/- KO DMSO treated 
cells (N=22; 344 cells). CLCC1-/- KO cells treated with DMSO (N=22; 466 cells). 
(iii) Wild type cells treated with thapsigargin (N=22; 456 cells) showed an 
increase of cleaved caspase-3 expression when compared to the wild type cells 
treated with DMSO (N=22; 420 cells) (Kruskal-Wallis test with Dunn’s multiple 
comparison test; p<0.05; **). Similarly, an increase of BiP protein expression 
was found in CLCC1-/- KO cells treated with thapsigargin (N=21; 381 cells) when 
compared with CLCC1-/- KO cells treated with DMSO (N=22; 573 cells) 
(Kruskal-Wallis test with Dunn’s multiple comparison test; p<0.05; *). These 
results showed an increase of BiP expression in CLCC1-/- KO cells only when 
they were treated with thapsigargin, consistent with the induction of ER stress 
response.  
Moreover, to verify the effect of the Asp25Glu alteration in a condition in which 
cells did not have any endogenous CLCC1, the CLCC1-Asp25Glu FLAG 
construct was nucleofected into CLCC1-/- KO cells. When CLCC1 Asp25Glu 
was introduced inside the cell, its localisation was similar to the one shown 
before. Staining with EMC1 (Fig. 4.37 (i)) STIM1 (Figure 4.37 (ii)), SigmaR1 
(Fig. 4.38 (i)), and BiP (Figure 4.38 (ii)) did not seem to change in comparison 






Figure 4.37 Re-introduction of CLCC1-Asp25Glu FLAG into CLCC1-/- KO 
cells, stained with EMC1 and STIM1. When CLCC1-/- KO cells were 
nucleofected with the CLCC1-Asp25Glu FLAG and stained with (i) EMC1 and 









Figure 4.38 Re-introduction of CLCC1-Asp25Glu FLAG into CLCC1-/- KO 
cells, stained with SigmaR1 and BiP. When CLCC1-/- KO cells were 
nucleofected with the CLCC1-Asp25Glu FLAG and stained with (i) SigmaR1 







4.2.13 Fractionation of CLCC1-/- KO cells 
Subcellular fractionation was attempted to separate ER and mitochondria and 
analyse protein levels in these organelles in wild type versus CLCC1-/- KO cells. 
Unfortunately, this experiment did not work however, western blot with the 
whole homogenate for wild type and CLCC1-/- KO cells gave some very 
preliminary results. In particular, ATP5A used as mitochondrial marker, and 
calnexin, calreticulin, BiP and EMC1 were detected (Fig. 4.39). For BiP and 
EMC1 the loading control was not detectable. Due to time constraints this 
experiment was performed only once and ought to be repeated with 




Figure 4.39 Western blot of wild type and CLCC1-/- KO cells. Western blot 
for the whole homogenate in wild type and CLCC1-/- KO cells. Protein levels 
were detectable for ATP5A, calnexin, calreticulin, BiP and EMC1.   
 
4.2.14 Proliferation and apoptotic rates of CLCC1-/- KO cells 
To understand if the loss of CLCC1 reduces the viability of cells, the MTT 
assay, which measures the metabolic rate of cells which is an indirect measure 
of their proliferative rate, was carried out over five days.  
Proliferative rate was calculated by subtracting the background readings (cell 
media) to the readings obtained for the wild type and CLCC1-/- KO cell. Two 
way-ANOVA with Bonferroni post test showed no significant differences 
between wild type and knockout at any time point (Fig. 4.40 (i)). Similarly, 
proliferative rate was also assessed when cells were treated for 30 min with 2 
µg/ml of tunicamycin (Fig. 4.40 (ii)) or 5 µM of thapsigargin (Fig. 4.40 (iii)) to see 
if an increase of ER stress could also decrease proliferative rate of CLCC1-/- KO 
cells, compared to the wild type. None of the treatments decreased the viability 
at any time point. A factor that might have influenced this experiment was the 
short time of treatment with ER stressors as once the drug was removed, 4 
hours were needed before the plate was read and therefore treatments for a 







Figure 4.40 MTT assay for WT vs CLCC1-/- KO cells. (i) Two ways ANOVA 
with Boneferroni post hoc on MTT assays in wild type versus CLCC1-/- KO cells 
(N=36) showed no significant difference between the groups. Thapsigarin (ii) 
and tunicamycin (iii) treatments did not decrease viability of wild type or 
knockout cells compared to the DMSO treated cells (N=9). Each experiment 
was carried in triplicate.  
 
To determine if the loss of CLCC1 cause unbalanced homeostatic conditions 
leading to cell death, wild type and knockout cells were stained with anti-
cleaved caspase-3 as indicator of apoptosis. Caspase-3 is the major 
executioner caspase that is cleaved and activated by the initiator caspases, 
caspase-8 and caspase-9 [263]. Activation of executioner caspases leads to 
cell death [263]. Expression of cleaved caspase-3 was analysed by confocal 
microscopy. For each image, 3 z-stacks were taken in 1 µm depth; with 
consistent zoom and laser gain. After thresholding, particles (number of cleaved 
caspase dots) were counted using Fiji, all the images were processed in the 






Figure 4.41 Example of caspase-3 fluorescent pictures processed for 
analysis. Confocal images (left) were transformed in 8-bit, inverted, threshold 
(right) and the number of particles were counted.  
  
CLCC1-/- KO cells (N=22; 451 cells) compared to the wild type (N=22; 476 cells) 
did not show any significant change in cleaved caspase-3 expression (Mann 
Whitney U test; p=0.55), indicating that the lack of CLCC1 does not induce 
increasing of cell death (Fig 4.42 (i)).  To understand if the CLCC1-/- KO cells 
were more sensitive to ER stress inducers, wild type and CLCC1-/- KO cells 
were treated with 5 µM of thapsigargin or 2 µg/ml of tunicamycin for 30 min at 
37 °C, and the same volume of DMSO as control. Cells treated with tunicamycin 
(Fig. 4.42 (ii)) showed a significant increase of the expression of cleaved 
caspase-3 in wild type cells (N=22; 640 cells) compared to the CLCC1-/- KO 
cells (N=25; 498 cells) (Kruskal-Wallis test with Dunn’s multiple comparison 
test; p<0.05; **). Similarly, wild type cells treated with thapsigargin (Fig. 4.42 
(iii)) showed increased expression of cleaved caspase-3 (N=22; 456 cells) 
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compared to the same cells treated with DMSO (N=22; 420 cells) (Kruskal-
Wallis test with Dunn’s multiple comparison test; p<0.05; **) and CLCC1-/- KO 
cells treated with DMSO (N=22; 573 cells) (Kruskal-Wallis test with Dunn’s 
multiple comparison test; p<0.05; *). Surprisingly, CLCC1-/- KO cells did not 
show an increase of cell death following treatments with drugs causing ER 
stress, while wild type cells were responsive to the ER stress stimuli. These 
results might indicate that the lack of CLCC1 has a protective effect from 
apoptosis. 
Future experiments using propidium iodine to evaluate the ratio between 
apoptotic, necrotic, and healthy cells are necessary to confirm these results. 
Also, to evaluate if ER stress signalling branches activates preferentially 
following the drug stimulus, qPCR and western blot could be performed for 
CHOP, ATF6, and ATF4 as their expression increases following ER stress, as 
well as marker for cell death such as caspase-3, BCL-2 and Bax.  
Taken together these results indicate that the lack of CLCC1 does not induce a 











Figure 4.42 Cleaved caspase-3 expression. (i) Wild type (N=22; 476 cells) 
and CLCC1-/- KO cells (N=22; 451 cells) showed no difference in cleaved 
caspase-3 expression (Mann Whitney U test; p=0.55). (ii) Wild type cells treated 
with tunicamycin (N=22; 640 cells) showed an increase of cleaved caspase-3 
expression when compared to CLCC1-/- KO cells treated with tunicamycin 
(N=25; 498 cells) (Kruskal-Wallis test with Dunn’s multiple comparison test; 
p<0.05; **). However, the increase was non-significant when compared to wild 
type + DMSO treated cells (N=12; 333 cells). CLCC1-/- KO cells treated with 
DMSO (N=22; 466 cells). (iii) Wild type cells treated with thapsigargin (N=22; 
456 cells) showed an increase of cleaved caspase-3 expression when 
compared to the wild type cells treated with DMSO (N=22; 420 cells) (Kruskal-
Wallis test with Dunn’s multiple comparison test; p<0.05; **), and when 
compared to CLCC1-/- KO cells treated with DMSO (N=22; 573 cells) (Kruskal-
Wallis test with Dunn’s multiple comparison test; p<0.05; *). CLCC1-/- KO cells 
treated with thapsigargin (N=21; 381 cells) did not showed any significant 













Figure 4.43 Graphical summary of the findings. Analysis of human, mice, 
zebrafish and chick retinal tissues revealed that CLCC1 in expressed in the 
retinal layers. The knockout or knockdown in zebrafish and mice of CLCC1 
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resulted in the loss of photoreceptors and disorganisation of retinal layers. In 
cells, CLCC1 colocalised with ER markers such as Calreticulin, KDEL, and 
Calnexin. Other potential binding partners of CLCC1 were identified using mass 
spectrometry which showed that CLCC1 could be involved in ER stress, 
Calcium signalling or protein insertion in membrane.  EMC1, SigmaR1 and 
STIM1 were thought to be interesting proteins to investigate however, only 
SigmaR1 showed colocalisation with CLCC1 at the MAM. The functional role of 
this interaction still needs to be defined. CLCC1 was knockout in a neuronal-like 
cell line using CRISPR-Cas9: no changes in proliferation, apoptosis or ER 
stress were found, indicating that the loss of CLCC1 might only impact the 




4.3 Discussion  
4.3.1 CLCC1 is necessary for retinal development 
This study provides multiple lines of evidence to define an important role of 
CLCC1 for maintaining normal retinal structure and function. In addition to the 
human genetic data, retinal morphology, and ERGs in zebrafish and Clcc1-/+ KO 
mice. In zebrafish, both knockdown and knockout influenced eye growth during 
early development, reduced the thickness of IPL and ONL layers, as well as 
impaired the morphology of photoreceptors. The pathogenicity of p.Asp25Glu 
CLCC1 in retinal development and homeostasis is illustrated by the inability of 
p.Asp25Glu mutant mRNA to rescue the phenotype in clcc1-/- KO zebrafish, 
which were similar in phenotype to the clcc1 knockdown zebrafish. These data 
highlighted the importance of clcc1 during early retina development.  
The time course of Clcc1 expression in mouse retina suggests a greater 
requirement for CLCC1 activity in the early postnatal period, at which time 
retinal cytogenesis has ended while changes in cell volume and especially the 
thickness of various retinal layers continue to occur, with the plexiform layers 
increasing and the nuclear layers decreasing in thickness and rearranging 
internally. In addition, retinal morphological abnormalities and decreased 
photopic and scotopic ERG amplitudes in Clcc1-/+ KO mice support the critical 
requirement for full activity of CLCC1 for retinal function and perhaps 
development and structural integrity. 
Broad expression of CLCC1 throughout the body, as well as embryonic lethality 
of Clcc1-/- KO mouse and zebrafish models, begs the question of why affected 
individuals in these families have isolated RP without any discernible systemic 
signs or symptoms. While the reason for the retinal specificity of the phenotype 
is currently unclear, there is ample precedent for isolated retinal degeneration 
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occurring as a result of higher retinal requirements for widely expressed 
proteins, including components of the spliceosome (PRPF31 [264], PRPF8 
[265], PRPF3 [266], SNRNP200  [267], PRPF6 [268], and PRPF4 [269]) and 
transcription factors (ZNF513) [270]. High levels of CLCC1 retinal expression 
and especially in the photoreceptors and RPE, are consistent with CLCC1 
alteration causing a retinal degeneration as is the finding that knocking out 
CLC3, another endosomal chloride channel, results in degeneration of the 
retina [271] and hippocampus [272].  
Recently Jia et al. [206] identified a retrotransposon insertion in the Clcc1 gene 
as a cause of autosomal recessive progressive cerebellar granule cell death 
and peripheral motor axon degeneration in mice, although they did not 
comment on retinal morphology or function. Patients with the p.Arg25Glu 
CLCC1 alteration showed no signs of cerebellar or peripheral nerve dysfunction 
on examination or compatible symptoms by history, although it is possible that 
subtle subclinical findings were not recorded. Besides the different phenotypes, 
there were additional differences in the two systems.  
4.3.2 CLCC1 is an ER-associated protein 
Molecular and functional characterisation of CLCC1 has been minimal since its 
initial description, and its role in cellular metabolism, and in particular its role the 
retina, remains unclear. Nagasawa et al. [205] showed that CLCC1 is not 
susceptible to inhibitors of known chloride channels, suggesting that it is 
functionally distinct to previously described anion channel protein families, to 
which it bears little sequence homology. Although several proteins contain 
portions of the MCLC domain present in CLCC1, a Blast search of Homo 
sapiens transcripts using the CLCC1 variant 1 mRNA displays significant 
similarity only to G-protein signalling modulator 2 (GPSM2), and a long 
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intergenic non-protein coding RNA (LINC00504). However, sequence 
alignments between GPSM2 and CLCC1 polypeptides identify no obvious 
regions of homology, and a BlastP search with the CLCC1 variant 1 polypeptide 
identifies only CLCC1 precursors and orthologues, and two hypothetical 
Macaca proteins.  
As CLCC1 is a poorly characterised protein, we firstly looked at its localisation 
within the ER, repeating the localisation experiment published by Jia et al. [206] 
on human cells and murine cells, confirming that CLCC1 is present in the ER 
and in the ER-nuclear envelope region in human and mouse cell lines, where 
CLCC1 partially co-localised with KDEL. The partial co-localisation might be 
due to the fact that the anti-KDEL antibody binds a variety of soluble proteins 
carrying the ER retention signal KDEL, which cannot be discriminated using a 
generic KDEL antibody. The staining of cells for calnexin, a calcium-binding 
chaperone, which does not have a KDEL sequence, showed absence of co-
localisation with CLCC1, while staining cells with calreticulin, which does have a 
KDEL sequence, showed both co-localisation and co-immunoprecipitation with 
CLCC1. However, these results do not necessarily suggest that CLCC1 
localises only with proteins carrying the KDEL sequence at their C-terminus. In 
chick RGC cells, a more physiologically relevant type of cells, CLCC1 was 
present in both soma and axonal ER; the localisation of CLCC1 in the axon 
might suggest its involvement in neuronal development.  
Plasmids for CLCC1 were used with a YFP tag at N-terminus or FLAG tagged 
to the C-terminus to overexpress the wild type and the mutant protein. While the 
tags did not affect the localisation of CLCC1, they affected the binding with 
calreticulin which was not pulled-down with the tagged CLCC1, neither wild type 
nor mutated. It is known that GFP can interfere with the folding, ubiquitination 
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[273] and normal cell physiology, for example impairing actin-myosin 
interactions [274], however the YFP, a derivative of GFP, seems to have an 
improved folding and sensitivity [275]. Nevertheless, CLCC1 seems to be 
sensitive when linked to fluorescent proteins as plasmids CLCC1-YFP, 
mCherry-CLCC1 and mCardinal-CLCC1 did not function when they were 
expressed in cells. The use of FLAG tag (DYKDDDDK) was considered a better 
choice as its hydrophilicity should not denature or inactivate proteins to which 
they are attached. Consequently, the use of tags should be carefully evaluated 
when used for mass spectrometry experiments, as we demonstrated that they 
might interfere with binding of partners to the protein of interest.  
CLCC1 localisation analyses defined that the alteration Asp25Glu does not 
induce any change in localisation of CLCC1 in HEK293 cells, the lack of mis-
localised mutant protein might be due to the presence of endogenous CLCC1 in 
the cells, however, experiments in CLCC1-/- KO cells suggest that this was not 
the case. Regardless of the effect the alteration promotes on the protein itself or 
on the binding with other proteins, the Asp25Glu variant does not promote mis-
localisation from the ER of CLCC1.   
CLCC1 is predicted to have four isoforms deriving from alternative splicing. 
Isoform 1 and 2 have three TM domains, isoform 3 one TM domain while 
isoform 4 has two TM domains. While isoform 1, 2 and 3 have the TM domains 
encoded by the same exons, one TM domain of isoform 4 derives from the 
corresponding exons 4 and 9 of isoform 1. We were able to identify by western 
blot isoform 1 and 2 however, the existence of isoform 3 and 4 still need to be 
verified. When cells were transfected with plasmids carrying the various 
isoforms, they all localised in the ER and nuclear membrane, confirming the 
results obtained with the staining of cells with the CLCC1 antibody which also 
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recognise all the isoforms. Unfortunately, the efforts to confirm the orientation of 
CLCC1 on the membrane, obtained with sequence analysis software, were 
fruitless, leaving the question still open. 
The ER is composed by continuous membrane structures including the nuclear 
envelope, ER sheets and the peripheral ER tubules. In each of these domains, 
structural proteins help to maintain its shape [276], changes in the amount of 
these proteins induce morphological alteration of the ER and changes in ratio of 
sheets/tubules. For example, overexpression of some reticulon isoforms induce 
the expansion of tubules [277], while overexpression of Climp63, an 
transmembrane ER protein, leads to proliferation of ER sheets [276, 278]. 
Whether changes in CLCC1 expressions lead to variation in ER domains ratio 
or ER shape was not thoroughly assessed, although substantial changes 
following overexpression or knockout have not being seen, future experiments 
using electron microscopy to exclude its involvement in these processes would 
be necessary. 
Liquid chromatography tandem-mass spectrometry (LC-MS/MS) is a widely 
used technique in proteomics and has become an established platform for 
proteins quantification [279] and for the identification of proteins interactome 
[280-283]. Therefore, mass spectrometry was used to identify binding partners 
of CLCC1. For endogenous CLCC1, binding partner analysis indicated that 
CLCC1 is likely to be involved in ER function, mRNA processing and 
intracellular transport. While this last category, containing tubulin and dynein, is 
probably enriched because the ER is tightly related to the cytoskeleton [284]. 
The high number of hits related to the ribosome and mRNA processing could be 
explained by the fact that the CLCC1 antibody might recognise newly translated 
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proteins still attached to the ribosome, the cluster related to protein processing 
in the ER seems to be the most relevant.  
The dataset for CLCC1-WT FLAG showed the presence of high represented 
proteasome pathway, which might be caused by the overexpression of plasmids 
itself, as the cells might increase protein degradation levels to reduce protein 
overload which due to overexpression. Indeed, this pathway was not 
represented in the endogenous CLCC1 dataset, where the presence of CLCC1 
is at physiological levels. Unless CLCC1 is related to the insertion of proteins in 
the ER membrane, the overexpression of CLCC1 could potentially explain the 
presence of the high number of hits related to protein translocation into the ER, 
which is induced by higher levels of translation than in homeostatic conditions. 
Although the overexpression of CLCC1 increases the rate of protein 
degradation, it does not induce the activation of the UPR as the number of 
chaperones present in several datasets seems quite consistent. CLCC1-WT 
FLAG also showed high representation in cluster analyses related to nuclear 
outer membrane-ER boundary which is consistent with the staining of cells 
where CLCC1 was found localising near the nuclear membrane. This might also 
indicate that CLCC1 is involved in the transport of mRNA outside the nucleus or 
translocation of proteins in the ER. 
To better look at the differences between CLCC1-WT and Asp25Glu FLAG 
datasets, the GO classification for cellular components was investigated. 
Molecular function and biological process GO terms had a lower FDR 
confidence which might be due by the fact that proteins present in the datasets 
have a variety of functions and implicated in different processes and their 
number in the dataset is not higher enough to reach a higher FRD confidence. 
The high number of hits deriving from mass spectrometry could also be 
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considered a limitation of the technique, as it does not uniquely point to a 
specific pathway. The cellular components classification provided evidence that 
the Asp25Glu alteration causes an increase of interactions with cytoplasmic 
proteins, which is consistent with the prediction of the topology of CLCC1, 
where the N-terminus tail containing the alteration is cytoplasmic. Therefore, a 
difference in cytoplasmic binding partners could explain the how the Asp25Glu 
alteration causes RP. 
Interestingly, calreticulin was not present in both filtered dataset and raw files. 
This might indicate two things; (i) although the mass spectrometry is a good 
technique, it may not be totally reliable, and (ii) despite sample processing 
between the pull down experiments being consistent, the binding of CLCC1 to 
calreticulin might be time dependent or related to a specific state of the cells.  
Trinkle-Mulcahy et al. [285] reported the specific proteome associated to the 
type of beads used to pull-down proteins in immunoprecipitation assays. Many 
of the proteins contaminating dynabeads, which we also used to pull-down our 
samples, were present in our dataset. For example, many chaperonin, 
coatomer-associated proteins, ribosomal proteins, and tubulins present in our 
datasets might be the result of inappropriate binding of proteins to the 
dynabeads. Some of these proteins (CLTC, DYNC1H1, XPO1, FASN and 
PSMA5) that result from the unspecific binding to the beads were not filtered out 
by our system, and they have also been associated with retinal function; none 
of these proteins was chosen for further analysis. These data validate our 
negative controls and demonstrate the strength of our two-layer filtering system 
based on the presence of the proteins in the mass spectrometry data and 
PubMed search.  
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Retinal degeneration is often a symptom of congenital disorders of glycosylation 
[286, 287]. N-glycosylation consists in modification of asparagine residues on a 
nascent protein in the ER, and the activity of calreticulin and calnexin amongst 
other chaperones ensure the secretion of glycoproteins from the ER [288, 289].  
Although the mass spectrometry identified proteins participating in this pathway 
as possibly associated to CLCC1-WT and Asp25Glu FLAG (such as ALG10, 
MAGT1, KRTCAP2, DAD1, STT3 and DDOST), N-glycosylation has not been 
investigated in this work for the lack of definitive evidence supporting the 
involvement of those pathways. In particular we could not exclude that high 
representation of these proteins in our datasets was not induced by 
overexpression of our protein of interest, and the technical difficulties that 
analysis of protein spectra carries.  
From the mass spectrometry results, four putative binding partners were 
selected. EMC1 is a member of the EMC complex; recently two papers in which 
mass spectrometry for EMC was performed identified CLCC1 as a candidate 
interacting partner. In particular, in Tian et al 2019 [290] performed mass 
spectrometry on extracts from HeLa cells, in which EMC4 and EMC6 were 
found binding CLCC1, while in Shurtleff et al 2018 [242] CLCC1 was found 
binding EMC2 in yeast. In our dataset EMC1 binds only CLCC1-WT FLAG 
however when looking at the raw, unfiltered data, EMC2, EMC6, and EMC8 
were present in a single replicate and therefore filtered out. Similarly, EMC6 
was present in both replicates in CLCC1-Asp25Glu FLAG, but filtered out as 
having a score of 5 as indicating low confidence matches. Thus the binding 
partner assays here are consistent with recently published other studies, 
strengthening a link between EMC and CLCC1. However, staining of cells both 
NIH/3T3 and SH-SY5Y cells with the anti-EMC1 antibody and CLCC1 did not 
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showed further a co-localisation, as EMC1 unexpectedly localised on the 
plasma membrane. Moreover, the knockout of CLCC1 did not change 
expression of EMC1 when visualised by staining. EMC inserts tailed-anchored 
proteins in the ER membrane, which are defined as single transmembrane 
protein whose transmembrane domain is located within 50-70 amino acids from 
the C-terminus, however has been observed that EMC loss impairs rhodopsin, 
which is a GPCR, insertion in Drosophila [291]. Whether CLCC1 is inserted in 
membrane by EMC or CLCC1 participates in EMC activity needs to be 
established. 
We also choose to look at calnexin although the staining previously performed 
did not show a great amount of co-localisation with CLCC1, its co-
immunoprecipitation of CLCC1-WT and Asp25Glu FLAG confirmed the mass 
spectrometry data. Interestingly, calnexin has been reported as residing in the 
MAM other than the rough ER, and interacts with SERCA2b [292]. 
SigmaR1 was also considered a good candidate interacting partner to 
investigate. SigmaR1 is a MAM protein which regulates ER-mitochondrion Ca2+ 
signalling [293]. SigmaR1 also displays a chaperone activity and binds BiP in 
homeostatic conditions but upon chronic ER stress, it dissociates and 
translocate into the ER [249]. Moreover, upon Ca2+ depletion or via ligand 
stimulation, SigmaR1 dissociates from BiP and binds IP3Rs, prolonging Ca2+ 
signalling from the ER into mitochondria [249].  We demonstrated that SigmaR1 
co-immunoprecipitate with CLCC1-WT and Asp25Glu FLAG confirming the 
mass spectrometry analysis. Staining of cells, showed that SigmaR1 and 
CLCC1 co-localise in the MAM, however pharmacological manipulation of 
SigmaR1 seems to not induce change in localisation of CLCC1.  
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The effect of calcium store-depletion on CLCC1 was also investigated because 
the ER is the major store of calcium inside the cells. Even though one of the 
mass spectrometry hits was SERCA2 common to CLCC1-WT and CLCC1-
Asp25Glu, STIM1 was selected for investigation as it has been demonstrated 
that SigmaR1 is involved in controlling the dynamics of binding between STIM1 
and ORAI1 [250]. Staining of endogenous CLCC1 and STIM1 showed little co-
localisation, and treatments with thapsigargin activate STIM1 which appeared to 
localise on the plasma membrane, and have no effect on the localisation of 
CLCC1. This experiment does not evidence or discredit the involvement of 
CLCC1 in calcium signalling because we did not verify the total ER calcium 
content or at the calcium currents in wild type and knockout cells. It would also 
be interesting to verify if the knockout of CLCC1 might interfere with the action 
of SigmaR1 on STIM1-ORAI1 binding. 
Jia et al. [206] reported that the knockdown of CLCC1 in HEK293 cells caused 
an increase of ER stress, measured with ATF6. Additionally, mice with a 
retrotransposone insertion in CLCC1 (believed to cause the loss of function of 
CLCC1) showed increase of BiP and ubiquitin expression in cerebellar granule 
neurons. Recently, Chu et al. [294] demonstrated that CLCC1 interacts with the 
microprotein PIGBOS at the ER-mitochondria contact sites but their interaction 
did not affect the number of ER- mitochondria contacts, supporting our finding 
that CLCC1 is present at ER-mitochondria contact sites where it interacts with 
SigmaR1. They also demonstrated that treatments with tunicamycin of CLCC1 
knockdown cells induced an increase of ER stress measured the ratio of XPB1 
spliced and unspliced form. Here, we measured the expression of BiP in wild 
type and CLCC1-/- KO cells, while the same levels of BiP were present in both 
cell types. Following thapsigargin treatments an increased expression of BiP 
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was present in CLCC1-/- KO and was significantly higher than wild type cells 
subject to the same treatment. It is interesting to notice that evidences reported 
in literature suggested that thapsigargin treatment increases or decreases BiP 
expression depending on the cell type, for example INS-1E cells treated with 
thapsigargin showed decreased BiP expression [295] while in SH-N-SH cells 
the treatment induced increased expression of BiP [296]. These might indicate 
that neuronal-like cells may be more sensitive to changes of intracellular 
calcium levels. Discordantly from the two papers aforementioned, we did not 
find any difference in ER stress response when cells were treated with 
tunicamycin, which could be related to the timespan in which the experiments 
have been performed, therefore a 12h treatments could give the same results 
as reported in literature. Hence, repeating the tunicamycin treatments for a 
longer period of time and verify with qPCR and western blot which branch or the 
UPR response activates would be necessary. 
Pathway analysis of mass spectrometry data evidenced that CLCC1 might be 
involved in metabolic pathways, and that the Asp25Glu alteration induces the 
increase of binding partners related to metabolism. Unfortunately, KEGG 
pathway did not give more information about which metabolic pathways our 
datasets were more enriched, and the KEGG term ‘metabolism’ comprises a 
variety of different metabolic pathways as energy metabolism, lipid metabolism, 
amino acid metabolism, glycan biosynthesis, etc. We decided to look at energy 
metabolism because glycolysis, oxidative phosphorylation, and Hsp90 inhibitors 
were already available in the lab. Moreover, photoreceptors metabolise glucose 
though aerobic glycolysis as cancer cells do, and the glucose uptake is 
necessary for the renewal of photoreceptors outer segment [297]. It has also 
been reported that in the later phases of RP, the stimulation of aerobic 
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glycolysis could induce the re-growth of the cone photoreceptors [297]. None of 
these inhibitors influenced the position of CLCC1 within the ER in NIH/3T3 cells. 
It would have been interesting looking at the protein levels of CLCC1 following 
the treatments but the anti-CLCC1 antibody does not detect protein levels of 
whole lysate on western blot. Energetic rate in wild type and knockout cells 
could also be measured with the Seahorse analyser which measure the oxygen 
consumption rate and extracellular acidification rate which are indicators of 
mitochondrial respiration and glycolysis. 
SH-SY5Y cells with CLCC1 knocked out did not show decrease of viability or 
increase of apoptosis, indicating that the lack of CLCC1 does not influence the 
viability of neuronal-like cells, however animal model showed increased death 
and mis-shaped photoreceptors when CLCC1 was knockout, indicating that 
would be better to study the function of CLCC1 in retinal cells. Furthermore, to 
study the effect of the Asp25Glu variant, CRISP-Cas9 could be used to perform 
a single nucleotide change in either retinal cell lines or animal models.   
In conclusion, the lack of identification of a clear functional outcome to explain 
the degeneration of retinal cells due to p.(Asp25Glu) CLCC1 substitution might 
relate to the fact that studies to date have primarily involved non-retinal cells. It 
is therefore possible that in these cell lines the CLCC1 pathway may be 
redundant, while in retinal cells its pathway has a more fundamental role. It is 
also important to consider that photoreceptors are post-mitotic cells, while cell 
lines are immortalised; therefore the lack of an apparent functional outcome of 
CLCC1 mutation/loss of function might be related to the constant division rate of 
SH-SY5Y cells and NIH/3T3, so the repercussions of the knockout of CLCC1 
are not visible in the short period in which these cells are in culture. 
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4.4 Future directions 
To fully uncover the role of CLCC1 into the cell, further investigation would be 
necessary. 
CLCC1 was found to be important for the development of mouse and fish and in 
particular for the retina development, photoreceptors morphology, and function. 
As the function of CLCC1 was not known additional studies were necessary. 
These identify CLCC1 as an ER protein, although the functional significance of 
the Asp25Glu variant has not been defined yet. Through mass spectrometry 
CLCC1 was found to interact with a multitude of ER, mitochondrial, and 
cytosolic proteins however, a definite pathway in which CLCC1 is involved was 
not evidenced. Amongst the potential binding partners calretilculin, BiP, 
SigmaR1, calnexin, and EMC1 were further analysed. In particular, it is notable 
that CLCC1 and SigmaR1 interact in the MAM, however the functional 
significance of this remains unclear. The localisation of CLCC1 at the MAM was 
also recently reported [294], consistent with these findings work. It has been 
demonstrated that CLCC1 is involved in ER stress, in particular cells with Clcc1 
knockout or knockdown showed an increase of ER stress when treated with 
tunicamycin [206]. The studies here did not define any change in expression of 
BiP following tunicamycin treatments, however and increase of ER stress was 
found in CLCC1 knockout cells following treatments with thapsigargin. The 
degree of involvement of CLCC1 in ER stress was not conclusively 
demonstrated, so additional experiments in this area would be valuable. 
In recent years the adoption of iPSC-derived retinal organoids from patients 
carrying the genetic alteration has become increasingly common and has 
allowed the discovery of pathogenic mechanisms as well testing of potential 
therapies [154, 298-300]. Thus, the use of patient-derived iPSC could help in 
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understanding the pathogenic effect of Asp25Glu CLCC1 on photoreceptors. 
Additionally, CRISPR-Cas9 gene editing could be employed to produce the 
Asp25Glu in CLCC1 in a retinal cell line.  
As the key roles of CLCC1 have not yet been uncovered, it may be helpful to 
perform cellular fractionation on wild type and CLCC1 KO cells to determine if 
the knockout impact the concentration of binding partners in different districts of 
the cells (e.g. MAM, ER, mitochondria), as well as to determine if calcium 
concentration and dynamics may change following the knockout of CLCC1, and 
whether this may be related to SigmaR1 and STIM1. As CLCC1 has been 
shown to be related to the ER stress, longer treatments of cells with 
thapsigargin and tunicamycin may define if there is a preferential branch of the 
UPR response activated in CLCC1 knockout cells. To assess if CLCC1 and 
binding partners such as SigmaR1 interact, FRET or split GFP fluorescence 
complementation assays could be used. Alternatively SPLICS [301], a split-
GFP-based methods to study narrow and wide ER-mitochondria contact sites, 
would be suitable to measure the range of interaction between SigmaR1 and 
CLCC1. SigmaR1 also binds sphingolipids, in which the MAM is enriched, and 
participates in cholesterol trafficking and steroidogenesis at the MAM [302]; 
therefore the potential role of CLCC1 in SigmaR1-related cholesterol trafficking 
could be investigated.  
The interaction between CLCC1 and EMC should be carefully studied. A split 
GFP fluorescence complementation approach could be employed to study the 
potential interaction of CLCC1 with EMC subunits. Biochemical assays following 
the experimental procedures used by Chitwood et al [243] would be 
instrumental to determine whether EMC inserts CLCC1 in the ER membrane. 
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CLCC1 homozygous knockout in fish and mouse were embryonically lethal, 
while the heterozygous knockout was viable, indicating that CLCC1 is 
necessary during early development. Therefore, zebrafish or mouse neuronal 
primary culture from embryos could be used to identify developmental pathways 
in which CLCC1 is implicated, and if CLCC1 expression is necessary for the 
development of other organs. The use of neuronal primary culture from 
heterozygous and homozygous animals could also be employed to verify if 
CLCC1, as it is present in the axonal ER, is implicated in axon guidance; for 
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CHAPTER 5 GENETIC SPECTRUM OF INHERITED RETINAL 
DYSTROPHIES IN PAKISTAN 
 5.1 Introduction 
Inherited retinal dystrophies (IRD) are a clinically and genetically heterogeneous 
group of ocular conditions, characterised by progressive degeneration of the 
retina, leading to visual impairment and even blindness [303]. Variants in 269 
genes have been identified to date in association with IRD encompassing either 
non-syndromic or syndromic forms of the condition. Prevalence of each subtype 
of IRD in Pakistan has not been extensively reported and even though several 
papers explore the recurrence of gene alteration, differences between reports 
might underlie the heterogeneity of the Pakistani population. A systematic 
review, carried out in 2015 [166], on the cause of IRDs in South Asia (Pakistan, 
India, and Bangladesh) involving 66 families, showed that mutations in TULP1, 
PRPF31 and CRB1 were the most common. Moreover, the 95% of causes of 
disease were autosomal recessive, consistent with geographical constraints 
and marriage patterns within communities which often give rise to genetic 
isolates with a higher frequency of certain disease-associated founder 
alterations [167] [169, 304, 305]. Similarly, an extensive study using 
homozygosity mapping on 144 consanguineous Punjabi families [169] affected 
by non-syndromic IRDs showed that the most commonly altered genes were 
RPE65 (6.9% of families), TULP1 (6.9%), RP1 (4.9%) which is most commonly 
mutated in Saudi Arabians [240], PDE6A (4.9%) and USH2A (3.5%). 
Homozygosity mapping failed in identifying the pathological variant underlying 
the disease in the 27.8% of families, a proportion in line with studies in other 
populations. Another review on Pakistani population [304] identified 103 non-
syndromic IRD families, with arRP encompassing for the 59% of cases, 
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followed by arLCA (19%), arCRD (10%), and arCSNB (9%). Syndromic IRD 
were found in 52 families with Usher syndrome and BBS the most common 
(36% and 33% respectively). Amongst the non-syndromic IRDs AIPL1, CRB1, 
TULP1, and RPGRIP1 were the most common genes mutated, while amongst 
the syndromic IRDs CDH23, TMEM67 and BBS10 were the most prevalent.  
This chapter describes the genetic bases of syndromic and non-syndromic IRDs 
27 families from Pakistan, and presents a review of all pathogenic gene variants 
associated with IRD in the Pakistani population, to generate a database of all 
gene variant found in this population and to highlight provinces where the 





In order to learn more about the nature, spectrum, and frequencies of IRD in 
Pakistan we undertook genomic studies in 27 families from Pakistan with 
individuals with a preliminary clinical diagnosis of IRD, nystagmus and 
congenital cataracts, as part of an ongoing international collaboration. A total of 
16 families (families 1 to 4, 6, 7, 9, 11 to 19) were recruited through the Exeter 
(IBCS) collaborator consortium while 11 families were investigated at the 
National Eye Institute (NEI), USA (families 5, 8, 10, 20 to 27). When possible 
detailed family history, geographical localisation, and clinical information were 
collected by local clinicians, and collated by Dr. Siying Lin (IBCS). IBCS families 
were investigated with WES or with Illumina Trusight One clinical exome 
sequencing panel, while NEI families were investigated with linkage analysis 
followed by WES/WGS and Sanger sequencing. Table 5.1 summarise the 






Table 4.1 Variants segregating with inherited retinal diseases identified in this study Abbreviations: ar, autosomal 
recessive; BBS, Bardet Biedl syndrome, gnomAD, genome aggregation database; MAF, minor allele frequency; NA, not 
available; SAS, South Asian; KPK, Khyber Paktunkhwa; RP; Retinitis pigmentosa; IRD, inherited retinal dystrophy; (-) 
indicates absence of additional clinical information.  Variants in shaded rows are interpreted as being of uncertain clinical 
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[322] 0.000/0.000 Not listed IRD - 





[308, 323] 0.00003579/ 
0.0001633 
Not listed IRD - 









5.2.1 Sequence alterations in CNGA3 associated with IRD in five families 
Family 1 (Fig. 5.1 (i)) was a large consanguineous family with four affected 
individuals presenting congenital nystagmus, visual impairment and strabismus. 
The family originated from Swabi, in the KPK region, and belonged to the 
Pashtoon tribe. Exome sequencing and co-segregation analysis revealed a 
variant in the gene CNGA3 c.955T>C; p.(Cys319Arg). This variant has a MAF 
of 0.0001307 in South Asian population and 0.000007741 in the North-Western 
European population, no homozygous individuals have been reported on 
gnomAD. This variant has been reported as causative of juvenile CRD with 
maculopathy in a Pakistani family [306] and in other families of unknown ethnic 
origin [307, 308].   
Family 2 (Fig. 5.1 (i)) was a large multigenerational family with individuals 
initially diagnosed with cone dystrophy. The five affected individuals showed 
severe photophobia, visual impairment, congenital nystagmus, and strabismus. 
The family originates from Jatoi, Muzzaffargarh, Punjab. Exome sequencing 
identified a candidate pathogenic homozygous missense variant in CNGA3 
gene, c.1556T>C, p.(Met519Thr), which co-segregates as appropriate in this 
family. This variant was previously reported by Huang et al. [309] in a Chinese 
family as a likely cause of CRD, and it was absent in gnomAD. 
Family 3 (Fig. 5.1 (i)) originated from Sagodha, Punjab, and has four affected 
individuals which were diagnosed achromatopsia. They presented visual 
impairment, impaired colour vision, photophobia, strabismus, and fundus 
examination showed a normal appearance. Genetic analysis identified that 
affected family members were homozygous for a CNGA3 c.1600G>A; 
p.(Gly534Arg) variant, which has not been reported previously and was also 
absent in gnomAD. 
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Family 4 (Fig. 5.1 (i)) was a small nuclear family originating from Peshwar, KPK. 
The two affected family members were diagnosed with nystagmus. 
Unfortunately, no other clinical information was available. Illumina Trusight One 
clinical exome sequencing panel identified a homozygous frameshift variant 
CNGA3 c.1443dup; p.(Ile482Hisfs*6) as the likely cause of disease. This variant 
has been reported as disease causing in unknown ethnic groups [310], and it 
was absent from gnomAD.  
In Family 5 (61421) (Fig. 5.1 (i)), the homozygous missense variant CNGA3 
c.1641C>A; p.(Phe547Leu) was found to co-segregate in the four affected (and 
other) family members, was identified as the likely cause. The variant has been 
already associated with IRDs [324-326], and has a MAF of 0.0007186 in South 
Asian population, and also present in European and Finnish populations. 
All the CNGA3 variants identified were highly conserved among vertebrates 
(Fig. 5.1 (ii)), and were located in functionally-relevant regions of the channel; 
Cys319 was in the ion channel transmembrane domain (Ion_trans), while 
Met519, Gly534, Phe547 are located in the cyclic nucleotide-binding domain 









Figure 5.1 Families with CNGA3 alterations. (i) Pedigrees and 
electropherograms for CNGA3 variants of families 1 to 5. (ii) Conservation in 
vertebrates of CNGA3 variants and protein domains to which they belong. 
Ion_trans= ion channel transmembrane domain; cNMP_binding= cyclic 
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nucleotide-binding domain; CLZ= C-terminal leucine zipper domain of cyclic 
nucleotide-gated channels. 
 
5.2.2 Sequence alterations in TULP1 and PDE6C identified in three 
families with RP 
Family 6 (Fig. 5.2 (i)) was diagnosed with RP and originated from Lahore, 
Punjab; family members belonged to the Mughal tribe. Exome sequencing 
identified the homozygous duplication TULP1 c.855dupC; p.(Val286Argfs*98), 
as the likely cause of the disease. This variant was absent in gnomAD and 
reported in a single individual of unknown origin in heterozygous state [312]. 
Family 7 (Fig. 5.2 (i)) was initially diagnosed with RP. The five affected 
individuals showed decreased vision with progressive deterioration, night 
blindness, photophobia, nystagmus. Fundus examination identified pigmentary 
retinopathy, optic disc pallor and attenuated vessels (Fig. 4.2 (ii), individual 
III:4). Individual III:2 also showed symptoms of bilateral maculopathy. This 
family originated from the Kohat district, KPK. Exome sequencing identified two 
possible pathogenic variants in TULP1 c.238C>T, p.(Gln80Lys), and PDE6C 
c.480delG, p.(Asn161Thrfs*33). Two of the affected individuals (III:1 and III:3) 
were homozygous for both the variants, while III:4, III:5 were homozygous for 
the TULP1 variant and heterozygous for the PDE6C variant. Individual III:2 was 
instead homozygous for PDE6C variant, and heterozygous for the TULP1 
variant. Therefore, in this family two potentially causative variants causing RP 
and CD were identified. None of these variants have been previously reported 
and were absent in gnomAD. Unfortunately, due to the lack of clinical 
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information, a definitive diagnosis of each affected member of the family was 
not possible to reach. 
Family 8 (61401) (Fig. 5.2 (i)) comprised an extended family with four affected 
individuals. No clinical information were available however exome sequencing 
identified a novel homozygous variant PDE6C c.1A>G; p.(Met1*). This variant 
has a MAF of 0.00006479 in gnomAD, and no homozygous individual were 
present in the database.   
Conservation (Fig. 5.2 (iii)) of TULP1 showed conservation of Gln80 only 
amongst humans and monkeys, while TULP1 Val286, PDE6C Met1, and 
Asn161 were conserved from humans to chicken. Both TULP1 variants lied in 
the protein domains outside the coiled coil regions or Tub domains.   












Figure 5.2 TULP1 and PDE6C co-segregation analysis. (i) Pedigrees of 
families 6, 7 and 8 and co-segregation of TULP1 and PDE6C. (ii) Fundus 
examination of individual III:4 of family 7, homozygous for the TULP1 p.(Gln80*) 
and heterozygous for PDE6C p.(Asn161Thrfs*33), showed attenuation of retinal 
vessels and optic disc pallor. (iii) Conservation analysis of the TULP1 and 
PDE6C variants. While TULP1 Val286, PDE6C Met1 and Asn161 were 
conserved amongst all the species examined, TULP1 Gln80 was conserved 
only amongst higher mammals. TULP1 has two coiled coil domains (cc), and a 
Tub domain. PDE6C has two GAF domains (cGMP-specific 
phosphodiesterases, adenylyl cyclases and FhlA), a cc domain and a PDEase I 
domain.   
 
5.2.3 RPGRIP1 sequence alterations in two families 
Family 9 (Fig. 5.3 (i)) belonged to the Syed, Pashtoon tribe, and originated from 
Pishin, Baluchistan. Two affected individuals were diagnosed with nystagmus, 
visual impairment, and strabismus. Illumina Trusight One clinical exome 
sequencing panel identified a homozygous duplication RPGRIP1 c.2789dup; 
p.(Pro931Thrfs*3), which has not been reported previously and is absent in 
gnomAD. This finding enabled a more precise diagnosis of the condition in this 
family, as affected by IRD. 
Similarly, affected individuals of Family 10 (61007) (Fig. 5.3 (i)) were found to 
be homozygous for a previously unreported RPGRIP1 variant c.2710G>A, 
p.(Gly904Ser). 
Conservation (Fig. 5.3 (ii)) of the residues impacted by these alterations showed 
that the Gly904 was conserved from human to xenopus, while the Pro931 was 
251 
 
conserved only amongst higher mammals. RPGRP1 protein has three coiled 
coils domains, two C2 domains, and a C-termini domain; the two gene variants 
we found to impact residues in proximity of the C2 domain. 
 
 
Figure 5.3 RPGRIP1 variants in Family 9 and 10. (i) Pedigrees and 
electropherograms of family 9 having a the variant RPGRIP1 c.2789dupT; 
p.(Pro931Thrfs*3), while family 10 carried the variant c.2710G>A, 
p.(Gly904Ser). (ii) Conservation showed that Gly904 was a stringently 
conserved amino acid which resides in the C2 domain of the protein, while 




5.2.4 Sequence alterations in other genes  
Family 11 (Fig. 5.4) was initially diagnosed with oculocutaneous albinism, 
displaying signs of photosensitivity, visual impairment, nystagmus and light skin 
and hair. This family originated in KPK and belonged to the Paktoon tribe. 
Illumina Trusight One clinical exome sequencing panel identified a ABCA4 
c.3364G>A; p.(Glu1122Lys) variant, which has a MAF of 0.00006533 in the 
South Asian population. This variant has never been reported in the Pakistani 
population however, it has been reported in Europeans including British [313, 
315, 327] and Han Chinese [56] populations, where it is known to be associated 
with Stargardt disease. 
Family 12 (Fig. 5.4) originated from Quetta, Balochistan and belonged to the 
Tajik, Afghan tribe. The two affected members were firstly diagnosed with 
nystagmus however, visual impairment, nystagmus, and strabismus were also 
associated with polydactyly, intellectual disability, obesity, myopia and RP, all 
classical symptoms of Bardet-Biedl syndrome. Illumina Trusight One clinical 
exome sequencing panel identified a novel homozygous splice site missense 
variant c.221-1G>A in BBS4 gene, which was absent from gnomAD. In 
Pakistan only one other BBS4 variant has been reported (BBS4 c.1463C>A; 
p.(Thr488Lys)), as affecting two siblings [328]. 
Family 13 (Fig. 5.4) belonged to the Dogar caste and originated from Borewala, 
Punjab. The three affected individuals were diagnosed with arRP and exome 
sequencing confirmed a novel homozygous deletion in CRB1 c.3735delA; 
p.(Gly1246Glufs*36).  CRB1 variants have been associated with both arRP and 
arLCA in the Pakistani population previously. 
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Family 14 (Fig. 5.4) was diagnosed with congenital cataract and originated from 
KPK. Illumina Trusight One clinical exome sequencing panel identified a 
homozygous variant in GUCY2D c.3056A>C, p.(His1019Pro). The variant has 
been previously reported as pathogenic in two other Pakistani families affected 
by LCA [314] but not in other populations, and it had a MAF of 0.00003347 in 
the South Asian population. 
Family 15 (Fig. 5.4) originated from Lahore, Punjab, with individuals diagnosed 
with RP. Exome sequencing identified the homozygous novel splice variant 
TTC8 c.768 +5G>A, which was also absent from gnomAD, as the likely cause 
of disease. Alterations in TTC8 have been associated with BBS and RP in the 
Pakistani population.  
Family 16 (Fig. 5.5) was diagnosed with nystagmus and visual impairment, and 
originated from Mastung, in the Baluchistan province. This family belonged to 
the Ababki, Bravi caste. Illumina Trusight One clinical exome sequencing panel 
identified a novel missense variant in the gene CACNA1F c.2254G>A; 
p.(Val752Met). This variant was not present in gnomAD, and alterations in this 
gene have never been reported in the Pakistani population. This gene encodes 
for the voltage-dependent L-type calcium channel subunit alpha-1F, alterations 
are known to cause either fundus albipuntatus or cone-rod dystrophy however, 
lack of clinical information about this family did not allow us to provide a final 
diagnosis.  
Family 17 (Fig. 5.5) has 3 affected individuals, 2 children and the mother. The 
family originated from the Karak district, in the KPK province, and was 
diagnosed with Usher syndrome. Audiogram performed to affected members 
showed hearing loss, and fundus examination showed pigmentary retinopathy, 
254 
 
optic disc pallor, attenuated retinal vessels, maculopathy, cataract, epiretinal 
membrane. Illumina Trusight One clinical exome sequencing panel identified 
the missense variant USH2A c.7334C>T; p.(Ser2445Phe), which has been 
ascertained in an individual of unknown origins in a compound heterozygous 
state [315] and present in gnomAD with a MAF of 0.006435. gnomAD also 
reported the presence of two homozygous individuals present in their cohort. 
Genetic analysis on this family confirmed the initial diagnosis of Usher 
syndrome.  
Family 18 (Fig. 5.5) originated from Raiwind in Punjab and belonged to the 
Chohan caste. This family was diagnosed with RP, confirmed with exome 
sequencing which identified a novel deletion of 48 bp in the beta subunit of the 
cyclic nucleotide-gated channel CNGB1 c.852_874+25del which resulted in the 
frameshift alteration p.(Ile286Aspfs*9). This has been associated only with RP, 
confirming the initial diagnosis for the affected individuals we examined. 
Family 19 (Fig. 5.5) was an extended family which was diagnosed with RP, 
affected members showed signs of strabismus and visual impairment. WES 
identified a novel missense variant in the Lecithin retinol acyltransferase gene 
LRAT c.196G>C; p.(Gly66Arg) which confirmed the initial diagnosis. This family 
















5.2.5 Sequence alterations identified in the NEI samples cohort 
Family 20 (Fig. 5.6) had five members affected by IRD. Genotyping showed that 
in this families two variants in different genes segregated in the affected 
members, CLCC1 c.75C>A; p.(Arg25Glu) and CDH23 c.1595C>T; 
p.(Thr532Met). Affected individuals were either homozygous for at least one of 
these variants. CLCC1 has been identified by our group as a founder alteration 
causing RP in the Pakistani population [316], while the CDH23 variant has been 
identified in people of unknown ethnic origins [317, 318]. CLCC1 c.75C>A has a 
MAF in the South Asian population of 0.0003924, while CDH23 c.1595C>T was 
absent from the database. 
In Family 21 (Fig. 5.6) affected individuals were homozygous for a LCA5 
c.1550_1551delGA; p.(Arg517Ilefs*3) variant. This variant has never been 
reported and only other three variants have been reported in the Pakistani 
population (see Appendix D).Investigations in family 22 (Fig. 5.6) showed the 
previously described splice variant RPGR c.310+1G>C, which was absent from 
gnomAD, but has been reported in a family in the USA [320] and in a family of 
unknown ethnic origins [319]. The three affected members of family 23 (Fig. 
5.6) segregated with the variant PDE6B c.12_15delAGTG; p.(Ser4Argfs*23), 
this variant has already been reported in a Pakistani family as causative of RP 
[321].  
Family 24 (Fig. 5.7) was homozygous for the novel homozygous variant RDH5 
c.838C>G; p.(Arg280Gly). Another four disease-causing variants for this gene 
have been reported exclusively in Pakistan. In Family 25 (Fig. 5.7), a 
homozygous  MERTK variant c.2194C>T; p.(Arg732*) was identified as the 
likely cause, this variant has been already reported as disease causing in a 
family of unknown origin  [322], and only another variant, MERTK c.718G>T, 
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p.(Glu240*) has been reported in two families in Pakistan [169, 329]. Affected 
members of family 26 (Fig. 5.7) were found to be homozygous for an OAT 
c.722C>T; p.(Pro241Leu) variant, which has been reported in German/Italian 
individuals [323];however, the OAT c.722C>T variant is the first to be identified 
in a Pakistani family. The OAT locus has been previously mapped in another 
Pakistani family [169]. In family 27 (Fig. 5.7), a ARL6 variant c.534A>G; 
p.(Gln178Gln), previously  reported in another Pakistani family with BBS [330], 
but not reported in other populations. Two other variants in the same gene have 

















Figure 5.7 Pedigrees and sequence chromatograms of families 24 to 27. 
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5.2.6 Literature review of IRD causes in Pakistan 
An overview of all genetic causes of IRD in Pakistan was undertaken to provide 
a more completed understanding of the causes of IRD in Pakistan. PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/) and Google Scholar 
(https://scholar.google.co.uk/) were used as platforms to search for publications. 
We explored the specific nucleotide and protein variants, phenotypes reported, 
the region in Pakistan where the affected families originate, the number of 
families and individuals affected by the alteration, the presence of the alteration 
in other ethnicities, and levels of confidence of causality according to the sub-
categorisation within NCBI ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/). 
Where the author has indicated that there may be some degree of doubt, or 
subsequent evidence has come to light in the literature, calling the deleterious 
nature of the variant into question [333], this was also noted. We identified a 
total of 519 families with candidate genetic variants in 118 genes or loci, 
creating the most comprehensive database on inherited retinal disorders 
population-specific (see Appendix D). 
Alterations in ABCA4 gene have been reported in 6 families (9 individuals) as 
causative of Stargardt disease, and in 2 families (7 individuals) as causative of 
IRD. Interestingly, the common pathogenic variant ABCA4 c.5882G>A, widely 
reported in many ethnicities, has only been reported in two Pakistani families. 
Bardet-Biedl syndrome has an estimated frequency of 1:100.000 in non-
consanguineous populations however, the frequency may vary depending on 
the population analysed. We found that in literature 34 variants described in 
BBS genes (ARL6, BBS1, BBS2, BBS4, BBS5, BBS7, BBS9, BBS10, BBS12, 
CEP19, CEP164, MKKS, TTC8, WDR60) in the Pakistani population, affecting 
44 families and a total of 97 individuals. Amongst the gene of which variants 
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have been associated with disease, variants in BBS10 were the highest in 
number in Pakistani population, accounting for the 17% of them (Fig. 5.8 (i)) 
and affecting eight families. Alterations in genes TRIM32, MKS1, WDPCP, 
SDCCAG8, LZTFL1, BBIP1, and IFT27 known to be associated with BBS, were 
not reported in the Pakistani population. 
From this data, Usher syndrome seems to be the most prevalent syndromic 
retinal disorder in Pakistan as literature review identified 66 families (162 
individuals) with the condition. Forty-nine variants were causative of the disease 
in this population, the most mutated genes being MYO7A (23 variants, 50% of 
total variants) and CDH23 (15 variants, 33% of total variants) (Fig. 5.8 (ii)).  
Other rare syndromic IRDs were found in the Pakistani population. Joubert 
syndrome (JBTS), is characterised by ocular features associated with 
developmental delay, hypoplasia of the cerebellar vermis, renal abnormalities 
and dysregulation of breathing pattern. Out of more than 30 genes associated 
with JBTS worldwide, six of them (AHI1, ARL3, ARL13B, CC2D2A, CEP290, 
TCNT2) have been reported as causing the disease in Pakistan. Meckel 
syndrome (MKS) is typically associated with kidney cysts, occipital 
encephalocele, polydactyly, and eye features. Six genes have been associated 
with this disease in the Pakistani population; TMEM67 was the most common 
mutated with eight variants associated with this disease, three were present in 








Autosomal recessive RP was the most common non-syndromic retinal disorder 
in the Pakistani community, with RP1 variants and CRB1 variants making up 
the 16% and 15% of the total disease-associated variants present in the 
population (Fig. 5.9). RP1 variants were identified in 14 families, with 6 of them 
originating from Punjab, while CRB1 variants were described in 13 families with 
no clear clustering in any specific region due to a lack of information reported in 
literature. Amongst the most common variants causing arRP in Pakistan, 
TULP1 c.1466A>G has been found in 15 families from Punjab, indicating that 
the variant was a founder alteration effect of that particular region. Similarly, the 
CLCC1 c.75C>A variant was identified in 9 families from Punjab, and 
represents a founder alteration which arose in that region. 
Regionalisation of disease-causing variants affecting high number of families 
was particularly observable for LCA where the variants RPE65 c.1087C>A was 
found in 10 families from Punjab, AIPL1 c.834G>A, p.(Trp278*), and 11 families 
in Northern Pakistan. The LCA5 c.1151delC variant was found in six families 
from both Northern Pakistan and Punjab. While these variants represent just a 
single founder event occurred in a community, seven different alterations have 
been reported for the gene RPGRIP1, which constitutes the 25% of the variants 
causing dieses and the most commonly mutated in the Pakistani population (Fig 
5.9 (ii)). 
Northern Pakistan has also been flagged as hot spot for Alström syndrome 
(MIM 203800), characterised by progressive cone-rod dystrophy, sensorineural 
hearing loss, obesity, type 2 diabetes, dilated cardiomyopathy, renal failure and 
pulmonary, hepatic, and urological dysfunctions. We found seven variants 
reported as associated with this disease in Pakistan, five of them present in the 
Northern Pakistani population. 
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Not surprisingly, autosomal dominant IRDs have been reported only in for three 
variants harbouring in the same gene, SEMA4A. The variants c.1033G>C and 
c.1049T>G have been reported as causing adCRD, and the c.2138G>A variant 
reported as associated with adRP. All of them have been described in four 
families each however, no geographical localisation was reported. Such a low 
number of variants-causing dominant diseases was probably due by endogamy 
practises, making recessive disorders more common. 
Non-progressive forms of retinal degeneration such as congenital stationary 
night blindness (CSNB), mainly rod-associated, has been found associated with 
GNAT1, GRM6 and SLC24A1 gene variants in a total of four families, while the 
cone-associated non-progressive achromatopsia (ACHM) has been found 
segregating in ten familes, with alterations in genes ATF6, CNGA3, CNGB3, 
and PDE6H.  
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Figure 5.9 Percentage of variants per gene associated with AR retinitis 




Our study entails the genetic analyses of 27 families of Pakistani descent, 
identifying a total of 29 likely disease-associated variants in 22 genes 
responsible for a range of IRDs in Pakistani communities. A previous study of 
144 families identified RPE65, TULP1, RP1, PDE6A, USH2A and RDH5 as the 
most common genes associated with autosomal recessive RP in Pakistan [169]. 
Our genetic studies, together with a comprehensive literature review, highlight 
other important genes commonly contributing to IRD in Pakistani communities, 
including ABCA4, AIPL1, CDH23, CNGA3, CRB1, RPGRIP1 and TMEM67. Our 
findings also include the first report of CACNA1F and PDE6C variants as a 
cause of IRD in Pakistani families, as well as known disease-associated 
variants described for the first time in Pakistani families including CNGA3 
p.(Met519Thr), p.(Phe547Leu) and p.(Ile482Hisfs*6), TULP1 
p.(Val286Argfs*98), ABCA4 p.(Glu1122Lys), USH2A p.(Ser2445Phe), MERTK 
p.(Arg732*), RPGR c.310+1G>C, CDH23 p.(Thr532Met), and OAT 
p.(Pro241Leu), and 14 other novel variants in established disease genes. 
Studies of IRD in Pakistan have mainly focused on families from the Punjab 
region, in which our literature review highlights CNGA3 and PDE6A variants as 
a common cause of IRD in this region. Additionally, our findings also highlight 
TMEM67 variants as a common cause of IRD in communities of the Kashmir 
region. As has been demonstrated for the CLCC1 gene variant [316] many 
common gene variants likely stem from a single gene alteration event that 
occurred in a founder ancestor individual, which was transmitted to subsequent 
generations and accumulated to an increased frequency in particular 
communities and regions. This includes AIPL1 p.(Trp278*) identified in 11 
families from Northern Pakistan, and RPE65 p.(Pro363Thr) in 10 families, 
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TULP1 p.(Lys489Arg) in 15 families, and CLCC1 p.(Asp25Glu) in 9 families, all 
from Punjab. As such founder alterations often represent important causes of 
disease in a particular region, and knowledge of their presence and clinical 
outcomes is of importance when designing community-appropriate genetic 
testing and counselling protocols.  
Further to regional founder alterations, recurrent (‘hot spot’) gene alterations 
also represent an important cause of disease globally. While a large spectrum 
of ABCA4 sequence variants have been previously described in Stargardt 
disease, including founder variants associated with individuals of German [334], 
Spanish [335], Danish [336], Mexican [337], African-American [338] and South 
Asian descent [170]. Stargardt disease variants are generally found distributed 
throughout the ABCA4 gene [339], although recurrent gene mutations have 
been described in populations of different ethnicities and geographical location 
[170]. The ABCA4 p.(Glu1122Lys) variant identified in our study, for example, is 
well described and has been identified in compound heterozygous form in 
affected individuals from diverse ethnicities including European and Han 
Chinese [12, 13], likely indicating that it represents such a recurrent gene 
alteration. As with ancestral founder alterations, knowledge of recurrent gene 
alterations is of great utility in the development of disease-specific genetic 
testing strategies. Our studies also provide improved knowledge of the relative 
frequencies of other causes of IRD in Pakistan. ARL6 and TTC8 gene variants 
are an uncommon cause of Bardet-Biedl syndrome globally, accounting for 
0.4% and 1% of all Bardet-Biedl syndrome cases respectively [340], whilst 
LRAT variants are an uncommon cause of Leber congenital amaurosis, 
estimated to account for only 1% of all cases [341]. However, our studies 
significantly expand knowledge of the molecular spectrum of disease-
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associated variants in these genes and identifies them as being more 
commonly represented in the Pakistani population, with 4/20 (20%), 5/19 (26%) 
and 5/26 (19%) of all reported IRD-associated disease-causing variants in 
ARL6, TTC8 and LRAT respectively identified in Pakistani families (Appendix 
D).  
In geographically and culturally isolated communities such as those which may 
occur in Pakistan, an enrichment of disease-associated alleles may increase 
the probability of two distinct autosomal recessive causes of disease 
manifesting within the same family [171]. This is supported by the findings in our 
study, in which two of the 27 of families investigated (families 7 and 20) were 
found to segregate likely pathogenic genetic variants in two distinct genetic 
causes of IRD. In family 7, all affected individuals presented with progressive 
deterioration of visual acuity and were initially diagnosed with RP. There was 
however some variability noted in the clinical phenotype, with nyctalopia and 
typical fundus findings of RP being the main clinical features in individuals III:1, 
III:3, III:4 and III:5, whilst individual III:2 instead described severe photophobia 
with predominantly macular involvement on ophthalmic examination. Our 
genetic studies subsequently confirmed the segregation of two separate novel 
predicted loss of function variants in two established IRD genes; TULP1 
p.(Gln80*) and PDE6C p.(Asn161Thrfs*33) within this family, likely accounting 
for the phenotypic variability seen in affected individuals. Interesting, the two 
individuals who were homozygous for both TULP1 and PDE6C variants (III:1 
and III:3) did not appear to be more severely affected compared to individuals 
III:4 and III:5 who were homozygous for only the TULP1 variant. Additionally, 
our studies identified two separate variants as segregating with disease in 
family 20; CLCC1 p.(Asp25Glu) and CDH23 p.(Thr532Met). CLCC1 has only 
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recently been described in association with RP [316], and is likely to represent a 
founder alteration in the Punjab region in Pakistan (Appendix D). The same 
CDH23 p.(Thr532Met) variant has been reported in only a single individual with 
Usher syndrome [317] and another individual with non-syndromic hearing loss 
[318], both in compound heterozygous form. However, as two homozygous 
individuals for this variant are present in the South Asian population in gnomAD, 
the clinical significance of this variant therefore remains unclear. The presence 
of >1 disease-associated variant in a family may give rise to atypical inheritance 
patterns or phenotypical outcomes, complicating clinical interpretation and 
patient counselling and management. This intra-familial locus heterogeneity is 
particularly relevant within isolated communities such as those which may occur 
in Pakistan, and has been demonstrated to occur in up to 15% of a cohort of 
Pakistani families with presumed autosomal recessive hearing loss [342]. Our 
findings underscore the value of knowledge of the specific molecular causes(s) 
of disease in each family, and highlights the importance of considering the 
possibility of multiple molecular diagnoses within the same family. These 
genomic evaluations also aided a revised and more precise clinical (and 
specific molecular) diagnosis to be provided for many other families in this 
study. This work also emphasises the considerable diagnostic difficulties 
encountered by clinicians in certain regions of Pakistan, in which access to 
specialised equipment for detailed and accurate ocular phenotyping may be 
limited. 
Further benefits of genetic studies to aid diagnosis are provided by studies of 
family 18 in which an apparently autosomal dominant form of RP was 
segregating in an affected parent (III:3) and offspring (IV:1, IV:2 and IV:5). 
However, exome sequencing of parental individual III:3 failed to identify any 
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candidate heterozygous variants in known dominant IRD genes, although it did 
identify a heterozygous likely loss of function variant in CNGB1 
c.852_874+25del, p.(Ile286Aspfs*9), a gene known to be associated with 
autosomal recessive IRD; indeed, segregation analysis subsequently confirmed 
this variant as the likely cause of the disease in homozygous form in the 
offspring of this family. Subsequent ophthalmic examinations in the family 
confirmed the clinical diagnosis of RP in homozygous offspring and on re-
evaluation the parental carrier (III:3) was found to have mature cataracts 
accounting for her decreased visual acuity, with no signs of RP noted. Our 
genomic evaluations also aided a revised and more precise clinical (and 
specific molecular) diagnosis to be provided for many other families in this 
study.  
This study also provides further insights into the likely pathogenicity of a second 
gene variant in USH2A [c.7334C>T, p.(Ser2445Phe)], identified in family 17. 
Disease-causing variants in USH2A are the most common cause of Usher 
syndrome, accounting for 29% of all cases globally, and are also one of the 
most common causes of nonsyndromic autosomal recessive RP, accounting for 
19–23% of all cases [16]. The USH2A variant [(c.7334C>T, p.(Ser2445Phe)] is 
predicted to be deleterious by in silico pathogenicity tools (SIFT, Polyphen and 
Provean) and was first reported by Carss KJ et al. [12] in a compound 
heterozygous form in a single individual with RP. However as with the CDH23 
variant discussed above, the clinical significance of this variant remains unclear 
due to the high allele frequency of the variant in genome databases (MAF of 
0.006435 with 193 heterozygote carriers out of 15,308 individuals) including the 
presence of two homozygous individuals in the South Asian population 
(gnomAD v2.1.1). While this high allele frequency seems incompatible with 
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pathogenicity, our finding of the USH2A p.(Ser2445Phe) variant segregating 
with disease in five genotyped individuals in family 17 (including three affected 
individuals and two unaffected siblings) may indicate the variant has a role in 
disease perhaps in combination with other USH2A gene variants on the same 
founder haplotype, and/or other gene variants elsewhere in the genome. 
Further studies investigating the functional impact and potential pathogenic 
basis of this variant may be useful in clarifying any possible disease 
association. 
Taken together our data highlight the value of using high-throughput genomic 
technologies to achieve an accurate molecular diagnosis, particularly where 
deep clinical phenotyping may be limited due to resource constraints, and a 
precise clinical diagnosis may be difficult to achieve. This has important 
implications for future therapeutic interventions, particularly given recent 
developments in the field of IRD, with Luxturna® (voretigene neparvovec), the 
first ever licensed gene replacement therapy for the treatment of a genetic 
disease in humans, approved for the treatment of patients with RPE65-
associated retinal dystrophy [343]; there are also numerous other emerging 
therapies currently under development and in clinical trials [344]. We have 
compiled the most comprehensive and curated review of genes and variants 
associated with IRD in Pakistan, highlighting regional founder mutations, 
clarifying likely disease associations (including some previously reported 
variants that are now considered likely to be benign) and enabling an improved 
scientific and clinical understanding of the genomic architecture of IRD in 
Pakistan. This knowledge will facilitate the development of hierarchical 
strategies for rapid and cost-efficient genetic testing assays to enable an 
accurate disease diagnosis to be achieved more rapidly, thus aiding the 
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development of diagnostic and clinical care pathways and policies throughout 
Pakistan. Our findings, together with potential improvements in access to IRD 
therapies, will bring about direct clinical benefits for IRD patients in Pakistan, in 

















CHAPTER 6: CONCLUDING COMMENTS 
The complexity of the origins of the Pakistani population, and specific cultural 
practices, have led to a higher risk of autosomal recessive inheritance of 
disease [166, 167]. The presence of numerous isolated rural communities, 
alongside limited freely available (and expensive private) healthcare provision 
and low literacy rate (http://uis.unesco.org/country/PK), provide significant 
healthcare limitations to many Pakistani communities.  
Cataract and refractive errors entail the main causes of blindness and visual 
impairment in Pakistan, with a prevalence of 3.4% and 4.9% respectively [345-
347]. Prevalence of inherited retinal diseases have not been reported, however 
a report on the Afghan refugee population in Hairpur and Ghazi in 1998 
reported that the 12.5% of blindness in the Afghan refugee community was 
caused by retinal degeneration/dystrophy [348]. The field of ophthalmology 
often faces many challenges with the diagnosis of inherited eye disease. In 
particular, IRDs entail a highly heterogeneous group of diseases, in which 
variable phenotypic manifestation may occur within a family carrying the same 
pathogenic variant, and additionally distinct alterations in the same gene may 
give rise to different clinical outcomes. Such heterogeneity may lead to 
misdiagnosis of IRDs, particularly in poorly clinically-resourced countries such 
as Pakistan in which access to specialised equipment for detailed and accurate 
ocular phenotyping may be limited, representing a significant challenge.  
The work detailed as part of this thesis involves genetic analyses in 27 families 
affected by a wide range of syndromic and non-syndromic IRDs. For some 
families, a definite diagnosis was not possible to reach, while for others genetic 
testing revealed that the initial diagnosis of cataract or nystagmus was incorrect, 
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enabling a new molecular diagnosis of (a specific) IRD to be provided. 
Moreover, in some other families the initial clinical diagnosis was instead 
confirmed by our molecular diagnosis. Using WES, new variants known genes 
associated with IRDs, as well as new variants in known genes never found in 
the Pakistan were reported, expanding knowledge of genetic ocular disease in 
the Pakistani population. 
Alongside this, a literature review on IRD in Pakistani population was performed 
to build a community-relevant database of gene variants associated with IRDs. 
This was used to better define the extent of IRDs in Pakistan and which gene 
variants are the most common, their association with specific retinal dystrophy 
as well their regional prevalence. This work enabled the identification of regional 
founder mutations in IRD associated disease genes including: AIPL1, TMEM67, 
RPE65, TULP1 and CLCC1, as well as the genes most often mutated to cause 
IRD in Pakistan. In turn this analysis will help clinicians to prioritise genes and 
specific gene variants for diagnostic evaluation to create a cost-effective and 
community-appropriate sequencing panel to be employed in those cases in 
which a clinical diagnosis is unclear. Other benefits of this work also relate to 
treatment as new therapies have been developed [158] for many retinal 
disorders. While unfortunately Pakistani families identified do not relate to 
genes for which these therapies are currently available, this will undoubtedly 
change in future years as new therapies and genetic disorders are identified. 
This again underlie the uniqueness of the genetic background of the Pakistani 
population.  
Amongst the IRDs RP was found to be the most prevalent. Over 70 genes have 
been associated with RP, however in about 20-30% of cases a genetic cause of 
disease has not been identified [47]. The work described in this thesis entails 
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the identification of a new genetic cause of arRP, identified initially in eight 
Pakistani families and a British-Bangladeshi family. We show that the variant 
(c.75C>A, p.(Asp25Glu)) in CLCC1 represents a founder mutation which arose 
in Punjab, and as such all families with the conditions descend from the same 
common ancestor,. Functional studies of CLCC1 found it to be important for 
retinal development, photoreceptors morphology, and function. As the function 
of CLCC1 was not known, functional studies were necessary, defining CLCC1 
as an ER protein, although the functional significance of the Asp25Glu variant 
has not yet been defined. While this work defines a new molecular cause of RP, 
many questions about the mechanism of disease remain open and further 
studies will be necessary to define the role of CLCC1 within normal cells, and 
the functional outcome of the Asp25Glu variant.   
Together the work presented in this thesis provides a greatly improved 
knowledge of the genetic causes of IRD in Pakistan. Targeted and cost-
effective genetic testing for Pakistani populations, based on detailed knowledge 
of the prevalence of specific genetic alterations in geographically isolated 
communities and their clinical outcomes, will ultimately provide substantial 
healthcare improvements and enable a more efficient path for the diagnosis of 
inherited disease.  Understanding the causes as well as the consequences of 













Table 1 Genes reported in RetNet as related to Inherited Retinal 
Dystrophies.  












adRP ADIPOR1 Regulator of fatty 
acid catabolism 















 ARL3 Cilia signalling   604695 




 CA4 Nitrogen 
metabolism 
 114760 




  FSCN2 Actin bundling 
protein 
  607643 
  GUCA1B Ca(2+)-sensitive 
regulation of 
guanylyl cyclase 
  602275 
  HK1 Glucose 
metabolism 
  142600 




  146690 




cells and adhesion 
of the neural retina 
to the retinal 
pigment epithelium. 
  602870 
  KLHL7 Proteins 
degradation 
  611119 
  NR2E3 Transcriptional 
factor that activates 
rod development 
and repress cone 
development 
  604485 
  NRL Transcriptional 
activator of rod 
genes 
  162080 
  PRPF3 Spliceosome 
assembly 
  607301 
  PRPF4 Spliceosome 
assembly 
  607795 
  PRPF6 Spliceosome 
component 
  613979 
  PRPF8 Spliceosome 
assembly 
  607300 
  PRPF31 Spliceosome 
component 
  606419 
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  PRPH2 Adhesion molecule 
involved in 
stabilization and 
compaction of outer 
segment discs 
  179605 
  RDH12 Retinoids 
dehydrogenase/red
uctase 
  608830 
  RHO Rhodopsin   180380 
  ROM1 Disc 
morphogenesis 
  180721 
  RP1 Microtubule-
associated protein 
regulating the 
stability and length 
of the microtubule-
based axoneme of 
photoreceptors 
  603937 
  RP9 pre-mRNA splicing   607331 
  RPE65 Involved in the 
visual cycle 
  180069 
  SAG Visual arrestin   181031 
  SEMA4A Regulator of axon 
guidance 
  607292 
  SNRNP200 Spliceosome 
assembly 
  601664 
  SPP2 secreted 
phosphoprotein 
member of the 
cystatin superfamily 
  602637 
  TOPORS E3 ubiquitin-protein 
ligase 
  609507 
 arRP ABCA4 ABC transporter   601691 
  AGBL5 Metallocarboxypept
idase that mediates 
protein 
deglutamylation 
  615900 
  AHR Ligand-activated 
transcriptional 
activator 





(GEF) for RhoA 
GTPases 
  616432 
  ARL6 Regulator of 
intracellular 
trafficking to cilia 
  608845 




activity of STAT3 
  615407 
  BBS1 Component of 
BBSome complex 
  209901 
  BBS2 Component of 
BBSome complex 
  606151 
  BEST1 Forms calcium-
sensitive chloride 
channels 
  607854 
  C2orf71 Normal 
photoreceptor cell 
maintenance and 




  C2orf37 Substrate receptor 
for CUL4-DDB1 E3 
ubiquitin-protein 
ligase complex 
  612515 
  CERKL Involved in 
autophagy and 
phagocytosis 
  608381 
  CLCC1 ER protein   617539 
  CLRN1 Ribbon synapse 
junctions 
  606397 
  CNGA1 Cyclic nucleotide-
gated cation 
channel subunit 
  123825 
  CNGB1 Subunit of cyclic 
nucleotide-gated 
(CNG) channels, 
  600724 
  CRB1 Photoreceptor 
morphogenesis 
  604210 
  CYP4V2 Omega-
hydroxylase 
  608614 
  DHDDS Glycoproteins 
biosynthesis 
  608172 
  DHX38 Component of the 
spliceosome 
  605584 





  616846 
  EYS Maintains the 
integrity of 
photoreceptor cells 
  612424 
  FAM161A Ciliogenesis   613596 
  GPR125 Planar cell polarity 
pathway 
  612303 
  HGSNAT Lysosomal 
acetyltransferase  
  610453 
  IDH3B Enzyme related to 
pyruvate 
metabolism 
  604526 
  IFT140 Required for 
retrograde ciliary 
transport and entry 
into cilia of GPCR 
receptors 
  614620 
 
  IFT172 Maintenance and 
formation of cilia 
  607386 




  607056 
  KIAA1549 Unknown   613344 
  KIZ Stabiliser the 
pericentriolar 
region prior to 
spindle formation 
  615757 




  604863 








  604705 
  MVK Peroxisomal 
enzyme involved in 
sterol synthesis 
  251170 
  NEK2 Serine/threonine-
protein kinase 
involved in mitotic 
regulation 
  604043 
  NEUROD1 Transcriptional 
activator 
  601724 
  NR2E3 Transcriptional 
factor that activates 
rod development 
and repress cone 
development 
  604485 
  NRL Transcriptional 
activator of rod-
specific genes 
  162080 
  PDE6A Alpha subunit of 
phosphodiesterase  
  180071 
  PDE6B Beta subunit of 
phosphodiesterase  
  180072 
  PDE6G Gamma subunit of 
phosphodiesterase 
  180073 
  POMGNT1 Participates in O-
mannosyl 
glycosylation 
  606822 
  PRCD Photoreceptor disc 
component 
  610598 
  PROM1 Regulator of disk 
morphogenesis 
  604365 
  RBP3 IRBP shuttles 11-





  180290 
  REEP6 Transport of 
receptors from the 
endoplasmic 
reticulum (ER) to 
the cell surface 
  609346 
  RGR Receptor for all-
trans- and 11-cis-
retinal 
  600342 
  RHO Rhodopsin   180380 
  RLBP1 Soluble retinoid 
carrier 
  180090 
  RP1 Microtubule-
associated protein 
regulating the 
stability and length 
of the microtubule-
based axoneme of 
photoreceptors 
  603937 
  RP1L1 Required for the 
differentiation of 
photoreceptor cells 
  608581 
283 
 
  RPE65 Involved in the 
visual cycle 
  180069 
  SAG Visual arrestin   181031 
  SAMD11 May play a role in 
photoreceptor 
development 
  616765 
  SLC7A14 Amino acid 
transporter protein 
  615720 
  SPATA7 Recruits and 
localises RPGRIP1 
in the cilium 
  609868 
  TRNT1 CCA-adding 
enzyme 
  612907 
  TTC8 Component of 
BBSome complex 
  608132 





  602280 
  USH2A Maintenance of 
periciliary 
membrane complex 
  608400 
  ZNF408 DNA binding 
protein 
  616454 
  ZNF513 Transcriptional 
regulator 




RP2 Trafficking between 
the Golgi and the 
ciliary membrane 
   




and cell contractility 
 
  312610 
























  OTX2 Transcription factor  600037 
 arLCA AIPL1 Chaperone of 
PDE6 
 604392 
  CABP4 Calcium-binding 
protein 
 608965 
  CCT2 Molecular 
chaperone 
 605139 
  CEP290 Involved in early 
and late steps in 
cilia formation 
 610142 
  CLUAP1 Cilia biogenesis  616787 
  CRB1 Photoreceptor 
morphogenesis 
 604210 
  CRX Transcription factor 
for photoreceptor-
specific genes 
  602225 
  DTHD1 Death domain-
containing proteins 
  616979 






differentiation in the 
retina 
  GUCY2D Retinal guanylyl 
cyclase 
  600179 
  IFT140 Required for 
retrograde ciliary 
transport and entry 
into cilia of GPCR 
receptors 
  614620 
 
  IQCB1 Ciliogenesis   609237 
  KCNJ13 Inwardly rectifying 
potassium channel 
  603208 
  LCA5 Involved in 
intraflagellar protein 
(IFT) transport in 
photoreceptor cilia 
  611408 




  604863 
  NMNAT1 Catalyse 
biosynthesis of 
NAD 
  608700 
  PRPH2 Adhesion molecule 
involved in 
stabilization and 
compaction of outer 
segment discs 
  179605 
  RD3 Regulates 
GUCY2D 
  180040 
  RDH12 Retinoids 
dehydrogenase/red
uctase 
  608830 
  RPE65 Involved in the 
visual cycle 
  180069 
  RPGRIP1 Interacts with 
GTPase regulator 
protein. Required 
for normal location 
of RPGR at the 
connecting cilium of 
photoreceptor cells 
  605446 
  SPATA7 Recruits and 
localises RPGRIP1 
in the cilium 
  609868 





  602280 
 adCSN
B 
GNAT1 Signal transducer 














  PDE6B Beta subunit of 
phosphodiesterase  
 180072 
  RHO Rhodopsin  180380 
 arCSNB CABP4 Calcium-binding 
protein 
 608965 
  GNAT1 Signal transducer  139330 
285 
 
for the rod 
photoreceptor RHO 
 
  GNB3 Heterotrimeric G 
protein subunit 
 139130 




  GRK1 Rhodopsin kinase   180381 
  GRM6 Glutamate receptor   604096 
  LRIT3 localise TRPM1 at 
dendrite tips in ON-
bipolar cells 
  615004 
  RHD5 Catalyzes the 
oxidation of cis-
isomers of retinol 
  601617 
 (Oguchi 
disease) 
SAG Visual arrestin   181031 
  SLC24A1 Controls calcium 
concentration of 
outer segments  
  603617 
  TRPM1 Cation channel 
essential for the 
depolarizing 
photoresponse of 
retinal ON bipolar 
cells. 






  300110 
  NYX Forms complex 
with TRPM1 





























  GUCA1A Regulator of retinal 
guanylyl cyclase 
 600364 
  GUCY2D retinal guanylyl 
cyclase 
 600179 








  PROM1 Regulator of disk 
morphogenesis 
 604365 
  PRPH2 Adhesion molecule 
involved in 
stabilization and 
compaction of outer 
segment discs 
  179605 
  RIMS1 Regulator of 
synaptic vesicle 
exocytosis 
  606629 
286 
 
  SEMA4A Regulator of axon 
guidance 
  607292 
  UNC119 Involved in synaptic 
functions in 
photoreceptor cells 
  604011 
 arCD/C
RD 
ABCA4 ABC transporter   601691 
  ADAM9 Disintegrin and 
metalloprotease 
  602713 
  ATF6 Transcription factor   605537 




calcium channels  
  608171 
  CFAP510 Cilia-associated 
protein 
  603191 
  CDHR1 Cadherin involved 
in disc 
morphogenesis 
  609502 
  CEP78 Ciliogenesis   617110 
  CERKL Involved in 
autophagy and 
phagocytosis 
  608381 
  CNGA3 Cyclic nucleotide-
gated cation 
channel 
  600053 
  CNGB3 Cyclic nucleotide-
gated ion channel 
  605080 
  CNNM4 Metal transporter   607805 
  GNAT2 Transducin   139340 
  IFT81 Transport of tubulin 
within the cilium 
  605489 
  KCNV2 Voltage-gated 
potassium 
channels. 
  607604 
  PDE6C Phosphodiesterase 
subunit. 
  600827 
  PDE6H Phosphodiesterase 
subunit. 
  601190 
  POC1B Centriole assembly 
and/or stability and 
ciliogenesis. 
  614784 
  RAB28 Intracellular 
trafficking. 
  612994 
  RAX2 Gene expression 
modulator in 
photoreceptors. 
  610362 
  RDH5 Catalyzes the 
oxidation of cis-
isomers of retinol. 
  601617 
  RPGRIP1 Interacts with 
GTPase regulator 
protein. Required 
for normal location 
of RPGR at the 
connecting cilium of 
photoreceptor cells. 
  605446 




  612268 
 X-
linked 
RPGR Regulates cilia 
formation by 











ATF6 Transcription factor   605537 
  CNGA3 Cyclic nucleotide-
gated cation 
channel 
  600053 
  CNGB1 Subunit of cyclic 
nucleotide-gated 
(CNG) channels, 
  600724 
  GNAT2 Transducin   139340 
  PDE6C Phosphodiesterase 
subunit. 
  600827 
  PDE6H Phosphodiesterase 
subunit. 















flakes at the 












rine (LPS) lipase 













 ADGRV1 G-protein coupled 
receptor which has 
an essential role in 
the development of 
hearing and vision 
  602851 
 ARSG Lysosomal 
sulfatase 
  610008 
  CDH23 Calcium-dependent 
cell adhesion 
proteins 
  605516 
  CEP250 Centrosome 
cohesion during 
interphase 
  609689 
  CEP78 Ciliogenesis   617110 
  CIB2 Calcium-binding 
protein 
  605564 
  CLRN1 Ribbon synapse 
junctions 
  606397 
  DFNB31 Member of the 
USH2 complex 
  607928 
  ESPN Actin-bundling 
protein 
  606351 
  HARS Plays a role in axon 
guidance 
  142810 
  MYO7A Actin-based motor 
molecules 
  276903 
  PCDH15 Calcium-dependent 
cell-adhesion 
protein 
  605514 
  USH1C Assembly of Usher 
protein complexes 
  605242 














arBBS ADIPOR1 Regulator of fatty 
acid catabolism 














  ARL6 Regulator of 
intracellular 
trafficking to cilia 
 608845 
  BBIP1 Component of 
BBSome complex 
 613605 
  BBS1 Component of 
BBSome complex 
 209901 
  BBS2 Component of 
BBSome complex 
  606151 
  BBS4 Component of 
BBSome complex 
  600374 
  BBS5 Component of 
BBSome complex 
  603650 
  BBS7 Component of 
BBSome complex 
  607590 
  BBS9 Component of 
BBSome complex 
  607968 
  BBS10 Chaperone and 
component of 
BBSome complex 
  610148 




  610683 
  C8orf37 unknown   614477 
  CEP19 Ciliogenesis 
initiator 
  615586 
  CEP164 Centrosomal 






  614848 
  CEP290 Involved in early 
and late steps in 
cilia formation 
  610142 
  IFT172 Maintenance and 
formation of cilia 
  607386 
  IFT27 Small GTPase-like 
component of the 
intraflagellar 
transport (IFT) 
complex B that 
promotes the exit of 
the BBSome 
complex from cilia 
  615870 
  INPP5E Controls cilia 
growth 
  613037 
  LZTFL1 Regulates ciliary 
localization of the 




  MKKS Chaperone, 
assembly of 
BBSome 
  604896 
 






the cilia and 
plasma 
membranes. 
  609883 
  SDCCAG8 Plays a role in the 
establishment of 
cell polarity and 
epithelial lumen 
formation 
  613524 
  TRIM32 E3 ubiquitin ligase 
activity 
  602290 
  TTC8 Component of 
BBSome complex 
  608132 
  WDPCP ciliogenesis and 
collective cell 
movements 
  613580 
 



















































  B9D1 
 
Component of the 
tectonic-like 
complex localised 
at the transition 
zone of primary 
cilia 
 614144 
  B9D2 
 
Component of the 
tectonic-like 
complex localised 
at the transition 
  611951 
290 
 
zone of primary 
cilia 




  615944 
  CC2D2A 
 
Component of the 
tectonic-like 
complex localised 
at the transition 
zone of primary 
cilia 
  612013 







  610523 
  CEP104 
 
Required for 
ciliogenesis and for 
structural integrity 
at the ciliary tip 
  616690 
  CEP120 
 
Plays a role in the 
microtubule-
dependent coupling 
of the nucleus and 
the centrosome 
  613446 
  CEP290 
 
Involved in early 
and late steps in 
cilia formation 
  610142 
  CPLANE1 
 






  614571 





  611654 
  IFT172 
 
Maintenance and 
formation of cilia 
  607386 
  INPP5E 
 
Control cilia growth   613037 









  616650 






  610178 




  611254 
  MKS1 
 






the cilia and 
plasma 
membranes. 
  609883 
291 
 
  NPHP1 
 
Control of epithelial 
cell polarity 
  607100 
  OFD1 
 
Component of the 
centrioles 
  300170 




  602676 
  POC1B 
 
Centriole assembly 
and/or stability and 
ciliogenesis 
  614784 
  RPGRIP1L 
 
Localise to the 
basal body-
centrosome 
complex or to 
primary cilia and 
centrosomes 
  610937 
  TCTN1 
 






the cilia and 
plasma 
membranes. 
  609863 
  TCTN2 
 






  613846 
  TCTN3 
 






development of the 
neural tube 
  613847 
  TMEM67 
 
Centriole migration 
to the apical 
membrane and 
formation of the 
primary cilium. 
  609884 
  TMEM107 Component of the 
primary cilia 
transition zone  
  616183 
  TMEM138 Ciliogenesis   614459 
  TMEM216 Part of the tectonic-
like complex which 
is required for 
tissue-specific 
ciliogenesis and 
may regulate ciliary 
membrane 
composition 
  613277 
  TMEM231 
 






the cilia and 





  TMEM237 
 
Tetraspanin protein 
involved in WNT 
signalling 
  614423 
  TTC21B 
 
Component of the 
IFT complex A 
  612014 
  ZNF423 Nuclear protein that 
belongs to the 
family of Kruppel-
like C2H2 zinc 
finger proteins. 
  604557 
 MKS B9D1 
 
Component of the 
tectonic-like 
complex localised 
at the transition 

















  B9D2 
 
Component of the 
tectonic-like 
complex localised 
at the transition 
zone of primary 
cilia 
 611951 
  CPLANE1 
 






  614571 
  CC2D2A 
 
Component of the 
tectonic-like 
complex localised 
at the transition 
zone of primary 
cilia 
  612013 
  CEP55 Plays a role in 
mitotic exit and 
cytokinesis 
  610000 
  CEP290 
 
Involved in early 
and late steps in 
cilia formation 
  610142 





  611654 







  611279 
  MKS1 
 






the cilia and 
plasma 
membranes. 
  609883 









  RPGRIP1L 
 
Localise to the 
basal body-
centrosome 
complex or to 
primary cilia and 
centrosomes 
  610937 
  TCTN2 
 






  613846 
  TMEM67 
 
Centriole migration 
to the apical 
membrane and 
formation of the 
primary cilium. 
  609884 
  TMEM107 
 
C omponent of the 
primary cilia 
transition zone 
  616183 
  TMEM216 Part of the tectonic-
like complex which 
is required for 
tissue-specific 
ciliogenesis and 
may regulate ciliary 
membrane 
composition. 
  613277 
  TMEM231 
 






the cilia and 
plasma 
membranes. 
  614949 
  TXNDC15 
 
Member of the 
thioredoxin 
superfamily 
  617778 
 SLS CEP164 Centrosomal 












  CEP290 
 
Involved in early 
and late steps in 
cilia formation 
  610142 
  IQCB1 Ciliogenesis   609237 
  NPHP1 
 
Control of epithelial 
cell polarity 
  607100 
  NPHP3 
locus 
 
    
  NPHP4 Involved in the 
organization of 
apical junctions 
  607215 
  SDCCAG8 Plays a role in the 
establishment of 
  613524 
294 
 






Interacts with TNF 
receptor-associated 
factor 3 tethering it 
to cytoskeletal 
microtubules. 
  607380 
  WDR19 Component of the 
IFT complex A 





























Table 1 Primary antibodies used in this study 








 CLCC1 ICC 
WB 
Co-IP 
0.3 mg/ml 1:100 
1:1000 
1:1000 


























ICC 1 mg/ml 1:100 
Atlas HPA04089
04 
 EMC1 ICC 
WB 
























GAPDH WB 1 mg/ml 1:5000 
Thermo 
fisher 




11076-200 10C3 KDEL ICC  1:200 









Sc-137075 B-5 SigmaR1  ICC 0.2 mg/ml  
Novus NBP2-
44168 
 STIM1 ICC 1.12 mg/ml 1:100 
Cell 
signaling 
5589 D4F5 Rab11 ICC  1:50 
abcam Ab14748 15H4
C4 
ATPA5A ICC 1 mg/ml 1:100 
Cell 
Signaling 
















Table 2 Secondary antibodies and phalloidin used in this study 
Supplie
r 




























































































  Alexa 
Fluor 568 
Phalloidin 












Figure 1 Schematics of pILES-EYFP vector. Based upon pBluescript SK (+/-) 
phagemid with an additional polylinker which adds the sites XhoI, BglII, MscI 






Figure 2 Schematics of the expression vector pCaβLink. Based on 
pCAGGS expression vector which had the SV40 iri removed between two 
BamHI sites, which were filled and re-ligated.  LacZ present between the chick 
β-actin and the rabbit β-globin poly was removed and CaβLink was inserted. 
Unique restriction sites for the CaβLink are reported in the bottom part of the 





Table 1 Genetic variants and mapped loci previously associated with 
inherited retinal disease in Pakistani populations. This includes a summary 
of ClinVar entries and PubMed reports defining possible pathogenicity of each 
variant, as well as other genetic information including the number of families 
and affected individuals reported in which each variant cosegregated.   





















Mapped locus only; 
gene not identified 
NA Severe 
arRP 
[195] Punjab 1 (9) 61030 NA Not listed 
1p36 Mapped locus only; 
gene not identified 
NA arLCA [349] Punjab 1 (6) LCA9 NA Not listed 
2p22.3-
p24.1 
Mapped locus only; 
gene not identified 
NA arRP [196] Punjab 1 (4) PKRP11
5 
NA Not listed 
11p11.2
-q13.1 
Mapped locus only; 
gene not identified 
NA arRP [169] NA 2 61103; 
61167 
NA Not listed 
11p11.2
-q13.2 
Mapped locus only; 
gene not identified 
NA arRP [169] NA 1 61061 NA Not listed 
15q24  Mapped locus only; 











1 (9) No ID NA Not listed 
17p13 Mapped locus only; 
gene not identified 
NA arLCA with 
keratoconus 
[351] NA 1 (4) No ID NA Not listed 
ABCA4 c.93T>C p.(Trp31Arg) Stargardt 
disease 




ABCA4 c.2023G>A p.(Val675Ile)  Stargardt 
disease 





























ABCA4 c.5243G>A p.(Gly1748Glu) Stargardt 
disease 
[170] NA (1) 29 [355] 
Caucasian 
Not listed 
ABCA4 c.5646G>A p.(Met1882Ile) Stargardt 
disease 




































































ABCA4 c.6098T>A p.(Leu2033His) Stargardt 
disease 
[170] NA 1 (1) 32 No Not listed 
ABCA4 c.6317G>A p.(Arg2106His) Stargardt 
disease 
























c.1952G>A p.(Arg651Gln) CRD [393] NA 1 (1) Family 3 No Not listed 
ADAMT
S18 
c.2159G>C p.(Cys720Ser) CRD [393] NA 1 (2) Family 2 No  Not listed 
AHI1 c.2367_2368insT p.(Asn790*) arJBTS [394] NA 1 (2) F799 [395] NA Pathogenic 
(VCV00000
2016) 
AIPL1 c.116C>A p.(Thr39Asn) arLCA [396] NA 1 (6) 011LCA No Not listed 
















AIPL1 c.773G>C p.(Arg258Pro) IRD [399] Punjab 1 (7) 61032 No Not listed 
































Mapped locus only; 
variant not identified 
NA Alström 
syndrome 
[409] NA 3 (7) No ID NA Not listed 




1 (2) Family D No Not listed 






ALMS1 1444 bp, IVS8+895 









2 (8) Family 
B; No ID 
No Not listed 






































1 (1) Family G [419] Indian Pathogenic 
(VCV00043
4136) 




ARL6 c.123+1118del53985 p.(?) arBBS [332] NA 1 61049 No Not listed 
ARL6 c.281T>C p.(Ile94Thr) arBBS [331] Remote 
regions 




ARL6 c.534A>G p.(Gln178Gln) arBBS/IRD [330], 
this 
study 




No Not listed 
301 
 
ARL13B c.223G>A p.(Gly75Arg) arJBTS [421] Baluchistan 2 (5) Family 
A; 
Family B 
No Not listed 





c.532G>A p.(Gly178Arg) EORD [423] NA 1 (6) PKRD10
4 
No Not listed 
ATF6 c.355dupG  p.(Glu119Glyfs*8
) 
arACHM [75] NA 1 (5) MA28 No Pathogenic 
(VCV00020
8171) 
BBS1 c.47+1G>T p.(?) arBBS [424] Central 
Punjab 
1 (2) Family A No Not listed 
BBS1 c.442G>A p.(Asp148Asn) arBBS [424] Central 
Punjab 











BBS2 c.1237C>T p.(Arg413*) arBBS/arRP [425] 
[169, 
332] 














1 (2) Family 
12 
No Not listed 




BBS5 c.2T>A p.(Met1Lys) arBBS [425] NA 2 (2) A2027; 
A2002 
No Not listed 
BBS5 c.196delA p.(Arg66Glufs*12
) 
arBBS [427] Bannu, 
KPK 
1 (2) Family 1 No Not listed 
BBS5  c.734_744del11 p.(Glu245Glyfs*1
8) 
arBBS [330] NA 2 (3) F02; F03 No Not listed 
BBS7 c.580_582delGCA p.(Ala194del) arBBS [428] KPK 1 (4) Family A No Not listed 
BBS7 c.719G>T p.(Gly240Val) arBBS [429] Peshwar 
city, KPK 





arBBS [428] Azad 
Jammu  



















No Not listed 
BBS9 c.1789C>T p.(Gln597*)  arBBS [330] NA 1 (1) F04 [432] Latino Not listed 




















BBS10 c.1075C>T p.(Gln359*) arBBS [331] Remote 
regions 
1 (5) Family B No Not listed 
BBS10 c.1091delA p.(Asn364Thrfs*5
) 







BBS10 c.1958_1967del p.(Ser653Ilefs*4) arBBS [436] Punjab 1 (2) MRQ19 No Not listed 
BBS10 c.2121dupT p.(Lys708*) arBBS [123] NA 1 (1) No ID No Not listed 








arBBS [328] NA 1 (2) 24/56 No Not listed 
BBS12 c.1589T>C p.(Leu530Pro) arBBS [425] NA 2 (2) A2003; 
A2015 
No Not listed 




BBS12 c.2102C>A p.(Ser701*) arBBS [437] NA 1 (3) MR-10 No Not listed 








c.902G>A p.(Gly301Asp) IRD [439] Punjab 1 (3) PKRD32
0 
No Not listed 
C8orf37 c.244-2A>C p.(?) arRP [440] Multan 
district, 
Punjab 
1 (3) MA48 No Pathogenic 
(VCV00041
7787) 











1 (2) Family 
16 
No Not listed 
CC2D2
A 
c.685_687delGAA  p.(Glu229del) arMKS [442] NA 4 66 F1; 
66 F2; 














2 (5) No ID; 
PK1 





arMKS [442] NA 2 (2) 158; 180 No Not listed 








[444] NA 1 (4) Family 1 No Not listed 
CDH3 c.965A>T p.(Asn322Ile) EEM [444] NA 1 (2) Family 5 [445] Danish Pathogenic 
(VCV00001
7640) 

















3; No ID 
No Not listed 





[447] NA 1 (4) Family A [448] NA Not listed 
CDH23 c.1114C>T p.(Gln372*) arUSH 
type1 
[449] NA 1 (3) PKDF17
6 
No Not listed 
CDH23 c.1595C>T p.(Thr532Met) IRD This 
study 



















[449] NA 1 (5) PKDF21
8 
No Not listed 
CDH23 c.3880C>T p.(Gln1294*) arUSH 
type1D 
[92] NA 1 (4) PKZA56 No Pathogenic 
(VCV00000
4921) 
CDH23 c.6047-9G>A p.(?) arUSH 
type1 
[451] NA 1 (1) DEM296 No Not listed 
CDH23 c.6049+1G>A p.(?) arUSH 
type1 
[92] NA 1 (4) 304 [452] NA Pathogenic 
(VCV00004
5999) 
CDH23 c.6050-1G>C p.(?) arUSH 
type1 
[449] NA 1 (5) PKDF82
4 
No Not listed 
CDH23 c.6050-9G>A p.(?) arUSH 
type1 

























[449] NA 1 (2) PKDF09
7 
No Not listed 















[449] NA 1 (3) PKDF52
2 
No Not listed 
CDH23 c.7198C>T p.(Pro2400Ser) arUSH 
type1 
[449] NA 1 (4) PKDF27
1 
No Not listed 
CDH23 c.8150A>G p.(Asp2717Gly) arUSH 
type1 
[449] NA 1 (3) PKDF15
1 









No Not listed 
CDH23 c.8530C>T p.(Pro2844Ser) arUSH 
type1 
[461] NA 1 (3) PKDF47
5 

















CEP19 c.194dupA p.(Tyr65*) arBBS [133] Southern 
Punjab 
1 (7) No ID No Not listed 
CEP164 c.277C>T p.(Arg93Trp) arBBS [330] NA 1 (2) F05 [466] USA Pathogenic 
(VCV00003
7296) 




CEP290 c.955delT  p.(Ser319Leufs*1
6) 
arMKS [442] NA 1 (1) 292 No Not listed 
CEP290 c.1429C>T  p.(Arg477*) arMKS [442] Mirpur, 
Azad 
Kashmir 





CEP290 c.5668G>T p.(Gly1890*) arJBTS [469] NA 1 (1) A1188- [354, 395, Pathogenic 
303 
 













arMKS [442] NA 1 (1) 333 No Not listed 




CERKL c.847C>T p.(Arg283*) arRP/IRD [169, 
389] 












CHM c.1695_1696delAT p.(Tyr565*) IRD [481] Punjab 1 (3) PKRD16
8 
No Not listed 
CIB2 c.192G>C p.(Glu64Asp) arUSH 
type1J 





CLCC1 c.75C>A p.(Asp25Glu) arRP [316], 
this 
study 














No Not listed 
CLRN1 c.92C>T p.(Pro31Leu) arRP [482] Punjab 1 (6) RP18 No Pathogenic 
(VCV00003
0575) 





arRP [483] Punjab 1 (7) 61039 No Not listed 
CNGA1 c.1091G>A p.(Gly364Asp) arRP [304, 
403] 
NA 2 (6) F08; No 
ID 
No Not listed 
CNGA3 c.822G>T p.(Arg274Ser) arACHM [484] Punjab 1 (4) RP26 No Not listed 




No Not listed 
CNGA3 c.952G>A p.(Ala318Thr) IRD [169] NA 1 (3) 61086 No Not listed 













CNGA3 c.991G>C p.(Gly331Arg) IRD/arACH
M 
[174] Punjab 1 (3) MA-69 No Not listed 






















1 (2) Family 4 
(61421) 
[310] NA Not listed 
CNGA3 c.1540G>A  p.(Asp514Asn) arACHM [486] KPK 1 (4) PKCN-
07 
No Not listed 





1 (5) Family 2 [309] 
Chinese 
Not listed 




1 (4) Family 3 No Not listed 
CNGA3 c.1641C>A p.(Phe547Leu) IRD This 
study 






CNGB1 c.413-1G>A p.(?) IRD/RP [174, 
487] 










1 (3) Family 
218 
No Not listed 
CNGB1 c.2284C>T p.(Arg762Cys) arRP [487] Punjab 1 RP42 [488] NA  Not listed 
CNGB1 c.2493-2A>G p.(?) arRP [403] NA 2 (18) F09; No 
ID 











No Not listed 

































CNGB3 c.1208G>A p.(Arg403Gln) IRD [169, 
495] 

















Mapped locus only; 
variant not identified 
NA arCRD [498] NA 1 (6) CORD8 No Not listed 
CRB1 c.107C>G  p.(Ser36*) arLCA [404] Northern 
Pakistan  
1 (10) MEP53 No Not listed 
CRB1 c.433T>C p.(Cys145Arg) IRD [169] NA 1 61186 No Not listed 
CRB1 c.1459T>C p.(Ser487Pro) arRP [377] NA 1 (1) Patient 7 No Not listed 










CRB1 c.2536G>A p.(Gly846Arg) arRP [396, 
506] 





CRB1 c.2966T>C p.(Ile989Thr) arLCA [396] NA 1 (8) 010LCA No Not listed 
CRB1 c.3296C>A p.(Thr1099Lys) arRP [487] NA 1 RP04 No Not listed 
CRB1 c.3343_3352del p.(Gly1115Ilefs*2
3) 
arRP [507] NA 1 (9) No ID No Not listed 







1 (3) Family 
13 
No Not listed 
CRB1 c.3961G>C p.(Cys1321Ser) arRP [507] NA 1 (5) No ID [508] NA Not listed 










DHX38 c.995G>A p.(Gly332Asp) EORP w/ 
macular 
coloboma 





















1 (3) No ID No Not listed 






EYS c.7187G>C p.(Cys2396Ser) arRP [169] NA 1 (2) 61016 [513] Indian Not listed 












c.1139G>T p.(Arg380Leu) arRP [169] NA 1 61239 No Not listed 
FAM161
A 












c.1600A>T p.(Lys534*) arRP [169, 
305]  
Punjab; -  2 (3) 61176; 
PKRD17
6 
No Not listed 
FDFT1 c.930C>G p.(Phe310Leu) arIRD [518] NA 1 (2) Family C No Not listed 
GNAT1  c.386A>G  p.(Asp129Gly) arCSNB [169, 
519] 
















NA 2 (11) No ID; 
No ID 
No Not listed 






GRM6  c.1336C>T p.(Arg446*) arCSNB [169, 
525] 
Punjab 2 (7) PKRP17
0; 
61170 
No Not listed 
GRM6  c.2267G>A  p.(Gly756Asp) arCSNB [169, 
525] 
Punjab 2 (6) 61172;  
PKRP17
2 
No Not listed 
GRK1 c.55C>T p.(Arg19*) IRD [169] NA 1 (2) 61015 No Not listed 




Punjab 1 (8) RP19 No Not listed 
GRK1 c.827+623_883del p.(?) Oguchi 
disease 2 





arLCA [528] Dera Ismail 
Khan, KPK 
1 (4) No ID No Not listed 
GUYC2
D 
c.2189T>C p.(Phe730Ser) IRD [169, 
305] 
Punjab 2 (3) PKRD10
3; 
61103 





arLCA [403] NA 1 (2) F3 No Not listed 
GUCY2
D 
c.2384G>A p.(Arg795Gln) IRD [169, 
305] 
Punjab 2 (3) PKRD07
7;  
61077  






c.3056A>C p.(His1019Pro) arLCA/IRD [314]; 
This 
study 




No Not listed 
HMX1 c.650A>C p.(Gln217Pro) Oculoauricol
ar syndrome 
[530] NA 1 (2) No ID No Pathogenic 
(VCV00019
2315) 










IFT140 c.1451C>T p.(Thr484Met) arRP [532] Northern 
Pakistan 
and Punjab 





IMPDH1 c.931G>A p.(Asp311Asn) arRP [169, 
534] 






















2 (9) Family 




IQCB1 c.488-1G>A p.(?) arSLSN [540] NA 1 (1) A364 [395] NA Not listed 














Mapped locus only; 
variant not identified 
NA arLCA [545] NA 1 (5) No ID No Not listed 
LCA5 c.643delC p.(Leu215Tyrfs*1
1) 




No Not listed 



















[548] Afgani Pathogenic 
(VCV00000
0966) 
LCA5 c.1550_1551delGA p.(Arg517Ilefs*3) arRP This 
study 
NA 1 (3) Family 
21 
(61393) 
No Not listed 
LCA9 
locus 
Mapped locus only; 
variant not identified 
NA IRD [404] Northern 
Pakistan 
1 (9) MEP34 No Not listed 




1 (3) Family 
19 
No Not listed 
LRAT c.418G>T p.(Glu140*) arRP [169] NA 1 (3) 61076 No Not listed 
LRAT c.538A>T p.(Lys180*) arRP [169] NA 1 61120 No Not listed 
LRAT c.541-15T>G p.(?) EOIRD [549] NA 1 (6) 61254 No Not listed 
LRP5 c.4268C>T p.(Pro1423Leu) IRD [169] NA 1 (2) 61169 No Not listed 
MERTK c.718G>T p.(Glu240*) arRP [169, 
329] 
Punjab 2 (4) 61173; 
PKRP17
3 
No Not listed 
MERTK c.2194C>T  p.(Arg732*) IRD This 
study 
NA 1 (5) Family 
25 
(61299) 
[322] NA Not listed 
MKKS c.119C>G p.(Ser40*) arBBS [428] Nawab 
Shah City, 
Sindh 




MKKS c.287C>T p.(Ala96Val) arBBS [550] NA 1 (2) Family B No Not listed 
MKKS c.775delA  p.(Thr259Leufs*2
1) 







arMKS [442] NA 4 (4) 102; 
103; 
244; 270 
No Not listed 
MYO7A c.252C>G p.(Asn84Lys) arUSH 
type1 B 





















MYO7A c.399dupC p.(Ile134Hisfs*6) arUSH 
type1 B 
[552] NA 1 PKDF12
4 
No Not listed 
MYO7A c.471-1G>A p.(?) arUSH 
type1 B 















[456] Italy Pathogenic 
(VCV00004
3266) 
MYO7A c.640G>A p.(Gly214Arg) arUSH 
type1 B 



















MYO7A c.721C>T p.(Arg241Cys) arUSH 
type1 















MYO7A c.745G>T p.(Glu249*) arUSH type 
1  
[451] NA 1(1) DEM279 No Not listed 
MYO7A c.977T>A p.(Leu326Gln) arUSH type 
1 B 
[552] NA 1 PKSR40
A 






MYO7A c.1309G>A p.(Asp437Asn) arUSH 
type1 B 




No Not listed 
MYO7A c.1355T>C p.(Leu452Pro) arUSH 
type1 B 
[461] NA 1 (3) PKDF80
3 
No Not listed 
MYO7A c.1591C>T p.(Gln531*) arUSH type 
1 B 






MYO7A c.1935+1G>A p.(?) arUSH type 
1 B 
[552] NA 1 PKDF29
0 
No Not listed 
MYO7A c.2476G>A p.(Ala826Thr) arUSH type 
1 B 













MYO7A c.2695-9A>G p.(?) arUSH type 
1 B 





MYO7A c.2914C>T p.(Arg972*) arUSH type 
1 B 













[552] NA 1 PKDF14
8 
No Not listed 
MYO7A c.3508G>A p.(Glu1170Lys) arUSH type 
1 B 















[552] NA 1 PKDF25
7 





[552] NA 1 PKSK12 No Pathogenic 
(VCV00043
8178) 
MYO7A c.5366+1G>A p.(?) arUSH type 
1 B 
[552] NA 1 PKDF42
6 
No Not listed 
MYO7A c.5899C>T p.(Arg1967*) arUSH type 
1 B 
[461] NA 1 (4) PKDF78
8 
























arSLSN [469] NA 1 (1) F1132 [395] NA Not listed 










c.25G>A p.(Val9Met) arLCA [565, 
566] 








c.838T>C  p.(*280Gln) arLCA [567] NA 1 (8) LCA9 No Pathogenic 
(VCV00003
7132) 
OAT c.722C>T p.(Pro241Leu) IRD This 
study 













Mapped locus only; 
variant not identified 
NA IRD [169] NA 1 61125 No Not listed 
PCDH1
5 
c.7C>T p.(Arg3*) arUSH 
type1F 









c.1927C>T p.(Arg643*) arUSH 
type1 







c.3389-2A>G p.(?) arUSH 
type1F 
[568] NA 1 (3) PKSR8b No Not listed 
PDE6A c.304C>A  p.(Arg102Ser) arRP [321, 
403]  































No Not listed 




PDE6A c.2028-1G>A p.(?) arRP [169, 
305] 
Punjab; -  2 (5) PKRP13
3; 
61133 
No Not listed 
PDE6A c.2098dupT p.(Tyr700Leufs*2
1) 
arRP [570] Punjab 1 (3) 61021 No Not listed 
PDE6A 
locus 
Mapped locus only; 
variant not identified 
NA arRP [570] Punjab 1 (4) 61081 No Not listed 
PDE6B c.12_15delTGAG p.(Ser4Argfs*23) arRP/IRD [321], 
This 
study 





No Not listed 
PDE6B c.243delG  p.(Arg82Alafs*68
) 
arRP [321] Punjab 1 (4) PKRP26
4 
No Not listed 
PDE6B c.1160C>T p.(Pro387Leu) arRP [169, 
571] 
NA 2 (6) PKRP18
3; 
61183 
No Not listed 
PDE6B c.1655G>A p.(Arg552Gln) arRP [169, 
571] 







PDE6B c.1722+1G>A p.(?) arRP [487] NA 1 RP23 No Not listed 
PDE6C c.1A>G p.(Met1*) IRD This 
study 
NA 1 (4) Family 8 
(61401) 







1 (5) Family 7 No Not listed 
PDE6H c.35C>G p.(Ser12*) Incomplete 
ACHM 














[575] KPK  1 (5) Family 1 No Pathogenic 
(VCV00016
2400) 







PROM1 c.1726C>T p.(Gln576*) IRD [577] Punjab 1 (6) 61037 No Not listed 
PROM1 c.1946C>T p.(Ser649Leu) IRD [169] NA 2 (6) 61237; 
61267 
No Not listed 
RBP3 c.3353_3354delCT p.(Ser1118Cysfs
*3) 
arRP [169] NA 1 (4) 61217 No Not listed 
RDH5 c.536A>G p.(Lys179Arg) FA [169, 
578] 













2 (3) No ID; 
Patient 
24 
No Not listed 
RDH5 c.758T>G p.(Met253Arg) FA [169, 
580] 
NA 3 (18) 61035; 
61126; 
Family B 
No Not listed 
RDH5 c.838C>G  p.(Arg280Gly) IRD This 
study 
NA 1 (3) Family 
24 
(61153) 







FA [580] NA 1 (2) Family A No  Not listed 
RDH12 c.506G>A p.(Arg169Gln) arLCA/EOIR
D 



















RDH12 c.619A>G p.(Asn207Asp) arLCA/EOIR
D 
[581]  NA 1 (2) Family 
19 







Bradyopsia [583] NA 1 (2) No ID No Not listed 
RHO c.448G>A p.(Glu150Lys) arRP; IRD [174, 
487]  






RLBP1 c.346G>C p.(Gly116Arg) FA [169, 
584] 







RLBP1 c.466C>T p.(Arg156*) FA [169, 
584] 
Punjab 2 (6) 61064; 
PKRP06
4 
No Not listed 
RP1 11,117 bp incl entire 
gene 
Gene deletion arRP [585] NA 1 (4) PKRP35
8 
No Not listed 
RP1 c.551_552dupTA  (p.Gln185Tyrfs*4
) 
arRP [585] NA 1 (4) PKRP34
4 
No Not listed 
RP1 c.787+1G>A p.(?) arRP [169, 
585] 
NA 2 (6) PKRP26
2; 61262 
No Not listed 












RP1 c.1126C>T p.(Arg376*) arRP [169] NA 1 (3) 61113 No Not listed 
RP1 c.1458_1461dupTG
AA 
p.(Glu488*) arRP [586, 
590]  









Punjab 2 (9) PKRP11
7; 
61117 
No Not listed 
RP1 c.4555delA p.(Arg1519Glufs*
2) 










Mapped locus only; 
no variant identified 
NA arRP [591] NA 1 (6) No ID No Not listed 
RPE65 c.95-1G>A p.(?) IRD [169, 
592] 
Punjab 2 (4) 61020; 
PKRP02
0 
No Not listed 
RPE65 c.119G>A p.(Gly40Asp) IRD [169] NA 1 (2) 61231 No Not listed 






RPE65 c.179T>C p.(Leu60Pro) IRD [169, 
592] 
NA 2 (4) 61160; 
PKRP16
0 



















RPE65 c.751G>T p.(Val251Phe) arLCA [404] Northern 
Pakistan  
1 (6) MEP55 No Not listed 
RPE65 c.782T>C p.(Leu261Pro) IRD [169] NA 1 61116 No Not listed 
RPE65 c.963T>G p.(Asn321Lys) IRD [169] NA 1 61116 No Benign 
(VCV00009
2860) 
RPE65 c.1087C>A p.(Pro363Thr) IRD [169, 
305] 




























RPGR c.310+1G>C p.(?) IRD This 
study 
















c.587+1G>C p.(?) arLCA [404] Northern 
Pakistan 
1 MEP1 No Not listed 
RPGRIP
1 
c.930+1G>A p.(?) arLCA [403] NA 1 (1) F5 No Not listed 
RPGRIP
1 
c.932delA p.(Asn311Ilefs*5) arLCA [169] NA 1 (3) 61312 No Not listed 
RPGRIP
1 
c.1180C>T p.(Gln394*) arLCA [404] Northern 
Pakistan  
1 MEP43 No Not listed 
RPGRIP
1 











c.2656C>T p.(Leu886Phe) IRD [174] NA 1 (2) MA-117 No Not listed 
RPGRIP
1 
c.2710G>A p.(Gly904Ser) IRD This 
study 
NA 1 (5) Family 
10 
(61007) 









1 (2) Family 9 No Not listed 
RPGRIP
1 









c.3620T>G p.(Leu1207*) arLCA [404] Northern 
Pakistan  
1 MEP3 No Not listed 
RPGRIP
1L 
c.466C>T  p. (Arg156Cys) arMKS [442] Gujarat 2(2) 36; 36A No Not listed 
RPGRIP
1L 
c.1945C>T  p. (Arg649*) arMKS [442] NA 2 (2) 336; 207 No Pathogenic 
(VCV00065
1948) 






SAG c.916G>T p.(Glu306*) Oguchi type 
1 





Mapped locus only; 
variant not identified 
NA IRD [169] NA 1 61129 No Not listed 
SEMA4
A 
































No Not listed 
SNRNP
200 
c.3269G>A p.(Arg1090Gln) arIRD [518] NA 1 (2)  Family G No Pathogenic 
(VCV00003
9746) 
SPATA7 c.253C>T p.(Arg85*) arLCA/arIR
D 
[606] NA 2 (3) Family 
1; 
Family 2 




























NA 2 (3) 67FB; 
67F 
No Not listed 
TMEM6
7 





2 (2) 73; 51 No Not listed 
TMEM6
7 
c.1127A>C p.(Gln376Pro) arMKS [442, 
611]  
NA 3 (3) P95; 
40T; No 
ID 
No Not listed 
TMEM6
7 














No Not listed 
TMEM6
7 
c.1645C>T  p.(Arg549Cys) arMKS [442] Mirpur, 
Azad 
Kashmir. 










TRNT1 c.569G>T p.(Arg190Ile) RP? [616] NA 1 (1) P3  No Pathogenic 
(VCV00015
7613) 




2 (4) 61179; 
PKRP17
9 
 No Pathogenic 
(VCV00000
2532) 
TTC8 c.235+1G>A p.(?) arBBS [618] NA 1 (2) 61/178 [619] NA Not listed 
TTC8 c.768+5G>A p.(?) IRD This 
study 
Lahore 1 (3) Family 
15 
No Not listed 
TTC8 c.1019+2_1019+4de
l 
p.(?) arBBS [120, 
425] 
NA 2 (5) A2827; 
BB12 
No Not listed 
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Mapped locus only; 
variant not identified 
NA IRD [169] NA 1 61147 No Not listed 




1 (5) Family 7 No Not listed 
TULP1  c.287_288delGA  p.(Glu96Glyfs*77
) 
IRD [168] NA 1 (6) PKRP36
4 






















No Not listed 
TULP1 c.1445G>A p.(Arg482Gln) arRP [620] NA 1 (6) Family B No Not listed 




































TULP1  c.1495+4A>C p.(?) IRD [168, 
169] 
NA 2 (4) 61268; 
PKRP26
8 
No Not listed 
TULP1  c.1561C>T p.(Pro521Ser) arRP [168, 
169] 
NA 2 (3) 61259; 
PKRP25
9 






















1 (4) HLRB12 No Not listed 
USH1G c.1373A>T p.(Asp458Val) arUSH 
type1G 











Mapped locus only; 
no variant identified 
NA arUSH 
type1H 









Mapped locus only; 
no variant identified 
NA arUSH 
type1K 




No Not listed 
USH2A c.4645C>T p.(Arg1549*) IRD [169, 
305] 















USH2A c.5740C>T p.(Gln1914*) RP/IRD [169] NA 1 (8) 61191 No Not listed 






1 (3) Family 
17 









Punjab 2 (5) PKRD13
8; 
61138 
No Not listed 
USH2A c.12523T>G p.(Trp4175Gly) IRD/RP [169, 
305]  
Punjab 2 (5) PKRP18
5; 
61185 
No Not listed 
USH2A 
locus 
Mapped locus only; 
no variant identified 









[632] NA 1 (2) No ID No Not listed 
ZNF408 c.1304G>A p.(Arg435Gln) IRD [439] Punjab 1 (3) PKRD32
0 
No Not listed 
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Abbreviations: ACHM, achromatopsia; ad, autosomal dominant; ar, autosomal 
recessive; BBS, Bardet-Biedl syndrome; CRD, cone-rod dystrophy; CSNB, Congenital 
stationary night blindness; Dist., District; EEM, Ectodermal dysplasia, ectrodactyly, and 
macular dystrophy; EOIRD, Early-onset inherited retinal dystrophy; EORP, Early-onset 
retinitis pigmentosa; FA, fundus albipunctatus; JBTS, Joubert syndrome; ID; identifier; 
IRD, inherited retinal dystrophies; LCA, Leber congenital amaurosis; MKS, Meckel 
syndrome; MORM, mental retardation, truncal obesity, retinal dystrophy, and 
micropenis; NA, not available; RP, Retinitis Pigmentosa; SLSN, Senior-Loken syndrome; 






Media 1  
Description: Time-lapse movie of wild type SH-SY5Y cell expressing mCherry-
KDEL and EGFP-SigmaR1. Images were captured with a 63x oil immersion 
objective, for 100 frames, every 7 sec. 
File name: control_SigmaR1_KDEL  
 
Media 2 
Description: Time-lapse movie of CLCC1 -/- KO cell (SH-SY5Y) expressing 
mCherry-KDEL and EGFP-SigmaR1. Images were captured with a 63x oil 
immersion objective, for 80 frames, every 7 sec. 
File name: CLCC1knockout_SigmaR1_KDEL  
 
Media 3  
Description: Time-lapse movie of wild type cell expressing mCherry-KDEL and 
EGFP-SigmaR1 and treated with DMSO for 30 min. Images were captured with 
a 63x oil immersion objective, for 80 frames, every 7 sec. 








Description: Time-lapse movie of CLCC1 -/- KO cell expressing mCherry-KDEL 
and EGFP-SigmaR1, and treated with PRE-084 for 30 min. Images were 
captured with a 63x oil immersion objective, for 80 frames, every 7 sec. 
File name: CLCC1knockout_SigmaR1_KDEL_PRE084  
 
Media 5  
Description: Time-lapse movie of wild type cell expressing mCherry-KDEL and 
EGFP-SigmaR1, and treated with BD1047 for 30 min. Images were captured 
with a 63x oil immersion objective, for 80 frames, every 7 sec. 
File name: Control_SigmaR1_KDEL_BD1047 
 
Media 6  
Description: Time-lapse movie of CLCC1 -/- KO cell expressing mCherry-KDEL 
and EGFP-SigmaR1, and treated with BD1047 for 30 min. Images were 
captured with a 63x oil immersion objective, for #### frames, every 7 sec. 







Table of primers used for genotyping the families 
Primer Primer sequences 
ABCA4 c.3364G>A  For: CTTGCGCACCAAGGTTAAGT 
Rev: TGAATTAGTTCCCTTGGGTTTT 
BBS4 c.221-1G>A For: TCTGACCCCAGGCTCCAT 
Rev: TGGACCTAGGAATGCATTTTACA 
CACNA1F c.2254G>A For: CCAGGGTGACTAGAGGCATC 
Rev: ATATGGTGGCCCCTTCTTCC 
CNGA3 c.1443dup For: CCAACAAGAAGACGGTGGAT 
Rev: TTGCCCTCGTTGATGATGTA 
CNGA3 c.955T>C For: GATGTGTTGTCCCTGGTCCC 
Rev: TCAATCTTGGCCTGGAACTCT 
CNGA3 c.1556T>C For: AAGGTTCGCATCTTCCAGGA 
Rev: TGCTCCCCTTGATGTTCAGA 
CNGA3 c.1600G>A For: ATCTTCCAGGACTGTGAGGC 
Rev: CTTTGAGAGGCAGAACAGGTC 
CNGB1 c.852_874+25del For: AGAGCATGGGGCTCTCTCAG 
Rev: CCCCACCTCAAATCCTTCAT 
CRB1 c.3735delA For: CCTGGATACACTGGTGTGAACT 
Rev: TCCCATCTGAACATGACCAA 
GUCY2D c.3056A>C For: CATCTCCACAGGTCCATGC 
Rev: GTCAGAAGGGTGAGCTGAGG 
LRAT c.196G>C For: AGAAGCTGCTCCTCATCTCC 
Rev: GATGCTGGCCACTTTGACAA 
PDE6C c.480delG For: TAGGTTGCTGGATGTCACCC 
Rev: GTGATCCTCTTCCCTGCCAC 
RPGRIP1 c.2789dup For: GGTGATTTTAACCTCACTGACC 
Rev: CTCCTTCAAATCTGCTCCATA 
TTC8 c.768+5G>A For: AAGCAGAAAAACAGTTTAAATCAGC 
Rev: GACAGTTACCCTCTATACGTTCTCA 
TULP1 c.855dupC For: CCACACTCCCTCCTCTGCT 
Rev: CTGCTCTAGCCAGCCTCTCT 
TULP1 c.238C>T For: CCAGCCCCTTCTCTCCTTAG 
Rev: AGTGTTGAAAGTGGAAACCCA 














Figure 1 Whole western blots showing fractionation of ER proteins in WT 
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